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Abstract 
CD23 is a Type II glycoprotein that exists in both membrane-bound (mbCD23) and 
soluble (sCD23) forms and functions as the low affinity receptor for IgE. CD23 
interacts with a range of proteins to fulfil its function in vivo. Through 
interactions with its ligands IgE and CD21, CD23 regulates the levels of IgE in 
serum. Soluble CD23 also interacts with members of the integrin family of 
membrane receptors. Integrins are heterodimeric transmembrane receptors that 
participate in bidirectional signalling across membranes and have a critical role 
in cellular adhesion reactions. CD23 interacts with four integrins, αVβ3 and αVβ5 
from the αV integrin family, and αMβ2 and αXβ2, from the β2 family of integrins.  
Using peptide array technology, we identified set of overlapping peptides 
derived from the soluble CD23 sequence that interact with integrins expressed 
on the surface of monocytic cells and with purified αVβ3 and αVβ5 integrins in in 
vitro Biacore assays. These peptides all contained a common basic tripeptide 
motif, termed the Arg-Lys-Cys (RKC) motif. Integrins traditionally recognise and 
bind the Arg-Gly-Asp (RGD) tripeptide in their ligands in a cation-dependent 
manner. However, the in vitro interaction between RKC-containing peptides and 
purified integrins was determined to be cation-independent, salt-sensitive and 
independent of RGD binding. The interaction was blocked by full length CD23. 
Substitution of the residues in the RKC motif reduced or abolished binding of the 
peptides to integrins expressed on cells and in vitro, as measured by Biacore 
analysis, and abolished the competition with CD23. Taken together, these data 
suggest that the RKC motif is the site in CD23 that is recognised and bound by 
αVβ3 and αVβ5 integrins. The RKC motif can be considered a novel recognition 
motif for integrins, as it is cation-independent, and its binding is not blocked by 
the presence of RGD-containing integrin ligands. Therefore it is likely that the 
RKC motif interacts with integrins at a site other than that used for RGD-binding, 
similar to the interactions that have been described for the binding of the HIV 
Tat protein. 
The interaction between sCD23 and its integrin receptors is important in the 
regulation of cytokine production by monocytic cells. Most monocytic cells will 
express a combination of the different CD23-binding integrins simultaneously 
and, therefore, the cytokine output of that cell will be the net result of the 
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interaction of CD23 with a combination of integrins. We used monoclonal 
antibodies to investigate the role of individual integrins in cytokine production. 
Antibodies were selected to allow comparision of the cytokine response 
between, a) integrin families, b) integrin subunits, and c) integrin epitopes.  
The cytokine profile induced by integrin ligation did not differ between the αV 
and β2 integrin families, although the concentration of cytokines produced 
varied depending on the heterodimer targeted. However, within a particular 
family, cytokine production induced by integrin ligation was specific and relied 
on the recognition of a precise epitope on the integrin. Cytokine production by 
CD23-binding integrins appears to require the ligation of the α subunit of the 
integrin heterodimer. We identified an antibody directed against the αVβ3 
integrin that induced high levels of cytokine production. Cytokine production 
following ligation of the integrin with this antibody was dependent on activation 
of the ERK/MAPK pathway in cells. This production of cytokines and 
phosphorylation of ERK was enhanced by the addition of macrophage colony 
stimulating factor (M-CSF) and partially inhibited by an anti-TLR-2 antibody. 
Chronic stimulation (<3 days) of THP-1 cells with the anti-αVβ3 antibody in the 
presence of M-CSF led to morphological changes in the cell line associated with 
the development of a more macrophage-like phenotype and the continued 
production of cytokines. Analysis of the changes in cell surface marker 
expression and cytokine profiles suggested that the THP-1 cells had undergone 
an M2b programme of macrophage activation in response to αVβ3 ligation. Data 
presented herein reinforce the importance of the role of integrins in the control 
of adhesion-independent signalling pathways in suspension cells.  
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1.1 The Immune System 
The immune system is the term used to describe the collection of mechanisms 
used by an organism to protect itself from injury and disease. It is composed of 
the innate and adaptive immune systems which work in conjunction to defend 
and heal the body. The adaptive immune system is a collection of highly 
specialised cells and processes that combat infections. The adaptive immune 
response is specialised, and recognises and mounts a specific immune response 
against a particular pathogen and also stores a memory of that infection for 
later challenges. The major effector cells of the adaptive immune response are 
B and T lymphocytes, which have distinct roles in cell-mediated adaptive 
immunity. The adaptive immune system is activated by the non-specific innate 
immune response, which often forms the first line of defence against infection 1.   
The innate immune system is an evolutionarily conserved mechanism of defence 
against pathogens and is capable of being activated in a non-specific manner. 
This means that the response to infection is rapid and does not rely on prior 
encounter with a pathogen to mount an innate immune response against it. The 
innate immune system, unlike the adaptive immune system, does not confer 
long-lasting or protective immunity to the host. It is comprised of cellular 
components, such as monocytes and neutrophils, and non-cellular components, 
such as the complement system, which work in conjunction to mount the innate 
defense against infection 1. 
1.1.1 Cells of the Innate Immune System 
The innate immune system is comprised of a number of leukocytes, with defined 
functions. These include basophils, eosinophils, neutrophils, mast cells and 
monocytes, each of which has a specific role in innate immunity. Neutrophils 
defend the body against bacterial or fungal infection and are usually first 
responders to microbial infection. Eosinophils are primarily involved in 
combating parasitic infections and are also the predominant cells in allergic 
reactions. Basophils are chiefly responsible for allergic and antigen responses by 
the release of the inflammatory mediator, histamine. Of particular interest in 
this thesis, is the role of monocytes and macrophages in innate immunity and 
inflammation 2. 
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1.1.2 Monocytic cells 
Monocytes are leukocytes that play a major role in the innate immune system. 
Monocytes are the precursors for a number of terminally-differentiated cells of 
the body, including cells such as macrophages 3, dendritic cells 4, and osteoclasts 
5. Monocytes develop in the bone marrow from a pluripotent stem cell via the 
common myeloid progenitor cell, which is the precursor for all cells of the 
granulocyte lineage. The earliest stage is the monoblast, which develops into a 
mature monocyte in the blood via a promonocyte stage. Mature monocytes 
circulate in the blood, where they constitute about 3-8% of the total leukocyte 
population. Monocytes also migrate into the tissues where they differentiate into 
macrophages, depending on the local environment 2.  They are phagocytic cells, 
which bind and engulf pathogens directly or via opsonising antibodies or 
complement. They also present antigen to T cells and produce a range of 
cytokines and chemokines. In the presence of specific stimuli, macrophages 
undergo regulated programmes of activation that give rise to either pro-
inflammatory or anti-inflammatory macrophages (discussed further in Chapter 5) 
6-8. 
1.1.3 Cytokines  
Cytokines are small (8-30kDa), water-soluble proteins that are secreted by a 
wide variety of cells and play an important role in cellular communication. 
Cytokines mediate their effects by binding to their cognate receptors and are 
critical mediators of both the innate and adaptive immune responses 9. In 
certain cases, cytokines will share receptors and receptor subunits and have 
overlapping functions. They are important in the recruitment, development and 
maturation or differentiation of cell types, as well as playing a role in a range of 
immunological situations. Cytokines can be broadly classified as either pro-
inflammatory or anti-inflammatory, although often this is misleading, as the net 
effect of the inflammatory response will be a result of the balance between pro- 
and anti-inflammatory mediators. The nature, duration and extent of cellular 
activities induced by a certain cytokine will be affected by the individual 
cytokine concentration and the combinations of other cytokines present. The 
target cell type, the micro-environment of that cell and the characteristics of 
neighbouring cells will also govern the effect of a particular cytokine 10.  
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1.1.3.1 Pro-inflammatory Cytokines 
Pro-inflammatory cytokines are those that generally favour the development of 
an inflammatory state. The group includes cytokines such as tumour necrosis 
factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukin-6 (IL-6) and 
interleukin-1 alpha/beta (IL-1α/β), which are responsible for early inflammatory 
responses. Other inflammatory cytokines include transforming growth factor-
beta (TGF-β), interleukin-12 (IL-12) and interleukin-8 (IL-8).  Pro-inflammatory 
cytokines induce the inflammatory state and also modulate the production of 
secondary mediators and the recruitment of immune cells 11.  
1.1.3.2 Anti-inflammatory Cytokines 
Anti-inflammatory cytokines are those immunomodulatory cytokines that control 
or counter-act the magnitude of inflammatory responses in vivo. They act by 
inhibiting the production or biological effects of pro-inflammatory cytokines. 
The major anti-inflammatory cytokines are interleukin-4 (IL-4), interleukin-10 
(IL-10) and interleukin-13 (IL-13), but the group also includes interleukin-16 (IL-
6), interferon-alpha (IFN-α), transforming growth factor-beta (TGF-β), and 
interleukin-1 receptor A (IL-1RA) 11.  
1.1.3.3 Chemokines 
Chemokines are chemotactic cytokines that regulate the migration of different 
cell types 12. Chemokines are generally small polypeptides (8-10 kDa) and often 
exhibit a degree of sequence similarity. All chemokines contain a number of 
conserved cysteine residues involved in intramolecular disulphide bond 
formation. Chemokines can be further classified as CXC-chemokines (α-
chemokines), CC-chemokines (β-chemokines), C-chemokines (γ-chemokines) or 
CX3C-chemokines (δ chemokines) depending on their structural features and 
genomic location. Certain α-chemokines also possess an additional Glu-Leu-Arg 
(ELR) sequence at the N-terminal end. The biological activities of chemokines 
are mediated by specific receptors, many of which have overlapping ligand 
specificities and can bind several of different chemokines. These transmembrane 
receptors belong to the large group of seven transmembrane domain receptors 
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that contain seven hydrophobic alpha-helical segments, which mediate signalling 
via coupling to heterotrimeric G-proteins 13.  
Chemokines have been shown to exert their effects on distinct subsets of cells. 
Some chemokines have been shown to induce selective migration of subsets of 
leukocytes. Chemokines containing the ELR motif are especially chemotactic for 
neutrophils, while chemokines lacking the ELR motif are chemotactic for other 
cell types (including monocytes, B-cells, basophils and eosinophils). The 
combined effects of multiple chemokines will affect the cellular composition at 
inflammatory sites.  The existence of clearly defined subgroups of chemokines 
on the basis of structural and functional properties illustrates the importance of 
chemoattractant diversity in the regulation of the leukocytes migration in vivo 
14, 15.  
In addition to mediating cell recruitment, chemokines influence a number of 
cellular processes, under both physiological and pathological circumstances. 
Chemokines, such as IL-8, are multi-functional cytokines that influence and 
enhance inflammation through chemotaxis and activation of cells at 
inflammatory sites 13. Certain chemokines activate granulocytes and/or 
monocytes, induce degranulation and lysosomal enzyme release. Others have a 
priming effect on immune cells, allowing them to respond to sub-optimal 
amounts of inflammatory mediators 16. Chemokines are important during the 
infection of cells by pathogens, such as the use of the chemokine receptors 
CXCR-4 and CCR5 as co-receptors for the HIV virus 17-19. The natural ligands (SDF-
1 and RANTES/MIP-1β, respectively) and antagonists of CXCR-4 and CCR5  
compete with HIV for binding to these receptors 20.  SDF-1 also has a role in the 
development and trafficking of cells during haematopoesis 21. Many chemokines 
are correlated with a number of pathological conditions including autoimmune 
diseases 22, chronic inflammatory diseases 23, atherosclerosis and cancer 24. 
1.1.4 Inflammation and Disease 
Inflammation is the complex vascular response of the body to a biological insult, 
such as an infection. The successful conclusion of inflammation is the removal of 
the harmful agent and healing of the wounded tissues. Inflammation can be 
classified as either acute or chronic. Appropriate inflammation is necessary to 
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establish the environment required to combat an infection, including factors 
such as the activation of the complement system, and the recruitment of 
phagocytic cells and B and T lymphocytes to the inflamed area 13, 25. However, in 
certain circumstances, inflammation can arise either due to an inappropriate 
stimulus or may be altered such that it leads to a disease state. Examples of 
such inflammatory diseases include disorders such as rheumatoid arthritis (RA), 
system lupus erythematosis (SLE), Sjogren’s syndrome, Crohn’s disease and 
certain cancers 9, 26-28. A common characteristic connecting a number of the 
inflammatory disorders described above is the high levels of the low affinity 
receptor for IgE, CD23 29, 30.  
1.2 The Low Affinity Receptor for IgE (FCεRII / 
CD23) 
CD23 (Blast-2, FcεRII) is a 45 kDa, Type II membrane glycoprotein 31, 32. CD23 is 
the only known Ig receptor that is not a member of the immunoglobulin 
superfamily 32. Membrane bound CD23 (mbCD23) is cleaved by membrane-
associated metalloproteases to yield soluble CD23 (sCD23) fragments of 37kDa, 
which are subsequently cleaved to yield CD23 species of 33kDa, 29kDa, 25kDa 
and 16kDa 33, 34. All fragments contain the C-type lectin domain of CD23 and 
varying portions of the stalk region. Cleavage of the mbCD23 to yield the 37 kDa 
species occurs at a site close to the membrane and the single site of N-
glycosylation 35. CD23 can exist as a monomer and trimer in both membrane-
bound and soluble forms. These soluble fragments retain many of the activities 
of membrane associated CD23 and also possess cytokine-like activity 36-41.  
CD23 is normally expressed on mature B cells, particularly activated cells, 
although its expression is significantly altered in a number of pathological 
conditions 42-54. The normal levels of CD23 detected in human serum range from 
0.5 – 5 ng/mL, with children and neonates having higher levels than adults 42. In 
some disorders, such as chronic lymphocytic leukaemia (CLL), elevated levels of 
CD23 may have prognostic value and may correlate with the progression of the 
disease 43-47. Elevated CD23 levels are also observed in disorders such as 
rheumatoid arthritis, where the levels of CD23+ B cells are increased, as is the 
level of sCD23 in the serum and synovial fluid 48-56.  
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In addition to being a marker for certain diseases, sCD23 possesses cytokine-like 
activities. Soluble CD23 acts as a growth factor for Epstein-Barr transformed cell 
lines 57, 58, prevents apoptosis of germinal centre B cells 59 and induces 
differentiation of prothymocytes 60. These combined activites make CD23 an 
interesting molecule in the regulation of cell growth and differentiation.  
1.2.1 CD23 Structure 
At the structural level, CD23 is comprised of a number of distinctive functional 
domains and motifs that define its activities (Figure 1-1) 32, 61, 62. The C terminal 
extracellular domain of CD23 shares structural similarity with the C-type lectin 
family. The 3-dimensional structure of the lectin head of CD23 has been 
determined by NMR spectroscopy 62 and X-ray crystallography 63. The CD23 
domain contains two α helices orientated at right angles relative to each other 
and two antiparallel β sheets, each made up of four β strands. The structure has 
a hydrophobic core, containing 7 tryptophans and other highly conserved 
residues, with 4 disulphide bridges maintaining the tertiary structure. The CD23 
lectin domain exhibits a polarity with respect to the distribution of its 
electrostatic charges. The positive and negative residues of the highly charged 
surface are located on different faces of the molecule. The authors postulate 
that this is essential for the interaction of CD23 with itself and its ligands 62.  
The stalk domain of CD23 contains 7 hydrophobic repeats that form an alpha 
helical coiled-coil structure 64. This region connects the lectin domain to the 
transmembrane domain and is the site of oligomerisation of CD23 into trimers. 
The leucine zipper region is near the transmembrane domain and has a 7 amino 
acid motif, beginning with a Leu or Ile residue, which is repeated 5 times in 
human CD23 61. The stalk is the site of proteolytic cleavage that generates sCD23 
species 33, 34. The N terminus of CD23 is cytoplasmic and associated with the 
cytoskeleton. There are two forms of CD23, CD23a and CD23b, which differ in 
the sequence of this region. CD23a contains the sequence ‘Met-Glu-Glu-Gly-Gln-
Tyr-Ser-Glu-Ile-Glu’ (MEEGQYSEIE) at the N terminus, while CD23b contains the 
sequence ‘Met-Asn-Pro-Pro-Ser-Gln-Glu-Ile-Glu’ (MNPPSQEIE) 65. The residues in 
bold represent the consensus N terminal pentameric sequence for the two splice 
variants of CD23.  
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Figure  1-1 Schematic representation of CD23 structure 
Membrane-bound (A) and soluble (B) CD23 species are comprised of a number of domains which 
define their function. Cytoplasmic sequence of mbCD23 can be comprised of either the a or b N 
terminal sequence.  
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CD23a is constitutively expressed and confined to certain cell types. CD23b is 
upregulated by exposure to IL-4 and expressed on a wide range of cell types 66. 
The a and b forms of human CD23 have different functions. The Asn-Pro motif of 
CD23b is associated with phagocytosis, while the Tyr based motif of CD23a is 
involved in endocytosis 65.  
Human CD23 contains an inverse RGD (DGR) sequence near the C terminus. The 
RGD sequence is a common recognition motif for integrin-mediated binding and 
is found in a wide range of diverse proteins that are involved in cell adhesion 
(discussed fully later) 67. The conformation of this DGR-containing region is not 
known. The DGR sequence is only found in human CD23 and not in CD23 from 
other species, although the role of this motif remains undefined. One suggestion 
is that this DGR sequence (inverse RGD) in CD23 may interact with an inverse 
‘RGD-binding inhibitory sequence’. This suggestion is based on a similar 
interaction with respect to the integrin gpIIb/IIIa. In this case, an RGD-binding 
inhibitory sequence in the platelet integrin gpIIb/IIIa blocks the binding of RGD-
containing ligand fibrinogen. Indeed, CD23 contains a possible ‘DGR-binding 
inhibitory motif’ in the stalk region near the membrane. Complete definition of 
the role of the DRG motif will rely on further information on the mechanism of 
RGD recognition and binding by integrins 61, 68.                    
1.2.2 CD23 Function 
CD23 participates in both protein-protein interactions and protein-carbohydrate 
interactions. To date, CD23 has been shown to form partnerships with IgE 62, 69, 
CD21 62, 70-73, αXß2 and αMß2 74 (leukocyte integrins)  and the vitronectin 
receptors αVß3 40 and αVß5 75 (Figure 1-2). The interaction of mbCD23 and sCD23 
with these ligands results in specific events in the cell, particularly in the 
context of allergy, inflammation and cytokine production.  
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Figure  1-2 Interactions of CD23 and its ligands 
Membrane-bound and soluble CD23 interact with a number of ligands, including (A) IgE, (B) CD21, 
(C) αMβ2 and αXβ2 integrins, and (D) αVβ3 and αVβ5 integrins. The interaction with CD21 and IgE 
is important in the regulation of serum levels of IgE, while the interaction of CD23 with its integrin 
receptors induces cytokine production (αMβ2, αXβ2, αVβ3) and cell proliferation (αVβ5). 
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1.2.2.1 CD23 interaction with IgE 
IgE is one of the classes of human antibodies and is produced exclusively in 
mammals. IgE is particularly effective in defending the body against parasitic 
infections and as such, B cells secreting IgE are found in high concentrations in 
areas of the body most susceptible to parasitic invasion (skin, lungs and gut). 
Allergy is caused by the over-expression of IgE in response to common 
environmental allergens found in a variety of substances. Although IgE comprises 
a very small fraction of the total antibody in human serum, its action is 
amplified significantly by the interaction between IgE and its receptors.  
CD23 is the low affinity receptor for IgE, binding IgE with an affinity of Ka ~107 
M-1. CD23 recognises the Cε3 domain of IgE, with Lys352 on IgE shown to be 
essential for CD23 binding 76. The site of interaction between CD23 and IgE has 
been determined from the recent NMR solution structure of the CD23 C-type 
lectin domain, which suggests a continuous interaction surface for IgE comprising 
selected CD23 amino acids in the region between residues Trp184 and Ala279 62. 
All of the fragments of sCD23 retain the ability to bind IgE, although only 
fragments greater than 28kDa promote IgE synthesis and the 16kDa species can 
in fact inhibit this activity 42. 
The CD23/IgE interaction is important in the regulation of IgE levels. The 
membrane-bound and soluble forms of CD23 have different roles in the 
regulation of IgE expression and associated activities 42 (Figure 1-3). Ligation of 
trimeric mbCD23 by IgE results in negative regulation of IgE synthesis, reducing 
serum levels of IgE 32, 77, 78. IgE binding to mbCD23 inhibits the release of sCD23 
from the membrane by stabilising the stalk region of CD23 and preventing 
proteolytic cleavage, thereby further repressing IgE synthesis. In contrast, 
ligation of IgE by soluble CD23 species leads to an upregulation in IgE synthesis. 
The ability of sCD23 trimers to enhance IgE production is thought to be through 
its ability to cross-link IgE and CD21, another CD23 ligand, on cells 32, 62, 79. 
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Figure  1-3 Regulation of IgE Synthesis by CD23 
The interaction of mbCD23 and sCD23 with its ligands CD21 and IgE differentially regulates IgE 
synthesis. (A)The interaction between mbCD23 and IgE leads to downregulation in the production 
of IgE. (B) The complex of CD21 and IgE with sCD23 upregulates the production of serum levels of 
IgE. 
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1.2.2.2 CD23 interaction with CD21 
CD21 is a 145 kDa, Type I transmembrane glycoprotein, also known as the 
complement receptor type 2 (CR2) that plays a major role in human B cell 
activation and proliferation 72. CD21 and CD23 interact in both their membrane-
bound and soluble forms and these interactions are mediated via protein-protein 
interactions and via N-linked sugar chains on CD21. The interaction site on CD23 
for CD21 is found in the C-type lectin head and involves residues Glu294, Gly295, 
Ser296 and Glu298 62.  
Binding sites for CD21 and IgE on CD23 are distinct from each other 37, 62. sCD21 
and sCD23 form a complex composed of a sCD23 trimer, sCD21 and IgE 42, 62. This 
soluble complex is similar to the trimeric CD23/IgE structure formed at the 
membrane, although the ability of sCD23 to form trimers remains contentious 80. 
In this case, two of the CD23 lectin heads bind IgE, leaving the third domain 
available for interaction with CD21. This interaction between sCD21 with sCD23 
was shown to be biologically relevant in inhibiting the production of IgE in IL-4 
stimulated B cell cultures 79. In addition the CD23/CD21 interaction is relevant in 
the regulation of IgE production, the survival of germinal centre B cells and B 
cell presentation of antigens to T cells. These results suggest a role for the 
sCD21/sCD23 interaction in the context of inflammation and allergy.  
1.3 Integrins 
CD23 is important in the regulation of IgE serum levels through its interaction 
with CD21 and IgE 73, 79, 81, 82. These interactions have been the focus of a 
significant quantity of research. In addition to these effects, CD23, and in 
particular sCD23, is able to induce the production of proinflammatory cytokines. 
It is the interactions between CD23 and members of the integrin family of cell 
adhesion molecules that may play a role in mediating these cytokine functions 40, 
41, 83, 84. The interaction between CD23 and integrins may therefore be a 
potential point of intervention for the treatment of inflammatory disorders in 
which overproduction of cytokines is a hallmark 85, 86.  
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Integrins mediate cell adhesion in a number of biological processes, including 
cell migration, morphogenesis and differentiation 87, 88. Cell adhesion is a 
fundamental event that is essential for a number of processes, such as 
embryonic development 89, tumour cell metastasis 90, wound healing 91 and 
monocyte extravasation 92. Integins physically link the extracellular environment 
with the cellular cytoskeleton. They participate in both the transmission of 
signals from the extracellular matrix (ECM) to the inside of the cell (‘outside in’ 
signalling) and from the cell to the ECM (‘inside out’ signalling) 88. They are a 
diverse family of receptors that mediate cell-matrix, cell-cell and cell-pathogen 
interactions 87.  
1.3.1 Integrin Structure 
Integrins are membrane-associated heterodimeric molecules formed by a non-
covalent interaction between two Type I transmembrane glycoproteins, named 
the alpha (α) and beta (ß) subunit. To date, 18 α and 8 ß subunits have been 
identified. These subunits associate to form 24 different αß integins, each of 
which has defined functions and cellular expression patterns and levels (Figure 
1-4). These features of integrins result in a large network of molecules that 
control cell adhesion and related events 93.  
The integrins are predominantly extracellular, with short cytoplasmic tails (with 
the exception of the ß4 integrin). The overall assembly of the structure 
represents an extracellular globular headpiece supported by two ‘legs’, one 
from each subunit, anchored in the membrane. The N-terminal extracellular 
region of the heterodimeric integrins contains 12 structural domains (Figure 1-
5). The headpiece is the site of the majority of interactions between the two 
subunits and is comprised of 4 domains from the α subunit and 8 from the ß 
subunit. The headpiece is made up of the ß-propeller domain from the α subunit 
and the ß subunit hybrid and ßA domains. The α subunit leg is made up of the 
Thigh and Calf-1 and Calf-2 domains. The ß subunit leg comprises the 
plexin/semaphorin/integrin (PSI) domain, 4 epidermal growth factor (EGF)-like 
domains and a ß tail domain. A flexible region between the globular headpiece 
and legs, known as the ‘genu’, is the site of bending during integrin activation. 
The main interactions between the two subunits are found in the globular head 
region, between the α subunit ß-propeller and the ß subunit ßA domain 93, 94.  
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Figure  1-4 Association of α and β subunits to form integrin heterodimers 
18 α and 8 β subunits associate to form 24 different integrin heterodimers with different cellular 
functions and distributions. The vitronectin family of integrins contain the common αV subunit and 
can all bind the ECM protein vitronectin. The leukocyte integrins all contain the common β2 subunit 
and are expressed on leukocytes. The integrins known to bind CD23 are shaded grey. 
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1.3.1.1 Alpha Subunit 
The α subunit is comprised of four or five domains. There are two types of α 
subunit, differentiated by the presence or absence of a domain known as the 
inserted (I)-domain. The I-domain contains 200 amino acids, inserted between ß 
sheets 2 and 3 of the ß-propeller domain. It is also known as the von Willebrand 
A domain due to similarities to this structure. The I-domain is only found in 
certain α subunits, although its presence has been predicted in other α subunits. 
This domain is the major ligand recognition and binding site in I-domain-
containing α subunits, via a metal ion-dependent adhesion site (MIDAS). Residues 
from this site (DXSXS) are integral for the coordination of metal ions, in 
conjunction with complementary sites on the ß subunit, during cation-dependant 
ligand binding by integrins 95.  
The N-terminal ß-propeller domain forms a seven-bladed ß-propeller structure, 
comprised of seven segments of approximately 60 amino acids that share weak 
homology. The ß propeller contains the ‘active site’ amino acids that, in 
conjunction with amino acids from the ß subunit, participate in ligand binding in 
integrins that lack an I-domain. In I-domain-containing α subunits, the ß-
propeller domain may cooperate with the I-domain residues during ligand 
binding. Ligand binding residues cluster at the top and side of the ß-propeller. At 
the base of the ß-propeller, opposite the αß interface, are four solvent-exposed 
calcium binding sites. The coordination of calcium at these sites and other 
numerous contacts between the ß-propeller and the Thigh domain suggests that 
the ß-propeller is structurally rigid 94.  
The remaining C terminus of the extracellular domain of the α subunit contains 
stalk-like structures of the Thigh and Calf-1 and Calf-2 domains.  These are 3 β-
sandwich domains. The Thigh region adopts an Ig-like structure, although it is 
significantly larger. The interface between the Thigh and ß-propeller is 
relatively large and elongated (about 700Å2) and is suggestive of possible 
interdomain movement. This movement may be rotation and may be mediated 
by the binding of calcium at the base of the ß-propeller 94.  
The two Calf domains share structural similarity. Both contain two antiparallel ß 
sheets, Calf-1 domains contain four ß strands and Calf-2 contains 5. Calf-2 also 
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contains the Arg860 residue that is the site of proteolytic cleavage that 
generates the heavy and light chains of αV. The interface between the Thigh and 
Calf-1 domain occupies approximately 200Å2. The base of the Thigh and the top 
of the Calf-1 domain that form the genu are rich in acidic residues that 
coordinate a calcium ion. This ion may stabilise these acidic residues when the 
integrin is in the open conformation 94.  
1.3.1.2 Beta Subunit 
The N-terminal 50 amino acids of the ß subunit are predicted to form a plexin-
semaphorin-integrin (PSI)-like domain. Despite being encoded at the N-terminus, 
structurally, this domain forms part of the ß subunit leg. The region is cysteine-
rich, 6 of which are common to other PSI domains. The first of the cysteines 
forms a long range disulphide bridge with the C terminal cysteine rich region of 
the ß subunit, which restrains the integrin in an inactive state 96.  
The highly conserved ßA domain, also known as the I-like domain, comprises a 
domain of approximately 240 residues (residues 100 – 340). The ßA domain 
adopts a Rossman fold and, aside from the presence of two extra loop regions, is 
identical to that observed in the integrin I-domain. It comprises a central ß sheet 
of 6 strands, surrounded by 8 α helices. This domain donates the majority of 
residues involved in ligand binding and contains two metal coordination sites 
that participate in ligand binding – the MIDAS (Metal Ion Dependent Adhesion 
Site) and LIMBS (Ligand Induced Metal Binding Site).  The MIDAS is formed by the 
side chains of residues Asp112, Ser121, Ser123 (DXSXS motif), Glu220 and 
Asp251. The MIDAS is located in a crevice at the top of the central ß strand. The 
LIMBS is defined by residues Asp158, Asn215, Asp217, Pro219 and Glu220. The 
Mn2+ ion coordinated by LIMBS does not directly contact the ligand, but ligand 
binding is reliant on the presence of the Mn2+ ion 94, 97.  
The Hybrid domain is formed from two stretches of linear sequence on either 
side of the ßA domain that fold into an Ig-like structure. The Hybrid and ßA 
domains form a relatively large, circular interface (approximately 650Å2) of 
mixed hydrophobic and hydrophilic nature. The numerous interactions between 
the Thigh and ßA domains suggest that interdomain movement is minimal 94.  
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Figure  1-5 Structural feature and conformational activation of αVβ3 integrin 
(A) Schematic representation of the domains comprising the α and β integrin subunits. (B) Bent 
(inactive) and extended (active) conformations of integrins as proposed by the switchblade model 
of integrin activation 98. 
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The Epidermal Growth Factor-like (EGF) domains (EGF1/2, EGF3 and EGF4) are 
contained in residues 340 to 700 of the ß subunit. Each domain contains 3 
disulphide bridges that are necessary for the integrin EGF structure. A fourth 
disulphide bridge links the domains. EGF1/2 is largely unstructured in the crystal 
structure, although the predicted sequence predicts a high degree of structural 
similarity with EGF3 and 4. These domains are one of 3 structural subtypes of 
EGF-like domain that occur in proteins. The EGF domains lie in the genu region 
and the lack of resolution may be a result of the movement in this area. EGF3 
and 4 are similar in structure and together form an extended rod-shaped unit. 
The interface between EGF3 and 4 is small (200Å2) and probably rigid due to 
extensive interdomain contacts, including a disulphide bridge, main chain 
hydrogen bonds and hydrophobic interactions. Antibodies that selectively 
recognise activated integrins have been shown to bind epitopes that map to 
these EGF domains 95. These ß subunit regions correspond to the α subunit stalk 
region and are considered important for signal transduction 99, 100.  
The very C-terminal region contains the ß tail domain (ßTD). The ßTD is 
comprised of a ß sheet of 4 antiparallel and parallel ß strands. Facing it is an α 
helix, that interacts hydrophobically with the ß sheet. The ßTD does not share 
any significant homology with other known domains and may be considered a 
new fold. This domain forms two weak hydrophobic interactions with the EGF 
domains, suggesting that this interface may be flexible 94.  
1.3.2 Ligand recognition by Integrins 
Binding of ligands by integrin is dependent on the presence of a particular motif 
within that ligand. The Arg-Gly-Asp (RGD) peptide was first discovered in 
fibronectin and is now widely recognised as the classical recognition sequence 
for most integrins 101. This sequence is found in a diverse range of receptors and 
integrin ligands. The presence of a small motif in a range of functionally diverse 
ligands creates an extensive system for recognition by cell adhesion molecules. 
Introduction of the RGD sequence to lysozyme and hirudin gave the proteins the 
ability to function in cell adhesion 102. 
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1.3.2.1 The Classical Recognition Sequence, ‘RGD’ 
The RGD tripeptide is the smallest unit that can be recognised and bound by 
integrins and in some cases is sufficient to mimic (when attached to a surface) 
or block (when in solution) the adhesive action of the natural ligand 103. The 
effect elicited by the RGD peptide is generally less than that mediated by its 
natural ligand. The sequence is specific and even conservative changes (such as 
Gly to Ala) significantly reduce the activity of the peptide. The conformation of 
the amino acid residues in the peptide is important for activity, with an RGD 
peptide containing D-arginine being inactive 101. Although the minimal unit 
necessary for activity is the RGD motif, there is a requirement for a further 
residue at the C-terminal end, to block the carboxyl group of Asp. The C 
terminal sequence affects the affinity and selectivity of the RGD peptide 
binding. Peptides with Gly, Trp or Phe residues C terminal to the RGD have 
higher binding affinities for the α5ß1 integrin, while the αVß3 and αVß5 integrins 
prefer Ser or Ala, and αIIBß3 requires a Tyr or Arg 104. The rigidity or flexibility 
of RGD containing loops has been linked in NMR studies to a narrow or wide 
range of recognition profile, respectively. Cyclisation of the RGD containing 
peptides increases interaction with vitronectin receptors, but not fibronectin 
receptors 105.  
Proteins containing RGD motifs and participating in cell adhesion include 
fibronectin, vitronectin, fibrinogen, von Willebrand factor, thrombospondin, 
laminin, entactin, tenascin, osteopontin, bone sialoprotein and under certain 
conditions collagens 106. Some proteins that do not naturally mediate cell 
attachment, such as Gamma II crystallin and Escherichia coli (E.coli) lambda 
receptor, are capable of binding integrins in vitro. This is most likely due to the 
recognition of the specific conformations of the RGD motif in these proteins by 
integrins (especially αVß3). The recognition of the RGD tripeptide is also 
exploited by pathogens to gain entry into the cell. Adenovirus penton protein, 
foot and mouth virus coat protein and Bordetella pertussis surface protein all 
contain RGD motifs capable of being bound by cell surface integrins.  The RGD 
site is evolutionarily conserved in other organisms and may mediate attachments 
in Drosophila and certain plants 101.  
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Recent interrogation of sequence databases revealed 7182 proteins containing 
RGD sequences. Of these 7182, 404 are membrane proteins, 120 of which have 
the RGD peptide located in their extracellular domain. These proteins contain a 
number of known cell adhesion proteins, in addition to 48 well-characterised 
receptors. In most cases the authors determined that the RGD motifs form or are 
predicted to lie in a loop structure similar to that observed in cell adhesion 
complexes. In addition, RGD motifs from receptors with known crystal structures 
were shown to assume a similar conformation, with the Arg and Asp residues 
pointing away from each other, to that observed in cell adhesion complexes. 
Receptors have not been considered as having cell adhesion properties before 
this study and the significance of these RGD sequences will need to be 
determined experimentally 102.  
While the RGD peptide is the smallest recognisable unit, the conformation in 
which the peptide is presented is essential for its function. The conformation of 
the peptide will influence binding by different integrins. α5ß1 preferred binding 
larger, RGD-containing fibronectin polypeptides, while αVß3 was more efficient 
at binding smaller RGD-containing fibronectin fragments 107. This could suggest 
that the presence of surrounding sequence will influence the peptide recognition 
and binding ability 104. Alternatively, while the RGD motif is the basic unit of 
recognition, binding specificity may also rely on the presence of synergistic 
sites.  The presence of synergistic sites has been suggested for ligands of 
integrins αIIbß3, α5ß1, αVß3 and αVß5 75, 108, 109.  
Insights into the binding of RGD containing ligands have been provided by the 
crystal structure of the extracellular domain of αVß3 integrin alone and in 
complex with a cyclic RGD-containing pentapeptide. The availability of both 
ligand-bound and ligand-free structures allows analysis of both the fundamental 
residues involved in the interaction and conformational changes that arise due to 
ligand binding 94, 98. 
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Figure  1-6 Binding of cyclic RGD containing peptide by αVβ3 
(A) Binding of the cyclic RGD containing peptide by αVβ3 involves residues from both subunits. 
(B)The conformation of the cyclic RGD containing peptide in complex with αVβ3.  
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Ligand binding is cation-dependent and mediated by residues from both the α 
and ß subunit. The Asp of the RGD sequence is coordinated by a divalent cation 
bound by the MIDAS on the α subunit. In I-containing α subunits the MIDAS is 
located in the I-domain and in non I-domain containing integrins there is a 
corresponding MIDAS on the ß subunit. In certain cases, the ß-propeller domain 
from the α-subunit also donates residues to bind the ligand. The ß subunit 
contains two sites capable of coordinating metal ions, the MIDAS and LIMBS, 
which participate in ligand binding. ADMIDAS (adjacent to MIDAS) coordinates 
either Ca2+ or Mn2+ in the presence and absence of ligand, while the LIMBS 
contains a Mn2+ when ligand is present, but not in the absence of ligand 98.  
The RGD peptide binds a shallow groove at the interface of the ß-propeller of 
the α subunit and the ßA domain of the ß subunit. The ArgRGD residue is bound by 
the ß-propeller groove. The ArgRGD guandinium group forms a bidentate salt 
bridge with Asp218 and another salt bridge with Asp150. These ß propeller 
residues are located at the base and rear of the groove, respectively. In this 
conformation, the majority of the upper ArgRGD sidechain is solvent-exposed, 
making it likely that the interaction is further stabilised by interactions with 
water molecules. The interaction with the ß subunit ßA domain is mediated 
primarily by the Asp carboxylate group. This group forms the centre of a network 
of polar interactions with the ßA residues and the MIDAS. One of the carboxylate 
oxygen atoms is coordinated by a Mn2+ ion at MIDAS, while the second hydrogen 
bonds with backbone amides of Tyr122 and Asn 215 and the Arg214 sidechain. 
The AspRGD residue is completely buried within its binding pocket, with the 
remainder of the chain forming hydrophobic contacts with the beta carbon of 
Asn215.  The central GlyRGD projects into the interface between the α and ß 
subunits. It interacts with the αV subunit, primarily via the carbonyl oxygen of 
Arg216. The main chain conformation of the RGD peptide in the structure is 
identical to that observed in the natural integrin ligand Echistatin 98 (Figure 1-6). 
The binding to the ßA domain is similar to that observed with the αA integrin-
ligand interaction. In both cases, an acidic residue contacts a metal ion at 
MIDAS. ßA differs from αA in that a ligand is required for divalent cation binding, 
however the αA domain can bind a metal ion in the presence or absence of 
ligand. This is explained by the conformation of the side chain of Glu220 in the 
unliganded ßA domain. Glu220 intrudes into the MIDAS, restricting cation binding 
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possibly through steric hindrance. The structure of the ligand-bound ßA domain 
shows a change in the conformation of the Glu220 sidechain, allowing access to 
the MIDAS for cations. The ßA domain also contains a second cation binding site 
termed LIMBS. At this site, the metal ion is coordinated by the other carboxylate 
oxygen of Glu220, the side chains of Asp158, Asn215 and Asp217, the carbonyl 
oxygens of Asp217 and Pro219. Although this site does not directly contact the 
ligand, it is required for metal ion coordination, as the coordination sphere is 
absent in the unliganded structure. Its most likely role is to stabilise the 
orientation of Glu220 and provide structural stability to the ligand binding region 
98 (Figure 1-6).  
Changes in the overall structure between the ligand-free and ligand-bound 
integrin are observed, despite the binding of only the small simple recognition 
sequence. At the tertiary level, there is a change in the conformation of some of 
the loops in the ßA domain. Quaternary changes are observed in the head region, 
with the ßA and ß-propeller domains coming closer together at the peptide-
binding site. The ß propeller is slightly rotated at the propeller-thigh interface, 
with a corresponding rotation observed from the ßA domain. These changes are 
analogous to the change observed with G proteins, where the ßA alters its 
orientation relative to the ß propeller. It is likely that this change is going to be 
more pronounced when the integrin is bound by one of the larger and 
structurally diverse natural ligands 98. 
1.3.2.2 Other Recognition Sequences 
Integrins also recognise sequences other than the RGD motif in their ligands. In 
certain cases, these recognition sequences are slight variations on the RGD 
motif. The Gly position of the RGD may be occupied by a number of residues or 
in certain cases by two residues and still be bound by integrins 101. A peptide 
containing the sequence NGR binds with low affinity to integrins, although the 
inverse RGD sequence, DGR, does not have any measurable integrin binding 
activity. This is interesting in the context of CD23, as it contains a DGR sequence 
and is known to interact with RGD-binding integrins. Whether the interaction is 
via this DGR sequence remains to be fully determined 67.  
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αIIbß3 also binds the sequence KQAGDV, an interaction that is blocked by RGD 
containing peptides and so presumably occurs at the same binding site. α4ß1 and 
α4ß7 recognise the LDV peptide 110. This motif is found in a splice variant of 
fibronectin. α4ß1 also recognises the IDA(PS) and REDV sequences in fibronectin. 
IDA could be regarded as a version of LDV and REDV as a version of RGD. α2ß1 
has been shown to recognise the DGEA motif, YGYYGDALR from laminin and 
FYFDLR from type IV collagen. The α1ß1 integrin recognises a motif composed of 
Arg and Asp residues on type I collagen. The αMß2 integrin recognises the 
sequence KRLDGS from fibrinogen and sequences containing L/IET in I-CAMs are 
recognised by ß2 integrins 101, 104.  
Despite the range of sequences recognised by integrins, in most cases, those 
alternative motifs described thus far all include an Asp, or the closely related, 
Glu residue. This requirement for the Asp may be due to its ability to coordinate 
metal ions essential for integrin-based ligand recognition. The group of snake 
proteins, the disintegrins, contain RGD motifs and can interact with integrins 111. 
In some cases the RGD sequence is replaced by KGD. The ADAM (a distintegrin 
and metalloproteinase) family of mammalian proteins is homologous to the 
disintegrins, although they do not contain the RGD motif. The recognition site 
determined for one ADAM, fertilin, was found to be TDE, which may be 
analogous to the disintegrin RGD 112, 113.   
The recognition of the RGD binding motif was fully determined by the solution of 
the structure of αVß3 bound to an RGD-containing pentapeptide. As such, full 
elucidation of the mechanism of recognition of these alternative motifs will rely 
on the future crystallisation of integrin-ligand complexes. 
1.3.2.3 Alternate Binding Sites 
In addition to the recognition of different sequences at the ‘RGD-recognition 
site’ of integrins, the existence of an additional, distinct ligand binding site on 
the αVβ3 and αVβ5 integrins has been suggested. These alternate binding sites 
have been suggested by the binding of ligands, such as tumstatin 114, HIV Tat 
protein 109 and entactin 115, to these integrins at RGD-independent sites. These 
studies have proposed either the existence of an additional distinct binding site 
or a synergistic ligand recognition site that cooperates with the RGD binding 
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site. Analysis of the binding of Type IV collagen indicates that this protein 
contains additional αVβ5 and αVβ3 binding sites 108. These sites, however, are 
recognised more efficiently when in the context of the intact protein (and 
potentially the RGD site), than as individual peptides. This may suggest a 
synergistic relationship or a requirement for a specific conformation during the 
binding of the non-RGD collagen-derived peptides. Similarly, studies with the 
HIV Tat protein have suggested the presence of a synergistic binding site in αVβ5 
109. A 9 residue basic peptide derived from Tat was shown to bind the αVβ5 
integrin in an RGD and divalent cation-independent fashion. This basic peptide 
was highly specific with respect to sequence and capable of mediating cell 
attachment. The authors postulate that, although Tat contains an RGD motif, it 
is not presented in a context that allows it to bind αVβ5. They suggest that the 
basic peptide binds a synergistic site on αVβ5 to mediate specific interactions. 
Studies on the binding of tumstatin-derived peptides to αVβ3 indicated that the 
protein contains an RGD-independent αVβ3 binding site, as the binding of the 
peptides was not inhibited by the presence of cyclic RGD peptides 114. Entactin 
was also shown to contain two distinct RGD-independent cell attachment 
peptides. Mutants of entactin lacking the RGD motif were still capable of 
mediating cell attachment, although identification of the integrin involved in 
binding still requires elucidation 115.  
1.3.3 Integrin Activation and Signalling 
Integrins are capable of transmitting signals bidirectionally across the 
membrane. They form a mechanical link between the cytoskeleton and the 
extracellular matrix and activate intracellular signalling pathways 116, 117. They 
are capable of transmitting signals from the ECM to the interior of the cell 
(‘outside-in’ signalling) and from the interior of the cell to the external 
environment (‘inside-out’ signalling) 88. Formation of mechanically stable 
integrin complexes is essential for the transduction of mechanical signals 
between the cell and ECM. Integrins are physically associated with the 
contractile cytoskeleton in the cytoplasm of cells and form transient interactions 
with ligands through their extracellular domains. Except for the β4 subunit, 
which is connected to intermediate filaments of the cytoskeleton, all of the 
cytoplasmic tails of integrins are linked to the actin-based microfilament system 
of the cell 118-120.  
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The transmission of a signal from a ligand-binding site, across the membrane and 
to the cytoskeleton (or vice versa), requires long-range conformational changes 
and cooperation between integrin domains. Many integrins are not constitutively 
active, but require activation prior to ligand binding and signalling. The signal 
for activation or inhibition may come from interactions between different 
integrins 95. The current model for integrin activation is based on the recently 
solved structure of the extracellular domains of the αVβ3 integrin 94, 97, 98. This 
model is referred to as the ‘Switchblade model’ and suggests the integrin 
changes between active and inactive forms by conformational rearrangement 
(Figure 1-5). The inactive form of the αVβ3 integrin has a bent shape, with the 
protein anchored in the membrane and the extracellular domains bent over to 
create a V-shape. The site of bending is the genu between the headpiece and 
stalk regions of the heterodimer. This structure was determined in the presence 
of Ca2+ ions, known to promote the inactive form of integrins. In addition, the 
lack of ligand or Mg2+ ions supports the interpretation that this is the inactive 
conformation of the integrin.  Structural analysis of integrins in the presence of 
ligand indicates an open extended conformation is the active structure. Thus the 
‘Switchblade’ model proposes that that activation of the integrin results in an 
extension of the headpiece away from the membrane, in a manner analogous to 
the opening of a switchblade knife. This conformational change makes the 
activation and functional binding residues accessible 94, 121.   
1.3.3.1 Inside-out signalling 
Inside-out signalling relates to the transmisson of signals from the interior of the 
cell to the ECM. For example, integrins on leukocytes and platelets will need to 
be activated by internal signals or agonists to bind their ligands. The current 
hypothesis is that the α subunit blocks the ß subunit contacts with the 
cytoskeleton when the integrin is in an inactive state. The activation of integrins 
by inside-out signalling is regulated by the movement apart of the areas of the α 
and β subunit domains in response to a stimulus 100, 122, 123. This is thought to 
supply the trigger for the upward switchblade movement of the extracellular 
headpiece, leading to activation of the integrin from within the cell. In addition 
to these changes in affinity, it has been suggested that changes in integrin 
avidity (clustering) affect signalling. Many studies report an increase in integrin 
activity and signalling due to receptor clustering. This would obviously lead to 
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improved efficiency of ligand binding, particularly in the case of multivalent 
ligands 95. It is difficult, however, to distinguish whether integrin clustering is 
the stimulus for, or the consequence of, an increase in ligand binding affinity. 
Despite this, changes in avidity are generally regarded as important for inside-
out signalling, not least because of the difficulties in direct quantitation of 
binding of soluble ligands that affect integrin affinity. The most likely situation 
of integrin activation will include a combination of changes in affinity and 
avidity, depending on the integrin and cell type of its expression 124.  
1.3.3.2 Outside-in signalling 
Integrin-mediated ‘outside-in’ signalling refers to the transduction of signals 
generated by ligand binding to the extracellular domains of integrins, across the 
membrane to activate intracellular signal pathways. The activation of integrins 
for ‘outside in’ signalling is also dependent on changes in integrin avidity, 
although avidity alone is not enough to stimulate complete outside-in signalling 
95.  Concurrent changes in affinity will also affect the ability of an integrin to 
participate in outside-in signalling. Using electron microscopy, Takagi and 
collegues showed that gross conformational changes occur when an inactive 
integrin (αVß3) is exposed to a high affinity ligand mimetic and Mn2+ ions. The 
inactive integrin opened in a switchblade-like manner, with an accompanying 
swinging out of the hybrid domain. The authors propose that integrin activation 
occurs in two stages. In the first stage, ligand or Mn2+ binding induces the 
opening of the inactive integrin and subsequent conformational changes in the 
integrin result in high affinity binding of the ligand 125. This suggests there are 
three activation states for the integrin- the closed conformation when the 
integrin is inactive, the extended conformation with a ‘closed’ headpiece due to 
ligand or Mn2+ binding and the high affinity state, where the integrin headpiece 
is open due to conformational changes and the ligand is bound. The 
susceptibility of individual integrins to activation will differ according to their 
ligand binding capabilities, requirements for divalent cations and biological 
function 126, 127.    
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1.3.3.3 Integrin cytoplasmic signalling cascades 
Outside-in signalling by integrins in response to binding of external ligands 
results in the activation of a number of signalling pathways within the cell, the 
ultimate consequence of which is a change in gene expression and behaviour of 
that cell depending on the nature of the particular stimulus. Integrin signalling 
controls a range of cellular functions including adhesion, cytokine production, 
cell growth and differentiation 128.  
The cytoplasmic tails of integrins are short and lack any inherent enzyme 
activity. Signal transduction from integrins is via a series of adaptor proteins, 
which link the integrin to the cytoskeleton, cytoplasmic kinases and 
transmembrane growth factor receptors. Integrins directly activate cytoplasmic 
kinase signalling pathways themselves and are also able to modulate the 
signalling pathways that arise from growth factor receptors. The major signalling 
pathways activated by integrins are summarised in Figure 1-7 90.  
1.3.3.3.1 Src-family kinases (SFKs) and Focal Adhesion Kinase (FAK) 
signalling by integrins 
Integrin-mediated signalling occurs predominantly through the activation of Src-
family kinases (SFK) and focal adhesion kinase (FAK) 128. FAK activation is most 
important in adhesion-based signalling mechanisms for integrins and controls the 
activation of a number of downstream pathways. FAK interacts with the β 
subunit cytoplasmic domains of integrins, either directly or via an interaction 
with the cytoskeletal proteins paxillin and talin. Activation results in the 
autophosphorylation of FAK on Tyr397 and acts as a scaffold for SFKs (Src and Fyn) 
in focal adhesions, leading to the phosphorylation of p130CAS and paxillin, 
recruitment of Crk-DOCK180n complex and activation of Rac. Active Rac can 
subsequently activate the NFκB transcription factors directly or lead to the PAK-
dependent activation of JNK (c-jun N-terminal kinase). Active Crk is also capable 
of activating C3G, leading to the Rap1/B-Raf/ERK (extracellular-regulated 
kinase) activation cascade. FAK can also directly or indirectly (via SFKs) activate 
the signalling molecule PI3K (phosphatidyl inositol-3-kinase), which in turn leads 
to the activation of the serine/threonine kinase Akt/PKB and GEF (guanine 
exchange factor) via the synthesis of phosphatidylinositol-3,4,5-triphosphate 
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(PtdIns(3,4,5,)P3). Cross talk between FAK and TLR signalling pathways (via 
MyD88) has also been shown to enhance of the activation of NFκB and 
transcription of NFκB-controlled genes, such as IL-6 129. 
1.3.3.3.2 Mitogen Activated Protein Kinase (MAPK) signalling by 
integrins 
Integrins can activate ERK via the GTPase-dependent Ras/Raf/MEK/ERK mitogen-
activated protein kinase (MAPK) pathway through a FAK dependent or 
independent mechanism 117. Integrin ligation can lead to the activation of SFKs 
or FAK, both of which lead to the activation of Shc, Grb2, and Sos and results in 
the phosphorylation of the Ras GTPase. Active Ras phosphorylates Raf, which 
activates MEK, which in turn activates ERK 130. The MAPK cascade which results 
in the activation of the ERK is a key regulator of a number of cellular processes. 
The effects of this pathway, activated by both adhesive and growth factor 
signals, are mediated by the dynamics of the magnitude and duration of ERK 
activation. Both FAK-dependent and Shc-dependent mechanisms of activating 
ERK are likely to be important during integrin mediated signalling. Shc, which 
activates rapidly, is most likey responsible for the initial high levels of ERK 
phosphorylation, while FAK, which is activated more slowly, may contribute to 
sustaining this ERK activation 128.  
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Figure  1-7 Cytoplasmic signalling cascades from integrins 
Integrin-mediated signalling can lead to the activation of a number of cytoplasmic signalling 
cascades that result in a change in gene expression. Integrin-mediated signalling can arise directly 
from the integrin itself or from the association between an integrin and growth factor receptor. 
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1.3.3.3.3 Nuclear Factor Kappa B (NFκB) signalling by integrins 
NFκB is the collective name given to the family of dimeric transcription factors 
(made up of combinations of the monomeric p50, p52 and p60 subunits) which 
control the transcription of a range of pro-inflammatory genes 131. The proteins 
are held in an inactive form in the cytoplasm by their association with the IκB 
(inhibitory κB) protein inhibitor. The targeted phosphorylation of IκB protein by 
the IκK (inhibitory κ kinase) and subsequent IκB degradation releases the active 
NFκB complex, which translocates to the nucleus and induces the transcription 
of target genes. NFκB activation has been implicated in many biological 
processes, including inflammation, apoptosis and cell proliferation. Integrin 
ligation leading to the production of cytokines, including TNF-α and IL-1, 
involves the activation of NFκB (p50:p65 dimer) via the activation of the Rac 
GTPase. FAK can either activate Rac via the Cas/Crk/Dock180 cascade or via 
PI3K and GEF 90.  
There is also evidence for cross-talk between FAK and MyD88 (myeloid 
differentiation factor 88) pathways. MyD88 is an adaptor protein that controls 
signalling from a number of Toll-like receptors (TLRs), which are a major group 
of surface receptors that activate NFκB and play an essential role in innate 
immune signalling and detection of pathogens (Figure 1-8). Signalling arising 
from different TLRs is either MyD88-dependent or MyD88-independent. MyD88 is 
associated with TLR cytoplasmic tails and activation leads to a signalling cascade 
involving TIRAP/Mal, IRAK and TRAF-6 signalling molecules, leading to NFκB 
activation 132.   
MyD88 and FAK are key adaptors involved in signalling downstream of TLR-2, 
TLR-4, and integrin α5β1, linking pathogen detection to the initiation of an 
inflammatory response. FAK activation leads to activation of the downstream 
components of the MyD88 signalling pathway and subsequent activation of MAPK 
and NFκB and synthesis of cytokines. The MyD88 and integrin pathways are 
interlinked, but the mechanism of this cross-talk is poorly understood at present 
129. The αMβ2 integrin was shown to signal using TLR pathway intermediates 
during the activation of NFκB in THP-1 cells. The αMβ2 integrin was shown to 
bind to IRAK and to activate the TRAF-6 and TAK signalling molecules. 
Interestingly, this αMβ2-mediated activation of NFκB was determined to be 
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MyD88-independent. The most recent study has identified a role for FAK in 
integrin-mediated activation of NFκB. FAK induced the activation of Etk (a 
member of the Tec family of kinases) and TIRAP/Mal (a TLR adaptor protein). 
FAK was shown to be associated with the Etk, MyD88, and TIRAP/Mal molecules 
in the cell 133.  
1.3.3.4 Integrin modulation of other receptors 
In addition to direct adhesion-based signalling, integrins modulate signalling 
from other receptors 116, 134, 135. Growth factors (GF) induce their activity through 
binding their cognate receptors on the surface of cells. In most cases, the 
interaction between integrin and growth factor receptor (GFR) is a synergistic 
one and leads to an enhancement of GFR signalling and an amplification of the 
response of the cell to the presence of the GF 116. The ability of integrins to 
activate ERK may be especially important when the concentrations of GF in the 
cell are low. Under these circumstances, the synergy between integrins and GFR 
leading to ERK activation will be essential for cell proliferation and 
differentiation. Activation of ERK in this case is usually via the 
Grb2/Sos/Ras/Raf/MEK/ERK pathway 136. Integrins can also modulate the GFR 
activity by influencing its localisation and/or internalisation and degradation 134.  
Integrin modulation of GFR activity has been described for a number of GFR 
including, basic fibroblast growth factor receptor (bFGFR) 137, vascular 
endothelial growth factor receptor (VEGFR) 138, platelet derived growth factor 
receptor (PDGFR) 139, insulin growth factor receptor (IGFR) 140, 141, and c-FMS (M-
CSF receptor) 142.  The β2 integrins also play an important role as part of the 
endotoxin signalling complex, which contains CD14, TLR-4 and β2 integrins 143.    
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Figure  1-8 Toll-like Receptor (TLR) signalling pathways 
TLR receptors are an evolutionarily conserved group of receptors with important roles in the innate immune sensing of pathogens. Signalling from TLR dimeric receptors 
may be depedent or independent of the MyD88 molecule. 
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1.3.4 CD23/Integrin Interactions  
1.3.4.1 CD23 interaction with beta-2 (CD18) Integrins. 
The ß2 integrins are exclusively expressed on leukocytes (and are often referred 
to as ‘the leukocyte intergrins’). They are heterodimeric αß integrins, formed by 
the association of one of 4 α chains (αD, αL, αM or αX) with the ß2 integrin. 
αMß2 and αXß2 bind a number of ligands, including CD54, fibrinogen, factor X, 
lipopolysaccharide (LPS), concanavalin A and zymosan 144. Integrins are proteins 
that play a critical role in cell adhesion and signalling across membranes. They 
control cell-cell and cell-extracellular matrix contacts and participate in 
signalling both from the cytoplasm to the exterior of the cell and vice versa. Cell 
adhesion is essential for cell migration, proliferation and differentiation.  Thus, 
integrins are crucial for correct cell development and function and are 
implicated in a number of pathologies 124. An absence of the ß2 integrin results 
in impairment of a variety of immune functions, including macrophage oxidative 
burst and phagocytosis and lymphocyte proliferation. The ß2 integrins control a 
number of leukocyte functions. The αMß2 and αXß2 integrins are responsible for 
regulation of functions in myeloid cells (aggregation, adhesion and spreading, 
phagocytosis and oxidative burst), while αLß2 predominates in lymphocytes 
(lymphocyte proliferation, T and B cell aggregation and cell killing) 145.   
CD23 interacts with the alpha chains of the leukocyte integrins αMß2 
(CD11b/CD18) and αXß2 (CD11c/CD18). Membrane-bound CD23 incorporated into 
liposomes was shown to interact with αXß2 and αMß2 expressed on the surface 
of monocytes. The interaction between CD23 and αMß2/αXß2 was determined to 
be cation-dependent and was inhibited by factor X, but not by the presence of 
fibrinogen. The interaction was reduced after tunicamycin treatment and 
increased in with the presence of calcium ions, supporting this hypothesis that 
this interaction between CD23 and these ß2 integrins is, at least in part, via 
carbohydrate moeties on αMß2 and αXß2. This suggests that the C-type lectin 
domain of CD23 is involved in this interaction. The lack of inhibition by 
fibrinogen also supports the fact that CD23 is unlikely to bind αMß2 or αXß2 at 
the RGD recognition site 74.  
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sCD23 was shown to bind αMß2 and αXß2 and induce production of the  pro-
inflammatory cytokines IL-1ß, IL-6 and TNFα.  This cytokine production was NOS 
dependent although, unlike the sCD21/sCD23 interaction that stimulates the 
inducible form of NOS, this interaction resulted in the activation of Type III 
constitutive NOS (cNOS). The induction of cNOS was due to increased catalytic 
activity due to an increase in intracellular calcium, as opposed to an 
upregulation of expression of cNOS. The nitric oxide produced by this interaction 
increased the levels of cGMP by the stimulation of guanylate cyclase, similar to 
the increase observed during sCD21/sCD23 interaction. cNOS stimulation is 
tightly regulated and declines rapidly after activation. This stimulation of cNOS, 
with a subsequent induction in pro-inflammatory cytokines supports the role for 
sCD23 in the early events of inflammatory responses 146.  
The exact signalling pathways of sCD23/ß2 integrin-stimulated cytokine 
production in monocytes are not well characterised. The pathway for the 
production of IL-1ß, a key pro-inflammatory cytokine, has been described. 
Expression of IL-1ß was controlled at the transcriptional level and the pathway 
shown to involve the activation of members of the mitogen-activated protein 
kinase (MAPK) family 84.  
1.3.4.2 CD23 interaction with alpha-V (αV) Integrins. 
The αV family of integrins includes the αV subunit in complex with one of β1, β3, 
β5, β6 or β8 subunits. All members of the aV group of integrins recognise and 
bind the RGD motif in substrates. Substrates for these integrins include 
vitronectin 147, fibronectin 148, osteopontin 149, fibrinogen 150, collagen 108, von 
Willebrand factor 151, tenascin 152 and thrombospondin 153. Apart from αVβ6, all 
the integrins bind vitronectin. Their ligand specificity is quite varied, although 
only αVβ1 and αVβ3 bind more than two different extracellular matrix proteins. 
However, the substrate preference for members of the αV integrin family is also 
influenced by the cell type of expression.  αV integrins are expressed on a range 
of cells, including smooth muscle cells, fibroblasts, keratinocytes and 
endothelial cells. Expression of different isoforms will also change during 
developmental stages. There is evidence for redundancy between the different 
αV isoforms. Many cells will express more than one receptor for a specific ECM 
protein (the best example is vitronectin). The expression of a number of 
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receptors for the same substrate may indicate a link to different pathways in the 
cell, culminating in different effector functions. αVβ3 and αVβ5 both bind 
vitronectin. FG carcinoma cells expressing αVβ5 bind but do not migrate on 
vitronectin, while cell variants expressing αVβ3 migrate on vitronectin. Addition 
of epidermal growth factor (EGF) to αVβ3-deficient FG carcinoma cells enabled 
these cells to spread on vitronectin in a PKC-mediated αVβ5-dependent manner 
154. This indicates that αV integrins are capable of acting independently or in 
cooperation with each other to fulfil specific functions 155.  
The lack of reagents has prevented the investigation of the cellular roles of 
some of the members of the αV family. The best described members in terms of 
function of the αV family are the αVβ3 and αVβ5 integrin isoforms. αVβ5 can 
only mediate spreading on vitronectin 156, 157. In contrast to this, αVβ3 can 
mediate spreading on several substrates such as vitronectin 158, fibronectin 148, 
fibrinogen 159, laminin 160, osteopontin 161 and collagen 108. The modified 
expression and function of αV integrins on many tumour cells has indicated a 
possible role for these proteins in tumour metastasis and progression. αV 
integrins are expressed on a variety of tumourogenic cell lines. αVβ3 expressed 
on melanoma cells mediates cell invasion 162. αV integrins have a role in 
formation of tumours in nude mice, demonstrating that they contribute to 
malignancy. Preliminary data indicate that αVβ1, αVβ6 and αVβ8 expression is 
altered during tumour progression. These isoforms show differing expression 
levels at specific stages of differentiation, restricted tissue expression and 
improve growth of transfected cells 118, 163. Elevated levels of αVβ3 are noted in 
infiltrating cells of breast carcinoma and renal cell carcinoma, while reduced 
levels are associated with angiosarcomas. In addition, αVβ3 expression is 
involved in tumour progression, with more advanced tumours containing higher 
levels of the protein 155, 164.  
CD23 interacts with the vitronectin receptor αVß3. αVβ3 is associated with 
CD47, a 50kDa multispan transmembrane protein, to form the αVβ3 integrin 
signalling complex.  This complex regulates leukocyte activation and mediates 
the phagocytosis of aging apoptotic leukocytes. This latter function is mediated 
by proinflammatory cytokines such as GM-CSF, TNF-α, IL-1 and IFN-γ 40. The 
highest level of expression of αVβ3 in vivo is the osteoclast, cells responsible for 
the resorption of bone. It is also expressed at lower levels in other cells, such as 
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megakaryocytes, kidney, smooth muscle and endothelium. Expression of αVβ3 is 
upregulated in certain malignancies and cultured cell lines. αVβ3 binds a wide 
range of RGD-containing ligands, particular bone proteins, and has a critical role 
in promoting cell migration and controlling the balance between cell 
proliferation and differentiation. αVβ3 also plays an important role in mediating 
heterotypic cell adhesion, analogous to the VCAM/α4β1 and ICAM-1/αMβ2 
interactions. αVβ3 plays a role in cytokine production through its interaction 
with CD23 155.  
Our laboratory has recently determined an interaction between CD23 and αVß5 
75. The interaction between sCD23 and αVß5 is implicated in prevention of 
apoptosis of pre-B cells and shown to be independent of the classical RGD 
recognition site on the integrin, as it was not inhibited by the presence of an 
RGDS peptide. The region of CD23 binding to αVß5 contains the motif RKC. 
Peptides containing this RKC motif were able to bind αVß5 and αVß3. This 
interaction motif may be relevant to the interaction of CD23 with its other 
receptors 75. This suggests an alternate interaction and recognition site for CD23 
and signifies an additional, undefined role for this multifunctional molecule.  
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1.4 Research Aims 
The interaction between CD23 and specific integrins is important in the 
production of cytokines by monocytic cells. We hypothesise that integrin-
mediated cytokine production occurs via an interaction distinct from that used 
in adhesion-based integrin interactions. We hypothesise that the interaction is 
highly specific and will be influenced by the individual characteristics of the 
integrin(s) involved. 
The specific aims of this project were as follows: 
1. To analyse the nature of interaction between commercially-available 
purified αVβ3 and αVβ5 integrins and CD23 in vitro.  
2. To analyse if the newly identified CD23 integrin receptor, αVβ5, plays a 
role in cytokine production by monocytic cells. 
3. To analyse the importance of integrin ligation to cytokine production by 
CD23-binding integrins. The effect of targeting different integrin 
heterodimers, different integrin subunits and different integrin epitopes 
will be investigated. 
4. To investigate the roles of the different CD23-binding integrins, namely 
αVβ3, αVβ5, αMβ2 and αXβ2, with respect to cytokine production and 
monocyte biology, and attempt to identify any potential hierarchy of 
importance that exists.  
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2 METHODS AND MATERIALS 
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2.1  Chemicals and Reagents 
All routine chemicals used were purchased from Sigma Chemical Co, Poole, UK 
unless otherwise stated. The details of purchase of speciality chemicals are 
indicated in the sections pertaining to their use.   
2.2 Antibodies, Oligonucleotides and Peptides 
Eighty-three (83) overlapping nonameric peptides derived from the 25kDa form 
of the human CD23a sequence were synthesised by Mimitopes, Victoria, 
Australia. The peptides were numbered according to their position in the original 
CD23 sequence 75 and were synthesised as biotinylated peptides (with a common 
SGSG linker and N-terminal biotin) and/or as unlabelled peptides (lacking the 
linker and N-terminal biotin moiety). The details and sequences of the 
unlabelled peptides used in this study are described in Table 2-1. The primary 
and secondary antibodies used for flow cytometry, immunofluorescence, 
Western analysis, neutralisation and stimulation assays are detailed in Table 2-2. 
Olignucleotides used in RT-PCR, PCR or EMSAs in this study are detailed in Table 
2.4. The details of commonly used buffers are in Table 2-3.  
In addition to the CD23-derived peptides, a peptide inhibitor of MyD88 signalling 
was purchased from Imgenex (CA, USA) and used in the analysis of TLR-2 
signalling. The details of this peptide and its control peptide are also detailed in 
Table 2-1.  
2.3 Cell lines and culture 
Dulbecco’s Modified Eagle’s Medium (DMEM), Trypan Blue, 200mM L-Glutamine 
and Penicillin-Streptomycin solution were purchased from Sigma Chemicals, 
Poole, UK. OptiMEM and RPMI-1640 media were from Invitrogen, Paisley, UK. 
Foetal Calf Serum (FCS) was supplied by TCS Cellworks, Buckingham, UK. 
Recombinant human cytokines M-CSF and GM-CSF were from Peprotech, UK.  
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Table  2-1 Table of Peptides used in this study 
 
 
PEPTIDE 
 
ABBREVIATION 
 
SEQUENCE 
 
SUPPLIER 
 
Peptide 8 
 
P8 
 
PEKWINFQR 
 
 
Peptide 9* 
 
P9 
 
KWINFQRKC 
 
 
Peptide 10* 
 
P10 
 
INFQRKCYY 
 
 
Peptide 11* 
 
P11 
 
FQRKCYYFG 
 
 
Peptide 12* 
 
P12 
 
RKCYYFGKG 
 
 
Peptide 13 
 
P13 
 
CYYFGKGTK 
 
 
Long Peptide* 
 
LP 
 
KWINFQRKCYYFGKG 
 
 
Peptide 58 
 
P58 
 
GSGRWNDAF 
 
 
 
 
 
 
 
 
 
 
 
 
Mimitopes, 
Victoria, 
Australia 
 
Anti-MyD88** 
  
DRQIKIWFQNRRMKWKKRDVLPGT 
 
 
Control anti-
MyD88 
  
DRQIKIWFQNRRMKWKK 
 
 
Imgenex, CA, 
USA 
 
* Common active RKC tripeptide motif is shown in bold 
** TIR homodimerisation sequence is in bold 
 
 
THP-1 165, U937166, Jurkat167 and IB4168 cell lines used in these analyses were 
from laboratory stocks. Purified primary human CD14+ monocytes from 
peripheral blood and bone marrow were purchased from Lonza, UK and cultured 
with or without 10ng/mL M-CSF (Peprotech) in RPMI-1640 medium supplemented 
with 10% (v/v) FCS, 2mM glutamine and 1% (v/v) penicillin/streptomycin. Unless 
otherwise stated, all stimulation experiments were conducted in OptiMEM 
lacking FCS but supplemented with 2mM glutamine and 1% (v/v) 
penicillin/streptomycin.  
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Table  2-2 Antibodies used in this study 
 
ANTIGEN* 
 
 
SOURCE 
 
 
CLONE 
 
ISOTYPE 
 
SUPPLIER 
 
CONJUGATE 
 
DILUTION OR 
WORKING 
CONCENTRATION 
 
USED IN 
Actin Rabbit polyconal - IgG1 Sigma Chemicals Co, Poole, UK  1/1000 WB 
Αv Mouse Monoclonal AMF7 IgG1 Millipore, MA, USA  1 µg/mL FACS, STIM 
Αv Mouse Monoclonal LM142 IgG1 Millipore, MA, USA  1 µg/mL STIM 
Αv Rabbit Polyclonal - IgG1 Millipore, MA, USA  1/500 WB 
αVβ3 Mouse Monoclonal 23C6 IgG1 Millipore, MA, USA  1 µg/mL FACS, STIM 
αVβ3 Mouse Monoclonal LM609 IgG1 Millipore, MA, USA  1 µg/mL FACS, STIM 
αVβ5 Mouse Monoclonal P1F6 IgG1 Millipore, MA, USA  1 µg/mL FACS, STIM 
αVβ5 Mouse Monoclonal 15F11 IgG2a Millipore, MA, USA  1 µg/mL FACS, STIM 
αVβ6 Mouse Monoclonal 10D5 IgG2a Millipore, MA, USA  1 µg/mL FACS 
β1 Mouse Monoclonal 47BR IgG1 Autogen Bioclear, Buckinghamshire, 
UK 
 1/500 WB 
β2 Mouse Monoclonal PAH9 IgG3 Millipore, MA, USA  1 µg/mL FACS, STIM 
β2 Mouse Monoclonal MEM48 IgG1 Millipore, MA, USA  1 µg/mL FACS,STIM 
αMβ2 Mouse Monoclonal 44 IgG1 Millipore, MA, USA  1 µg/mL FACS, STIM 
αMβ2 Mouse Monoclonal ICO-GMI IgG2a Millipore, MA, USA  1 µg/mL FACS, STIM 
αXβ2 Mouse Monoclonal 3.9 IgG1 Millipore, MA, USA  1 µg/mL FACS,STIM 
αXβ2 Mouse Monoclonal HC1/1 IgG1 Millipore, MA, USA  1 µg/mL FACS, STIM 
Phospho-p44/42 MAP 
kinase(Thr202/Tyr204) 
Rabbit polyclonal  - Cell Signalling Technologies, MA, USA  1/1000 WB 
p44/42 MAP kinase Rabbit polyclonal  - Cell Signalling Technologies, MA, USA  1/1000 WB 
Phospho-Beta3 
(Tyr785) 
Rabbit polyclonal  - Millipore, MA, USA  1/1000 WB 
Phospho-Beta3 
(Tyr773) 
Rabbit polyclonal  - Millipore, MA, USA  1/1000 WB 
CD1a Mouse Monoclonal NA1/34 IgG2a Abcam, Cambridge, UK PE 1 µg/mL FACS, IFA 
CD14 Mouse Monoclonal  IgG2a Millipore, MA, USA FITC 1 µg/mL FACS,IFA 
CD23 Mouse Monoclonal  IgG3 Autogen Bioclear  1 µg/mL FACS 
CD25 Mouse Monoclonal ACT-1 IgG1 DAKO, Glostrup, Denmark  1 µg/mL FACS 
CD86 Mouse monoclonal B-T7 IgG1 Diaclone, Besancon,France  1 µg/mL FACS 
HLA-DR Mouse Monoclonal B-F1 IgG1 Abcam, Cambridge, UK Biotin 1 µg/mL FACS,IFA 
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Table 2.2  contiuned. 
 
ANTIGEN* 
 
 
SOURCE 
 
 
CLONE 
 
ISOTYPE 
 
SUPPLIER 
 
CONJUGATE 
 
DILUTION OR 
WORKING 
CONCENTRATION 
 
USED IN 
CCR5 Mouse Monoclonal  IgG1 R&D Systems, Abingdon, UK  1 µg/mL FACS 
cFMS Rabbit polyclonal  - Santa Cruz Biotechnology, CA, USA  1/1000 WB, NEUT 
TLR2 Mouse monoclonal TL2.1 IgG2a Santa Cruz Biotechnology, CA, USA  1/500 WB, NEUT 
IRAK-1 Rabbit polyclonal H-273 - Santa Cruz Biotechnology, CA, USA  1/500 WB,IFA 
TRAF-6 Mouse monoclonal D-10 IgG1 Santa Cruz Biotechnology, CA, USA  1/500 WB,IFA 
p65 Rabbit polyclonal  - Cell Signalling Technologies, MA, USA  1/500 WB,IFA,EMSA 
IFN-γ receptor subunit 
1 
Mouse monoclonal 92101 IgG1 R&D Systems, Abingdon, UK  1/500 WB,IFA,NEUT 
IgG1 Mouse isotype 
control 
 - Sigma Chemicals Co, Poole, UK  1/1000 FACS,STIM 
IgG2a Mouse isotype 
control 
 - Sigma Chemicals Co, Poole, UK  1/1000 FACS,STIM 
IgG3 Mouse isotype 
control 
 - Sigma Chemicals Co, Poole, UK  1/1000 FACS,STIM 
Streptavidin-HRP   - BD Bioscience, Oxford, UK. HRP 1/1000 WB 
Anti-mouse IgG HRP   - Sigma Chemicals Co, Poole, UK HRP 1/1000 WB 
Anti-rabbit IgG HRP   - Sigma Chemicals Co, Poole, UK HRP 1/1000 WB 
Secondary PE   - BD Bioscience, Oxford, UK. PE 1/1000 FACS,IFA 
Secondary FITC   - BD Bioscience, Oxford, UK. FITC 1/1000 FACS,IFA 
 
*All antibodies are against human antigens unless otherwise stated. Abbreviations used: FITC-fluorescein isothyanate; PE-phycoerythrin; WB-Western Blotting; FACS – 
flow cytometry; IFA-immunofluorescence assay; STIM-stimulation assays, NEUT-neutralisation assays, EMSA-electromobility shift assays 
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2.4 Flow cytometry 
Expression of surface markers on cells and cell lines was measured by indirect 
immunofluorescent staining (flow cytometry). Cells were harvested by 
centrifugation and washed twice with ice-cold phosphate-buffered saline (PBS). 
100 µL of cell suspension in ice-cold PBS (5x106 cells/mL) was incubated with 
primary antibody and isotype-matched controls (Table 2-2) or biotinylated CD23-
derived peptides and controls (Table 2-1) for 30 – 60 mins at 40C. The cells were 
washed twice with ice-cold PBS and incubated with secondary antibody (for 
unlabelled primary antibodies) or streptavidin (for biotinylated primary 
antibodies and CD23-derived peptides) conjugated to either a FITC or PE 
fluorescent label. After 30 – 60 mins incubation at 40C, cells were washed twice 
with ice-cold PBS and resuspended in PBS/formaldehyde for flow cytometry 
using the Becton Dickinson FACScan machine and CellQuest software (BD 
Bioscience, NJ, USA).  
2.5 Biotinylation of Antibodies and Proteins 
Antibodies and CD23 were biotinylated using N-hydroxysuccinimidobiotin (NHS-
Biotin) treatment. NHS-biotin was purchased from Sigma Chemicals Co, Poole, 
UK. CD23 (0.1mg/mL) or antibodies (1mg/mL) were incubated with 1mg/mL 
NHS-Biotin/DMSO on a rotator overnight at 40C. Uncongujated biotin was 
removed by dialysis against PBS. 
2.6 Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE), Western Blotting 
and chemiluminescent based detection of 
proteins 
Western analysis and chemiluminescence-based immunodetection was used to 
detect the presence of specific proteins. Discontinuous SDS-PAGE using the 
Invitrogen NuPage system was conducted according to the manufacturer’s 
instructions (Invitrogen, Paisley, UK). Buffers used are described in Table 2-3. 
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Cells (1 x 106) in OptiMEM were stimulated with integrin-specific antibodies, 
CD23, CD23-derived peptides, LPS or Zymosan at 37 ºC at concentrations and 
time periods indicated in figure legends. Cells were harvested by centrifugation, 
lysed in radio immunoprecipitation assay (RIPA) buffer (50mM Tris-HCl pH7.4, 
150mM NaCl, 1mM EGTA, 1mM Na3VO4, 1% (w/v) NP40, 1mM Na deoxycholate, 
1mM PMSF and 2µg/mL Leupeptin) and the lysate cleared by centrifugation at 
13,000 x g for 15 min. Protein concentrations were measured by Bradford Assay 
(BioRad Laboratories Ltd, Hampstead, UK), using BSA as a standard. Equal 
quantities of total protein (20-40µg) were loaded per lane and resolved on a 4-
12% NuPAGE Novex Bis-Tris gradient gels (Invitrogen, Paisley, UK) according to 
manufacturer’s instructions (based on the standard SDS-PAGE method 169).  
Proteins on the gel were transferred to nitrocellulose (Amersham, 
Buckinghamshire, UK) and non-specific sites on the membrane blocked for 1 h in 
5% (w/v) bovine serum albumin (BSA) in Tris-buffered Saline with Tween-20 
(TBST).  Proteins on the membrane were detected by incubation overnight at 4ºC 
with specific primary antibodies (1/200 – 1/1000 dilution in TBST with 5% (w/v) 
BSA). Membranes were washed extensively in TBST and incubated with 
secondary antibodies for 1 h (1/10000 dilution in TBST with 5% (w/v) BSA) 
conjugated to HRP. The chemiluminescent signal was detected by exposure of 
the membrane to Kodak MXB film, after a 5min incubation period with the 
SuperSignal Pico Western Chemiluminescence Substrate (Pierce, Rockford, USA). 
The membrane was subsequently stripped and total protein in each lane 
quantified (to standardise any signals for loading inaccuracies) using matched 
primary and secondary antibodies to actin according to the above mentioned 
procedure. Bands were recorded and quantified by densitometry using the 
ImageJ program. 
2.7 Cell Migration Assays  
The migration of cell lines in response to conditioned media from integrin-
stimulated THP-1 cells was assessed using disposable transwell plates (Corning 
NY, USA). The plates consisted of a polycarbonate membrane insert, with a pore 
size of 5µm, separating the upper and lower chambers. Cells were washed twice 
and resuspended in OptiMEM (Invitrogen, Paisley, UK). 5x105 cells were placed in 
the upper chamber and 500uL of cleared supernatant (undiluted or diluted as 
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stated in figure legends) from stimulated THP-1 cells was placed in the lower 
chamber.  The plates were incubated at 370C in 5% CO2 for 3 hours, after which, 
cells that had migrated to the lower chamber were harvested by centrifugation, 
washed in PBS and resuspended in equal volumes of PBS/formaldehyde. 
Unstained total cell counts were collected by flow cytometry over a defined 
time period (30-60 sec). The effect of proteins on migration across the 
membrane was tested by coating the polycarbonate membrane with FCS, 
vitronectin (VN), fibronectin (FN), fibrinogen (FBGN) or BSA (control) for 1 hour 
at 370C or overnight at 40C prior to setting up the migration experiments. All 
these coating proteins were purchased from Sigma, Poole, UK. 
Table  2-3 Composition of buffers in routine use 
 
BUFFERS 
 
ABBREVIATION 
 
COMPOSTION 
 
Phosphate-buffered 
saline 
 
 
PBS 
 
13mM NaCl, 27mM KCl, 4.3mM 
Na2HPO4, 1.4mM KH2PO4, pH 7.2 
 
Tris-buffered saline 
 
TBS 
 
50mM Tris-HCl pH 7.4, 150mM 
NaCl  
 
 
Tris-buffer saline with 
Tween-20 
 
TBST 
 
50mM Tris-HCl pH 7.4, 150mM 
NaCl, 0.1% w/v Tween20, 
 
 
Tris-Acetate-EDTA 
buffer 
 
TAE 
 
40mM Tris-Acetate pH 8.5, 2mM 
Na2EDTA  
 
 
Tris-Borate-EDTA buffer 
 
TBE 
 
45mM Tris-Borate pH 8.3, 1mM 
EDTA 
 
 
Western transfer buffer 
  
25mM Tris, 192mM Glycine , 20% 
v/v methanol 
 
 
Nitrocellulose stripping 
buffer 
  
62.5 mM Tris HCl pH 6.7, 2% w/v 
SDS, 100mM β-mercaptoethanol 
 
 
NuPAGE MOPS buffer 
 
MOPS 
 
Invitrogen proprietry information 
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2.8 Cell stimulation and Analysis of Cytokine 
Production  
The antibodies used for cell stimulation are indicated in the figure legends and 
described fully in Table 2-2. DerCD23 62 was a kind gift of Dr. Jim McDonnell 
(Oxford, UK). Bacterial LPS, dibutryl cyclic AMP (db-cAMP) and yeast zymosan A 
were purchased from Sigma, Poole, Greiss reagent was purchased from Promega, 
WI, USA and the nitroblue tetrazolium assay (NBT) was from Sigma Chemicals Co, 
Poole.  
Cells were stimulated with antibodies against specific integrins (0.5µg/mL – 
10µg/mL), bacterial lipopolysaccharide (LPS) (1ng/mL – 1µg/mL), zymosan 
(10ng/mL – 20ug/mL), derCD23 (0.1µg/mL – 1µg/mL), CD23-derived peptides 
(0.5µg/mL – 20µg/mL), either alone or in conjunction with cytokines/growth 
factors (M-CSF at 5ng/mL and GM-CSF at 1ng/mL). After incubation 370C for 24 
to 72 hours, supernatants were collected, cleared by centrifugation and stored 
at -200C until analysis.   
Cytokines in cell supernatants were detected using sandwich ELISA assays and 
Cytokine protein array techniques (Biosource, UK). The cytokine arrays Human 
Cartesian Array Set II, and ELISAs for detection of IL-8, IL-12, IL-4, VEGF, 
RANTES, and MIP-1β were from Biosource, Invitrogen, Paisley, UK. ELISA kits for 
TNF-α detection were from R&D Systems and those for detection of IL-10 and 
IFN-γ were from Peprotech. All cytokine protein arrays and ELISAs were 
performed as per manufacturer’s instructions.   
2.9 Analysis of mechanisms of cell signalling and 
cytokine production 
The activation of MAPK signalling pathways was analysed by Western blotting 
over time and in response to different stimuli, as indicated in figure legends. 
The importance of ERK phosphorylation to cytokine production was analysed by 
ELISA (enzyme-linked immunosorbent assay) after incubation with the specific 
MEK inhibitor, U0126.  The MEK inhibitor U0126 was purchased from Sigma, 
Poole, UK. 
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2.10 Differentiation of monocytes 
THP-1 cells or CD14+ primary human monocytes were grown in OptiMEM 
supplemented with M-CSF (5ng/mL), GM-CSF (2ng/mL) or db-cAMP (100µM) for 4 
days. The effect of these differentiating agents on the cytokine production and 
integrin expression profile was determined by ELISA and flow cytometry, 
respectively. Morphological changes observed in THP-1 cells treated with 
antibodies and M-CSF (5ng/mL) were recorded by phase contrast microscopy 
using the Zeiss Axiovert 135 microscope. M-CSF and GM-CSF were from 
Peprotech and dibutryl cyclic AMP (db-cAMP) was purchased from Sigma 
Chemicals (Poole, UK). 
2.11 RNA extraction and Reverse Transcription-
Polymerase Chain Reaction (RT-PCR)  
Total RNA was extracted using the Trizol reagent (Invitrogen, Paisley, UK) 
according to the manufacturer’s instructions. Briefly, 106-107 cells were 
harvested and resuspended in 1mL Trizol/107 cells. Chloroform (0.2mL/1mL 
Trizol) was added and the sample shaken vigorously for 15 seconds by hand. 
Phase separation was achieved by centrifugation at 12 000 x g at 40C for 15 min 
and the colourless aqueous phase collected and RNA precipitated by addition of 
isopropanol (0.5mL/1mL Trizol) for 10 min at room temperature, followed by 
centrifugation at 12 000 x g at 40C for 10 min. The RNA pellet was washed with 
75% (v/v) ethanol (1mL/1mL Trizol), air-dried and resuspended in 50µl of 
nuclease free water (Sigma, Poole, UK). RNA concentration and purity were 
determined spectrophotometrically by absorbance at 260nm and 280nm.  
Table  2-4 Table of Primers for RT-PCR and PCR 
 
TARGET 
 
SUPPLIER 
 
AMPLICON SIZE (BP) 
CXCL8 
 
R&D Systems 158 
GAPDH 
 
R&D Systems 576 
M-CSF 
 
R&D Systems 464 
IFN-γ 
 
R&D Systems 453 
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Total RNA extracted was used for RT-PCR reactions. First strand cDNA synthesis 
was performed at 37 ºC for 1 hour using the M-MLV reverse transcriptase enzyme 
and random primers (Promega, Southampton, UK) according to the 
manufacturer’s instructions. Subsequent PCR reactions were performed using 
Taq polymerase (Promega, Southampton, UK) and the transcript specific primers 
(Table 2.4) and cycling parameters described below.  
Initial denaturation 94 ºC / 2min 1 cycle 
Denaturation 94 ºC / 45 sec 
Annealing 55 ºC / 45 sec 
Extension 72 ºC / 45 sec 
 
30 cycles 
 
Final extension 72ºC / 5 min 1 cycle 
Hold 4 ºC / hold  
 
 
2.12 Indirect Immunofluorescence Assay (IFA) and 
Confocal Microscopy 
Primary and secondary antibodies used in IFA are described in Table 2.2. The 
DAPI nuclear stain (4',6-diamidino-2-phenylindole) was from Sigma, Poole, UK. 
Stimulated cells were prepared for confocal microscopy using the 
acetone/methanol method. Subsequent to stimulation as indicated in figure 
legends, cells (1 x 106/mL) were washed in PBS and 50µL spread on multiwell 
microscope slide. Cells were fixed with ice-cold acetone/methanol (1:1) solution 
for 5min and air dried. Cells were permeablised with 0.02% (w/v) Triton-
X100/PBS solution for 30min at room temperature and blocked with 3% (w/v) 
BSA in PBS for 15min, before incubation with primary antibody (1/50 dilution in 
3% (w/v) BSA in PBS) for 30 - 60 min at 370C. Cells were washed with 0.1% (w/v) 
BSA/PBS and incubated for 30 – 60 min at 370C with the appropriate secondary 
antibody conjugated to a fluorescent label (FITC, Cy5 or PE). Cells were washed 
with 0.1% (w/v) BSA/PBS, nuclei stained with DAPI solution (1ug/mL), and the 
slides air-dried and mounted in Citifluor before analysis using the Zeiss LSM 510 
confocal microscope.   
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2.13 Electrophoretic Mobility Shift Assays (EMSA) 
The activation of NFκβ transcription factors was performed using the 
radioactively labelled NFκβ consensus oligonucleotide (Santa Cruz 
Biotechnology, CA, USA) in EMSA reactions. The [γ-32P] ATP was purchased from 
Perkin-Elmer (MA, USA) and polynucleotide kinase oligonucleotide end labelling 
kit was from Promega. The antibodies used are described in Table 2-2. 
Nuclear extracts were prepared from 1x107 cells stimulated with agents as 
indicated in figure legends. Cells were collected by centrifugation and 
resuspended on ice in Sucrose Buffer with NP-40 (0.32M sucrose, 10mM Tris-HCl, 
pH 8.0, 3mM CaCl2, 2mM MgOAc, 0.1 mM EDTA, 0.5% (w/v) NP-40, 1mM DTT, 
0.5mM PMSF). Nuclei were harvested by centrifugation at 500 x g at 40C for 5 
min. The nuclear pellet washed with Sucrose Buffer without NP-40 (0.32M 
sucrose, 10mM Tris-HCl, pH 8.0, 3mM CaCl2, 2mM MgOAc, 0.1 mM EDTA, 1mM 
DTT, 0.5mM PMSF), collected by centrifugation at 500 x g at 40C for 5 min and 
resuspended in Low Salt Buffer (20mM HEPES-KOH pH 7.9, 1.5 mM MgCl2, 20 mM 
KCl, 0.2 mM EDTA, 25% (v/v) glycerol, 0.5 mM DTT, 0.5 mM PMSF). An equal 
volume of High Salt Buffer (20mM HEPES-KOH pH 7.9, 1.5 mM MgCl2, 800 mM KCl, 
0.2 mM EDTA, 25% (v/v) glycerol, 1% (w/v) NP-40, 0.5 mM DTT, 0.5 mM PMSF) 
was added in small aliquots and the samples incubated on a rotary shaker at 40C 
for 45 min. Samples were cleared by centrifugation at 14 000 x g at 40C for 15 
min and the protein content of the resultant supernatant containing the nuclear 
fraction quantitated by Bradford’s assay prior to use in EMSA assays.    
Olginucleotides were labelled with [γ-32P] ATP using the polynucleotide kinase 
oligonucleotide end labelling kit according to manufacturer’s instructions. The 
labelled oligonucleotides were purified by ethanol precipitation. 1ng of 
radioactively labelled (“hot”) oligonucleotide was incubated with 10 µg of 
nuclear extracts for 30 mins at room temperature, prior to resolution on a 5% 
polyacrylamide gel in 0.5 x TBE. The gel was dried and exposed to X-ray film at   
-800C for various lengths of time (overnight-2 weeks) until an acceptable signal 
was obtained. Specificity of reactions was confirmed by addition of 2ng of 
competing unlabelled NFkappaB consensus oligonucleotide (“cold” oligo) and the 
inclusion of 1µg of antibodies to specific NFκβ signalling proteins (supershift). 
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2.14 Surface Plasmon Resonance (SPR) analysis 
using the BIACORE System 
Interactions between CD23-derived peptides and αVβ3 and αVβ5 integrins were 
performed at 250C using the automated Biacore 2000 machine (Biacore AB). The 
integrins were immobilised at approximately 4000 response units on a C1 chip 
using amine coupling chemistry. An underivatised reference cell was employed 
as a control surface. CD23-derived peptides in HBS-EP buffer (0.01 M HEPES-KOH 
pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% (v/v) Surfactant P20) were injected 
over the test and control chip surfaces at a flow rate of 40µL.min-1 and allowed 
a 3min association phase followed by a 6 min dissociation phase. The sensor 
surfaces were regenerated to baseline by injection of 0.2M glycine-HCL, pH2.5, 
where necessary. In all experiments, peptides bound exclusively to the test cell, 
there was no non-specific binding to the control reference cell and regeneration 
of a stable baseline was readily achieved. Data collected was standarised using 
control and blank injections prior to kinetic analysis, according to standard 
double referencing data subtraction methods 170. All kinetic analysis was 
performed using BIAevaluation 3.0.2 software (Biacore AB). 
2.15 Ellman’s Assay for free Sulphydryl groups in 
CD23-derived peptides 
CD23 derived peptides contain a single cysteine, so the moles of total sulphydryl 
(SH) can be determined from the peptide concentration (i.e. equivalent to the 
moles of peptide contained in the sample). The proportion of this total 
sulphydryl (SH) existing as free SH was determined by reaction with Ellman’s 
Reagent (5,5'-Dithio-bis 2-nitrobenzoic acid/DTNB) 171. DNTB was purchased from 
Sigma Chemicals Co, Poole, UK. 50µL of CD23-derived peptides were incubated 
with 200µL of DNTB for 30mins and the absorbance at 415nm recorded. The 
moles of free SH were calculated and the data represented as a percentage of 
total SH.  
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3 ANALYSIS OF THE CD23-αV INTEGRIN 
INTERACTION 
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3.1 INTRODUCTION 
3.1.1 The Classical Recognition Sequence ‘RGD’ 
Binding of ligands by integrins is dependent on the presence of a particular motif 
within that ligand. The Arg-Gly-Asp (RGD) peptide was first discovered in 
fibronectin and is now widely recognised as the classical recognition sequence 
for most integrins 101. This sequence is found in a diverse range of receptors and 
integrin ligands. The presence of a small motif in a range of functionally diverse 
ligands creates an extensive system for recognition by cell adhesion molecules 
102.  
3.1.2 Integrin ligand recognition 
Insights into the binding of RGD-containing ligands have been provided by the 
crystal structure of the extracellular domain αVß3 integrin alone 94 and in 
complex with a cyclic RGD-containing peptide 98. The availability of both ligand-
bound and ligand-free structures allows analysis of both the fundamental 
residues involved in the interaction and conformational changes that arise due to 
ligand binding. Ligand binding is cation-dependent and mediated by residues 
from both the α and ß subunit of the integrin heterodimer (Figure 1.6). The RGD 
peptide binds a shallow groove at the interface of the ß-propeller of the α 
subunit and the ßA domain of the ß subunit. The central GlyRGD projects into the 
interface between the α and ß subunits. It forms hydrophobic interactions with 
the αV subunit, primarily via the carbonyl oxygen of Arg216. The main chain 
conformation of the RGD peptide in the structure is identical to that observed in 
the natural integrin ligand Echistatin 98. 
In addition to the recognition of different sequences at this ‘RGD-recognition 
site’ of integrins, the existence of an additional, distinct ligand binding site, for 
ligands such as tumstatin, HIV Tat protein and entactin, on the αVβ3 and αVβ5 
integrins has been suggested. These studies have proposed either the existence 
of an additional distinct binding site or a synergistic ligand recognition site that 
cooperates with the RGD binding site.  
 75 
3.1.3 CD23-integrin interactions 
CD23 exists in both membrane-bound and soluble forms. Soluble CD23 binds four 
members of the integrin superfamily of proteins, in addition to its ligands CD21 
and IgE. CD23 has been shown to bind the αMß2 (CD11b/CD18), αXß2 
(CD11c/CD18) 83 and αVβ340 integrins on monocytic cells. Our laboratory has 
recently identified αVβ5 as a new integrin ligand for CD23 75. The interaction 
between CD23 and these integrins on monocytes is functionally important in the 
production of pro-inflammatory cytokines, including IL-1ß, IL-6 and TNFα40, 41, 83, 
but the site of interaction between CD23 and these integrins remains to be fully 
elucidated.  
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3.2  RESULTS 
3.2.1 Macrophage cell lines express integrin receptors for 
CD23 
CD23 interacts with four members of the integrin family of receptors – two 
members of the β2 family (αMβ2 and αXβ2) and two members of the αV family 
(αVβ3 and αVβ5) 40, 75, 172. The expression of these integrins on the surface of 
model cell lines, THP-1 and U937, was determined by flow cytometry (Figure 3-
1). The antibody staining for individual integrins is shown as black lines with the 
isotype matched controls shown in grey shading.  
Both THP-1 and U937 cell lines showed high levels of surface expression of αVβ3, 
αVβ5 and αXβ2 integrins, shown by an increase in staining compared to the 
isotype control staining. Of these integrins, the αVβ3 and αVβ5 heterodimers 
were expressed at higher levels on the surface of cells than the αXβ2 
heterodimer. Both THP-1 and U937 expressed only low levels of the αMβ2 
integrin heterodimer. Overall, there was no major difference in the levels or 
relative ratios of expression of different integrin isoforms between the two cell 
lines, THP-1 and U937. 
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Figure  3-1 Expression of CD23 binding integrins on monocytic cell lines 
Surface expression of CD23-binding integrins on U937 (A) and THP-1 (B) cell lines was 
determined by flow cytometry. Cells were incubated with antibodies against specific integrins, as 
indicated in the right hand corner of the plots. Primary antibody binding was detected using 
secondary antibody conjugated to PE. The binding of isotype matched controls is shown as grey 
shading and the integrin staining shown as a bold black line.  
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3.2.2 Identification of the recognition sequence in CD23 
for αV integrins 
The classical sequence recognised and bound by integrins is the RGD motif. This 
RGD (or a closely related sequence) is found in most integrin ligands. CD23 has 
been shown to bind integrins, but it does not contain a classical RGD motif. CD23 
does, however, contain a DGR motif (inverted RGD motif) near the C terminus 
(Figure 1-1). There has been much debate as to whether this DGR motif is 
functionally equivalent to an RGD motif and is the site of integrin recognition of 
CD23 61, 67, 173.  
In order to define the integrin binding motif on CD23, we generated a library of 
83 overlapping nonameric peptides derived from residues 131-321 of the 25kDa 
soluble CD23 sequence. The peptides are numbered sequentially as they occur in 
the CD23 sequence (starting with P1 from residue 131) and included an SGSG 
linker and an N-terminal biotin label 75. The biotinylated CD23-derived peptides 
were assessed, for their ability to bind to the surface of SMS-SB cells by flow 
cytometry (Figure 3-2). SMS-SB cells express the αVβ5 integrin as the only CD23 
receptor 174. The binding of CD23-derived peptides was detected using 
streptavidin-conjugated PE, which was used to detect the biotin label on the 
peptides. Figure 3-2 shows the mean fluorescence values for the binding of the 
83 biotinylated peptides to the surface of SMS-SB cells.  
A peak in binding was observed for four peptides, named P9 - P12, which 
corresponded to residues Lys166 to Gly180 in the soluble CD23 sequence. 
Interrogation of the sequence of the CD23-derived peptides identified a common 
RKC motif in these peptides (Figure 3-3). A low level of binding was observed 
with peptides P60 - P63. These peptides (P60-P63) all contain a common 
sequence, which includes a RK dipeptide. This is similar to the RK dipeptide in 
the RKC containing CD23 peptides and may account for the low levels of binding. 
Peptides P78 - P80, which contain the DGR motif, did not bind to SMS-SB cells.  
The preliminary screening for binding was conducted using SMS-SB cells, a pre-B 
cell line which expressed only a single CD23 binding integrin (αVβ5). It was 
therefore necessary to establish whether the RKC containing peptides were 
capable of binding other cell types expressing CD23 binding integrins. Binding of 
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P9 - P12 to the established model monocytic cell lines THP-1 and U937 was 
tested by flow cytometry. THP-1 and U937 cells did not express CD23 (data not 
shown). Figure 3.3 shows the binding of CD23 and RKC containing CD23-derived 
peptides to THP-1 cells. CD23/CD23-derived peptide binding is shown as a solid 
black line and background staining shown as grey shading. CD23 and CD23-
derived P9 - P12 bound to THP-1 cells, as indicated by an increase in 
fluorescence (Figure 3-3A). All these species contain a common RKC motif 
(Figure 3-3B). CD23-derived P8, which does not contain the RKC motif but does 
have some sequence similarity with P9, did not bind to THP-1 cells. An identical 
binding pattern was observed for the second monocytic cell line, U937 (data not 
shown). Subsequent to identification of the RKC motif, an additional peptide, 
named LP (long peptide), was also synthesised. The LP contained 15 residues 
spanning the entire sequence from the beginning of P9 to the end of P12 and 
contained the entire putative CD23 binding sequence.  
Cell binding analysis represents the overall binding of the CD23-derived peptides 
to multiple integrins on the cell surface. Most cells will express more than one 
CD23 ligand (Figure 3-1) and, therefore, to establish these peptides as bone fide 
integrin ligands, it was essential to analyse their binding characteristics with 
respect to individual purified integrins. Binding of peptides to purified αVβ3 and 
αVβ5 integrins, which are commercially available, was measured by surface 
plasmon resonance (SPR), using the BIACORE system. Interactions between CD23-
derived peptides and immobilised αVβ3 and αVβ5 integrins were performed at 
250C using the automated Biacore 2000 machine. In all experiments, peptides 
bound exclusively to the test cell, there was no non-specific binding to the 
control reference cell and regeneration of a stable baseline was readily 
achieved. Data collected were standarised using control and blank injections, 
according to standard double referencing data subtraction methods 170. Figure 3-
4 shows the sensorgram for the binding of CD23-derived peptides (Figure 3-4A) 
and CD23 (Figure 3-4B) to the purified αVβ5 integrin. Both CD23 and the RKC 
containing CD23-derived peptides showed characteristic binding curves over 
time, with association and dissociation phases indicative of a specific 
interaction. The control P58, which is derived from the CD23 sequence but does 
not contain the RKC motif, did not bind to the purified integrin, as shown by the 
lack of any association or dissociation curves on the sensorgram. This binding 
trace appears as a flat line on the sensorgram (Figure 3-4A, black line).  
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A qualitative hierarchy of the strength of binding can be obtained by observation 
of the amplitude of the binding response for equivalent concentrations of 
different peptides. This suggested that under these conditions the LP interacted 
most strongly with the immobilised αVβ5 integrin, as this peptide gave the 
largest binding response, even at a ten-fold lower concentration than the other 
peptides (1µM for LP compared to 10µM for the other CD23 derived peptides).  In 
this manner, the peptides were ranked in order of highest to lowest binding as 
follows; LP > P11 > P12 > P9 > P10. Equivalent traces and qualitative binding 
hierarchy data was obtained for the immobilised αVβ3 integrin (data not shown).  
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Figure  3-2 Binding of biotinylated CD23-derived peptides to SMS-SB cells 
The binding of biotinylated CD23-derived nonameric peptides was determined by flow cytometry analysis. Biotinylated peptides were incubated on ice with SMS-SB cells 
and peptide binding detected using streptavidin conjugated to the fluorescent label PE. The mean fluorescence intensity for each peptide binding is plotted against peptide 
number in the bar chart. Data are representative of at least 3 separate experiments. The error bars indicate standard deviations (SD).  
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Figure  3-3 Binding of CD23 and CD23-derived peptides to THP-1 cells 
The binding of CD23 and CD23-derived peptides P9-P12 to THP-1 cells was determined by flow 
cytometry. The grey shading indicates autofluorescence and peptide binding is show as a black 
line. (A). Cells were incubated on ice with biotinylated peptides or CD23. Binding of biotinylated 
peptides was detected using streptavidin conjugated to PE. CD23 binding was detected by anti-
CD23 antibody conjugated to PE. Analysis of the sequence of CD23-derived peptides which bind to 
cells reveals a common RKC motif (B). *Long peptide (LP) was synthesized subsequent to the 
identification of P9-P12 and contains the entire CD23-derived sequence spanning P9-P12. 
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Figure  3-4 BIACORE analysis of binding of CD23-derived peptides and CD23 
to purified αVβ5 integrin 
Interactions between (A) CD23-derived peptides, (B) derCD23 and integrins were performed at 
250C using the automated Bicore 2000 machine (Biacore AB). Purified αVβ5 integrin was 
immobilized on the chip surface and CD23-derived peptides (10µM) or derCD23 in solution were 
injected over the chip surface. An underivatised reference cell was employed as a control surface. 
In Panel A, the different peptides are shown as distinct line colours as indicated in the legend, and 
in Panel B the different colours indicate different concentrations of soluble derCD23 injected over 
the integrin surface. Data collected were standarised using control and blank injections prior to 
kinetic analysis, according to standard double referencing data subtraction methods 170, using 
BIAevaluation 3.1 software (Biacore AB). 
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3.2.3 CD23-derived peptides compete with CD23 for 
binding 
Integrins are known to recognise the tripeptide RGD motif in their ligands at the 
interface of the α and β subunit of the heterodimer. As the RKC motif is also a 
tripeptide motif, we examined whether this RKC motif was a variant of the RGD 
motif and would therefore compete with RGD-containing ligands and/or CD23 for 
integrin binding.  
The RKC-containing peptides compete with CD23 for binding to the cells, as 
shown by the inhibition of binding of one species by the other in flow cytometric 
binding assays (Figure 3-5A). These assays showed that CD23 was capable of 
blocking the binding of P11 to THP-1 cells, when incubated with cells prior to 
CD23 binding and, vice versa, P11 was capable of blocking the binding of CD23 to 
THP-1 cells. (Figure 3-5A). However, preincubation with RGD-containing integrin 
extracellular matrix proteins vitronectin and fibronectin, failed to prevent the 
binding of biotinylated P11 to THP-1 cells (Figure 3-5B). 
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Figure  3-5 CD23 but not RGD containing ligands compete with CD23-derived 
peptides for binding 
CD23, CD23-derived peptides, vitronectin (Vn) and fibronectin (Fn) were assessed for the ability to 
compete for binding to THP-1 cells by flow cytometry. Binding of biotinylated peptides and CD23 
was detected using streptavidin conjugated to PE. The identity of the staining is indicated on the 
histograms.(A) THP-1 cells were incubated with P11 or CD23 prior to binding of biotinylated CD23 
or P11, respectively. (B) THP-1 cells were incubated with vitronectin (Vn) or fibronectin (Fn) prior to 
binding of biotinylated P11. In Panel A, the binding of CD23 or P11 alone is shown as grey shading 
and the competiion binding is shown as black line. In Panel B, the autofluorescence (auto) of cells 
is shown as grey shading and the binding of P11 with or without RGD-containing ligands is shown 
as a black line.  
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3.2.4 Substitution of RKC motif abolishes both integrin 
binding and competition with CD23 
The importance of the RKC motif to integrin binding was determined using 
peptides carrying substitutions in the residues comprising the RKC motif. 
Peptides with mutations in the RKC motif were synthesised to exactly the same 
specifications as the previous peptides and assessed for their ability to bind 
monocytic cell lines by flow cytometry and purified integrins by Biacore analysis. 
Figure 3-6A shows the binding of P9 to THP-1 cells (grey shading), as measured 
by flow cytometry. Background binding and the binding of mutant peptides is 
shown as a solid black line. Mutation of any of the residues in the RKC (RA, 
RQ, KA, RKAA and CS) abrogated peptide binding to cells and resembled 
the background staining. The analysis of the binding of these mutant peptides to 
purified αVβ3 and αVβ5 integrins was extended using Biacore analysis. 
 
Figure 3-7 shows the binding of P9 and mutants in solution to immobilised 
integrin αVβ5. Mutation of any of the residues affects the binding of the 
peptides to the immobilised αVβ5 integrin. Peptides carrying the RKAA and 
CS substitutions showed no binding to the immobilised αVβ5 integrin. Mutant 
peptides P9RK, P9KA and P9RQ showed some residual binding, although the 
binding was reduced compared to wild type P9. The binding of mutants P9RK and 
P9RA was reduced by approximately 50% and 75%, respectively. The P9RQ 
mutant showed only a very low level of residual binding, approximately one-
tenth of the wild type P9 binding. Equivalent binding traces were obtained for 
the binding of mutants of P11 to αVβ5; and for the binding of mutants of P9 and 
P11 to the αVβ3 integrin (data not shown).  
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Figure  3-6 Mutation of the RKC motif abrogates cell binding and competition 
(A) Mutation of residues of the RKC motif abolishes binding of P9 to cells. The cells were incubated 
with biotinylated peptides and peptide binding detected by streptavidin conjugated to PE. The 
autofluoresence of cells (auto) is shown as grey shading and binding of biotinylated P9 mutants is 
shown as a bold line. The particular mutation is indicated in the top right corner of the plot. (B) 
Mutation of the RKC motif abolishes the ability of CD23-derived P11 to compete with CD23 for 
binding. Cells were incubated with CD23 with or without non-biotinylated P11, prior to detection of 
CD23 binding by anti-CD23 antibody conjugated to PE. The binding of CD23 alone is shown in 
grey shading and the binding of CD23 in the presence of P11 or P11RKAA is shown as a bold 
black line. (C) Sequences of CD23-derived peptides and mutants thereof (with substitutions 
indicated in bold). 
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Figure  3-7 Mutation of the RKC motif abrogates binding to purified integrins 
Binding of CD23-derived peptides in solution to immobilized αVβ5 integrin was measured by 
BIACORE analysis. Purified αVβ5 integrin was immobilized on the chip surface and CD23-derived 
P9 and mutants (10µM) in solution injected over the chip surfaces. An underivatised reference cell 
was employed as a control surface. Data collected were standarised using control and blank 
injections prior to kinetic analysis, according to standard double referencing data subtraction 
methods 170, using BIAevaluation 3.1 software. The colour coding used for identification of each 
injected peptide is shown in the the panel itself. 
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3.2.5 In vitro kinetic analysis of interaction between CD23 
or CD23-derived peptides and αV integrins 
Figures 3-4 and 3-7 demonstrate the type of qualitative information that can be 
obtained from the Biacore sensorgram. Extending this analysis using kinetic 
modelling and a range of analyte concentrations allows the calculation of 
quantitative parameters to define the interaction. 
Figures 3-8 and 3-9 show the Biacore sensorgrams for the binding of a range of 
concentrations of CD23-derived peptides to immobilised αVβ3 and αVβ5 
integrins, respectively. For both integrins, the RKC containing peptides (P9-P12 
and LP) show characteristic association and dissociation curves. As the 
concentration of the peptides increases, so does the amplitude of the 
interaction. The control P58, which is derived from CD23 but does not contain 
the RKC motif, does not bind at any concentration. These data were used to 
quantify the interaction between the αVβ3 and αVβ5 integrins and derCD23 and 
CD23-derived peptides.  
As the exact site and mechanism of interaction between the integrins and 
CD23/CD23-derived peptides remains to be identified fully, we applied a simple 
1:1 binding model to the kinetic analysis. The Langmuir binding model is based 
on the fact that the interaction involves the Analyte A (in this case the peptide 
in solution) binding to a Ligand B (in this case the immobilised integrin). 
The kinetic constants derived from the analyses are shown in Table 1-1. All 
constants were generated using BIAevaluation 3.1 Software. For both the αVβ3 
and the αVβ5 integrin, the qualitative hierarchy of binding (LP > P11 > P12 > P9 
> P10) noted by visual observation of the sensorgram is confirmed by the values 
obtained for the dissociation constants (KD) for peptides binding to integrins. 
DerCD23 binds with an affinity similar to P11, so the hierarchy for binding 
affinities under these conditions for both αVβ3 and αVβ5 integrins including 
derCD23 is LP > P11 and derCD23 > P12 > P9 > P10.  
The affinities of the individual peptides for the different integrins are similar, 
for example, derCD23 binds to αVβ3 with a KD of 6.00 x 10
-6M and to αVβ5 with a 
KD of 6.04 x 10
-6M and LP binds to αVβ3 with a KD of 2.33 x 10
-7M and to αVβ5 
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with a KD of 3.68 x 10
-7M. Only P9 and P10 have KD values that differ significantly 
for αVβ3 and αVβ5 (two orders of magnitude). The KD values determined in this 
study are in a similar range to those determined for the interaction between 
derCD23 and its other ligands CD21 and IgE 62.  
3.2.5.1  Potential role for disulphide bond in CD23 derived 
peptides during integrin binding 
The integrin-binding CD23-derived peptides contain a cysteine residue which 
may be capable of forming an inter-peptide disulphide bond. To test the ability 
of the RKC containing peptides to form disulphides, peptide solutions were 
prepared and stored at 40C for up to 30 days. Samples were removed at intervals 
and reacted with Ellman’s reagent to detect the molar concentration of free 
sulphydryl groups.  
Reaction of Ellman’s reagent with free sulphydryl groups can be followed by an 
increase in absorbance at 405nm and the concentration determined using Beer’s 
Law 171. As P9-P12 and LP contain only a single cysteine, the molar concentration 
of total sulphydryl can be calculated from the peptide concentration. The 
percentage disulphide for each peptide over time was calculated by determining 
the molar concentration of free sulphydryl by reaction with Ellman’s reagent.  
All of the peptides exhibited some degree of disulphide formation (reduction in 
free sulphydryl concentration) over time (Figure 3-10). Peptide P9-P12 had a 
significant proportion (between 80-90%) disulphide after 1 day of storage at 40C. 
The LP exhibited a lower percentage of disulphide (approximately 30%) after 1 
day of storage at 40C. After 10 days storage, all peptides displayed increased 
levels of disulphide formation. P58, which does not contain any cysteines, was 
used as a control and did not produce any change in absorbance at 405nm with 
Ellman’s reagent.  
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3.2.5.2 Effect of cations and salt concentrations on CD23-αV 
integrin binding 
As RGD binding is cation dependent, we tested if CD23-derived peptide binding 
to αV integrins required divalent cations. Magnesium, supplied as chloride salts, 
was spiked into the Biacore running HSB buffer and the effect on peptide binding 
determined.  
After testing the binding of the peptides in the presence of the magnesium 
chloride, fresh buffer containing EDTA (ethylenediaminetetraacetic acid) was 
added, the system equilibrated and the binding of the same CD23-derived 
peptides tested. The data for the binding of selected peptides to immobilised 
αVβ3 and αVβ5 integrins in the absence (black lines) and presence of magnesium 
chloride (red lines) are shown in Figure 3-11. In all cases, the peptides bound to 
the integrins in the absence of divalent cations and the presence of the 
chelating agent EDTA. Addition of magnesium chloride to the system prevented 
binding of peptides to both αVβ3 and αVβ5 integrins, as shown by the lack of 
characteristic association and dissociation curves. The sensorgram traces for the 
binding of LP and P9 in the presence of chloride (red lines) resembles the 
binding traces for the control peptide P58, which does not bind to the integrins 
(grey lines).   
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Figure  3-8 BIACORE analysis of binding of CD23-derived peptides to purified 
αVβ3 integrin 
Purified αVβ3 integrin was immobilized on the chip surface. CD23-derived peptides at different 
concentrations in solution were injected over the test and control chip surfaces. Data collected 
were standarised using control and blank injections prior to kinetic analysis, according to standard 
double referencing data subtraction methods 170, using BIAevaluation 3.1 software (Biacore AB). 
For P9-P12 and P58, the light grey line is 5µM, the dark grey line is 10µM and the black line is 
20µM. For the LP, the light grey line is 0.25µM, the dark grey line is 0.5µM and the black line is 
1µM.  
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Figure  3-9 BIACORE analysis of the binding of CD23-derived peptides to 
purified αVβ5 integrin 
Purified αVβ5 integrin was immobilized on the chip surface. CD23-derived peptides at different 
concentrations in solution were injected over the test and control chip surfaces. Data collected 
were standarised using control and blank injections prior to kinetic analysis, according to standard 
double referencing data subtraction methods 170, using BIAevaluation 3.1 software (Biacore AB). 
For P9-P12 and P58, the light grey line is 5µM, the dark grey line is 10µM and the black line is 
20µM. For the LP, the light grey line is 0.25µM, the dark grey line is 0.5µM and the black line is 
1µM.  
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Table  3-1 Kinetic Constants determined for the binding of derCD23 and 
CD23-derived peptides to immobilised integrins 
 
αVβ3 
 
αVβ5 
Ligand 
 
Kd (M) 
 
Kd (M) 
 
P9 
 
8.98 ± 3.14  
x 10-4 
 
1.30 ± 0.08 
x 10-6 
 
P10 
 
8.13± 6.19  
x 10-4 
 
1.55 ±0.76  
x 10-6 
 
P11 
 
9.87 ±0.12  
x 10-6 
 
8.92 ± 0.2  
x 10-6 
 
P12 
 
1.07 ± 0.14 
x 10-5 
 
3.73 ± 0.35 
x 10-6 
 
LP 
 
2.33 ± 0.068  
x 10-7 
 
3.68 ± 0.04  
x 10-7 
 
derCD23 
 
6.00 ± 4.21 
x 10-6 
 
 
6.04 ± 3.59  
x 10-6 
 
 
Published constants for derCD23 and its other ligands62 
 
Ligand 
 
Kd (M) 
CD21 8.70 ± 0.9 x 10-7 
IgE 1.3 ± 0.3 x 10-6 
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Figure  3-10 Analysis of disulphide formation in CD23-derived peptides by 
Ellman's Assay 
(A) Ellman’s reagent was used to determine disulphide bond formation in CD23-derived peptides. 
Peptide solutions at 10µM were prepared and stored at 40C for a month. The percentage 
disulphide was determined at specified time points by incubation with Ellman’s Reagent and 
measurement of absorbance at 450nm. (B) RKC-containing CD23 long peptide sequence contains 
a single cysteine, possibly capable of forming two disulphide-bonded dipeptide species.  
 
 
 
 
 
 
 
 
 
 
 
 
 96 
 
 
 
 
 
 
 
Figure  3-11 BIACORE analysis of effect of salt concentration on binding of 
CD23-derived peptides 
Panel A shows the binding of CD23-derived peptide LP to the purified αVβ3 (Ai) and αVβ5 (Aii) 
integrins. Panel B shows the binding of CD23-derived peptide P9 to the purified αVβ3 (Bi) and 
αVβ5 (Bii) integrins. In all graphs, the black line shows the binding sensorgram for the specific 
peptide in the absence of divalent cations or chloride ions. The grey line shows the binding of 
CD23-derived P58. This peptide P58 did not bind the purified integrins and therefore is considered 
a control for absence of binding. The red line shows the binding of the specific peptide in the 
presence of divalent cations and chloride ions. Data collected were standardized using control and 
blank injections prior to kinetic analysis, according to standard double referencing data subtraction 
methods 170, using BIAevaluation 3.1 software. 
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3.3  DISCUSSION 
CD23 binds to four members of the integrin family of proteins, αMβ2, αXβ2, 
αVβ3 and αVβ5. Using cell lines that express CD23-binding integrins and 
commercially-available purified αVβ3 and αVβ5 integrins, we investigated the 
interaction between CD23 and these integrins. We generated a library of 
nonameric peptides derived from the CD23 sequence (residues 131-321) and 
identified a set of peptides (P9-P12) which bound to integrins expressed on the 
surface of cells and purified αVβ3 and αVβ5 integrins in in vitro Biacore analysis. 
Although many protein recognition motifs are cryptic and non-linear, this protein 
array technique was determined suitable for our purposes as integrins are well 
known to bind small, linear peptide motifs (RGD) 175.  
3.3.1 RKC is a new integrin recognition motif 
Those CD23-derived peptides that bound cells and integrins were found to 
contain a common, linear tripeptide recognition sequence, termed the RKC 
motif. Peptides containing this motif bound to cells expressing integrins in flow 
cytometry assays and to purified αVβ3 and αVβ5 integrins in Biacore analysis. 
The interaction between RKC-containing peptides was determined to be 
independent of divalent cations, salt sensitive and not inhibited by the presence 
of RGD-containing integrin ligands. Mutation of residues in the RKC motif 
abolished the interaction with cells and purified integrins as judged by Biacore. 
These data suggest that the RKC is a new recognition motif for αV integrins and 
that the sequence is recognised and bound by the integrin at a site distinct from 
that used for RGD binding.  
The classical integrin recognition motif is the tripeptide RGD motif, found in 
numerous integrin ligands. Initial observations suggested that the RKC motif 
might be a new variant of the RGD motif, given that it was a tripeptide motif 
and that CD23 does not contain an RGD sequence, but is known to bind integrins. 
Integrins do bind variations of the RGD tripeptide motif at the site usually bound 
by RGD-containing ligands, for example the KQAGDV sequence is bound by 
αIIbβ3, the LDV is bound by α4β1 and α4β7 and REDV sequence from fibronectin 
is bound by α4β1 101, 110.  
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3.3.2 RKC binding is independent of RGD binding 
All of the alternative integrin recognition sequences described previously are 
considered variants of the RGD motif and are bound at the same site on the 
integrin at the RGD-binding site. The inverse RGD sequence, DGR, does not have 
any measurable integrin binding activity. This is important in the context of 
CD23, as it contains a DGR sequence and is known to interact with RGD-binding 
integrins 67. Our data support the fact that DGR is not an integrin recognition 
motif, as peptides from the CD23 sequence containing this DRG motif (P60-63) 
failed to bind to cells in our assays.  
Despite the range of sequences recognised by integrins, in most cases, those 
alternative motifs described thus far all include an Asp, or the closely related, 
Glu residue. The RGD peptide binds a shallow groove at the interface of the ß-
propeller of the α subunit and the ßA domain of the ß subunit (Figure 1.6). The 
requirement for the Asp may be due to its ability to coordinate metal ions 
essential for integrin-based ligand recognition. In addition to binding the metal 
ion at the MIDAS site, the AspRGD side chain makes contacts with residues Tyr122 
from the α subunit and Arg214 and Asn215 from the βA domain on the β subunit. 
The ArgRGD residue is bound by the ß-propeller groove from the α subunit, where 
the guanidinium group forms a bidentate salt bridge with Asp218 and another 
salt bridge with Asp150 (Figure 1-6). This group forms the centre of a network of 
polar interactions with the ßA residues and the MIDAS. The central GlyRGD residue 
projects into the interface between the α and ß subunits. It interacts with the 
αV subunit, primarily via the carbonyl oxygen of Arg216.  
In view of this binding information obtained from the crystal structure of the 
αVβ3 integrin in complex with a cyclic RGD containing peptide, the 
characteristics of the RKC make it improbable that the RKC would be bound at 
the RGD site. The RKC motif lacks the acidic residue and therefore would be 
unable to coordinate the divalent cation; indeed our data show that the RKC 
binding is independent of divalent cations and can occur in the presence of the 
chelating agent EDTA. CD23-derived peptides do not compete for binding with 
RGD containing ligands. In addition, a predicted conflict between the Arg216 
carbonyl group integral to RGD binding and the large, charged lysine group of 
the RKC means the LysRKC is unlikely to be accommodated in the GlyRGD position 
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at the interface of the two subunits. Taken together, these data suggest that the 
RKC is a novel recognition sequence and is bound at a site distinct from that 
used for RGD binding.  
Although the RGD-binding site is the most extensively studied interaction site on 
integrins, there are precedents for the existence of an alternative binding site 
from other studies. These alternate binding sites have been suggested by the 
binding of ligands, such as tumstatin 114, HIV Tat protein 109 and entactin 115, to 
the αVβ3 and αVβ5 integrins at RGD-independent sites. These studies have 
proposed either the existence of an additional distinct binding site or a 
synergistic ligand recognition site that cooperates with the RGD binding site 109, 
176, 177. In most cases, this additional non-RGD site recognises basic sequences. 
Analysis of the binding of Type IV collagen indicates that this protein contains 
additional αVβ5 and αVβ3 binding sites 108. Studies on the binding of tumstatin-
derived peptides to αVβ3 indicated that the protein contains two RGD-
independent αVβ3 binding sites, as the binding of these peptides was not 
inhibited by the presence of cyclic RGD peptides 114. Entactin was also shown to 
contain two distinct RGD-independent cell attachment peptides. Mutants of 
entactin lacking the RGD motif were still capable of mediating cell attachment, 
although the integrin involved in binding remains to be identfied 115. The α2β1 
integrin also recognises a basic tetrapeptide RKKH site in the protein 
jararhagin177 and α3β1 recognises a basic sequence in laminin 176. 
3.3.3 Substitution of the RKC affects integrin binding 
The interaction of CD23/CD23-derived peptides and integrins required the 
presence of the RKC motif. Substitution of residues in the RKC tripeptide 
affected the interaction between the peptides and both the αVβ3 and αvB5 
integrins.  Mutation of any of the residues in the RKC motif abolishes the 
interaction of these peptides with cells, while the Biacore analysis was more 
sensitive and reveals that some of the mutant peptides retain some binding 
ability. P9 carrying a mutation of the ArgRKC to a similarly charged Lys residue 
shows a reduction in binding to approximately half of that of the wild type P9, 
but did not completely prevent binding in our assays. Mutation of the same 
residue to a Gln almost completely abolished any binding to the purified 
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integrin. Mutation of the LysRKC to Ala also results in a significant reduction in 
binding. These three mutations highlight the importance of the basic nature of 
the RKC motif in the binding to integrins. Any mutation that reduces the basic 
nature of the motif reduces the interaction. The double mutant RKAA mutant 
displays no binding in the context of either P9 (Figure 3-7) or P11 (data not 
shown).  
Interestingly, the P9CS mutant completely ablates the binding between the 
RKC containing peptides and the integrins. Analysis of the structure of the RKC 
motif in complete CD23 reveals that this residue is part of a disulphide bond 
(Figure 3-12). We investigated the abilty of the CD23-derived peptides to form 
inter-peptide disulphide bonds using Ellman’s reagent. Our analysis revealed 
that the peptides did appear to form disulphides, as indicated by a lower 
concentration of free sulphydryl groups than total sulphydryls over time. This 
disulphide bonding may be important for peptide binding, indicated by the lack 
of binding in the P9CS mutant (which cannot form an inter-peptide disulphide 
bond). Work from another member of the laboratory has highlighted the 
importance of the CysRKC to the biological role of the CD23 derived peptides in B 
cells. RKC containing peptides stimulate the proliferation of B cell precursors 75. 
A specific murine cell line, BAF03 requires β-mercaptoethanol in the growth 
medium for survival. This fact was exploited to examine the role of the 
disulphide bond in RKC containing peptides. P9 was boiled with β-
mercaptoethanol to reduce the disulphide bond and then tested for its ability to 
stimulate the growth of BAF03 cultures (including β-mercaptoethanol in the 
medium). Untreated P9 was capable of stimulating cell growth, but the β-
mercaptoethanol treated P9 was not (Dr. Mridu Acharya, unpublished data). 
These data support the important role of the CysRKC in the binding and activity of 
these peptides. The mechanism underlying this characteristic remains to be 
determined. It is possible that the disulphide provides a degree of structural 
rigidity to the peptides that is required for binding or activity. Alternatively, the 
dimeric peptide may cause dimerisation of the integrins to which it bound. 
These are only theories at present and will need to be determined conclusively 
by crystallisation/structural analyses.  
Although the RKC motif is the core unit important for binding, the hierarchy of 
binding obtained from the Biacore analysis (both qualitative and in KD values) 
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reveals that other regions of the peptides must be important for binding. Were it 
only the RKC motif that was the critical determinant for binding, all peptides 
containing that tripeptide should bind with equivalent affinities. We observed, 
however, that peptides bound with different affinities, suggesting an important 
role for the flanking sequence in integrin binding (Table 1-1). The  LP (2.33 x   
10-7M and 3.68 x 10-7M for the αVβ3 and αVβ5 integrin, respectively) shows the 
highest affinity binding, higher than any of the other P9-P12 and in fact higher 
that obtained for CD23 (KD 6 x 10
-6M and 3 x 10-7M for the αVβ3 and αVβ5 
integrin, respectively, from which all the peptides were derived). The fact that 
the LP binds more strongly to both αVβ3 and αVβ5 than the other CD23-derived 
peptides indicates that, although the RKC is required for binding, the flanking 
sequence influences the strength of that interaction. The LP contains the whole 
sequence encompassing those peptides which bind the integrins and therefore 
must contain the majority of the complete binding sequence. The increased 
affinity of the LP for the integrin is interesting, as the natural ligand (CD23) 
binds with lower affinity than the LP derived from it. It may be that there is 
some structural arrangement or induced-fit conformation that the LP is capable 
of achieving that the full length CD23 is prevented from by steric hindrance. 
Whether this is true or has physiological relevance remains to be determined.  
The hierarchy of binding determined from the kinetic analysis is also observed 
qualitatively by looking at the relative responses of equivalent concentrations of 
CD23-derived peptides in the Biacore sensorgrams (Figure 3-4). It is worth 
noting, however, that the kinetic parameters determined for this interaction are 
only relevant in the context of our experiment and the interaction model used to 
fit the data. In the absence of knowledge of the exact mechanism of the 
interaction between CD23/CD23-derived peptides and αV integrins, we applied a 
simple 1:1 interaction model to calculate kinetic parameters. This may not be 
the most accurate method of fitting the data. We determined by Ellman’s assay 
that these CD23-derived peptides are capable of forming disulphide bonds. Given 
that the peptides contain only a single disulphide bond, the only possible 
disulphide bonded species would be an inter-peptide bond. Mutation of the CS 
abolishes the potential to form a disulphide and prevents binding; a peptide 
treated with the reducing agent β-mercaptoethanol loses its functional activity 
(Dr Mridu Acharya, unpublished data).  This suggests that a dipeptide, which 
possibly might contain 2 recognition sites (RKC) for the integrin, may be the 
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active conformation. Visual observation of the shape of the association and 
dissociation curves suggests a biphasic reaction (Figure 3-4). If this were correct, 
a model that incorporated this would give more accurate kinetic data. This 
model would need to address the different binding scenarios that could arise 
from this, possibilities that include a ligand in solution with two binding sites for 
a single integrin molecule or a single dipeptide binding two integrin molecules.  
Further investigation of the interaction will allow re-analysis of these data as 
more information regarding the interaction between these species becomes 
available. Care should be taken therefore when making assumptions about in 
vivo binding, although it does not, however, detract from the value of these 
data in comparing the in vitro interaction characteristics of the different CD23 
derived peptides and mutants thereof.  
3.3.4 RKC binding is cation independent and salt 
sensitive 
A 9 residue basic peptide derived from the HIV Tat protein was shown to bind 
the αVβ5 integrin in an RGD and divalent-cation independent fashion. This basic 
peptide was highly specific with respect to sequence and capable of mediating 
cell attachment 109. The authors postulate that, although Tat contains an RGD 
motif, it is not presented in a context that allows it to bind αVβ5. They suggest 
that the basic peptide binds a synergistic site on αVβ5 to mediate specific 
interactions 109. The binding of this peptide may give a clue to the binding of the 
RKC motif, as there are similarities with the CD23-derived peptides. In CD23 the 
DGR is not presented in a format that can be recognised and the interaction was 
rather mediated by an interaction of the RKC with a basic domain binding site on 
the integrin. Moreover, the interaction between the basic peptide from Tat and 
the αVβ5 integrin was cation independent and salt sensitive (chloride), similar to 
that observed for the binding of RKC peptides to the αVβ3 and αVβ5 integrins in 
the Biacore analysis. The addition of the magnesium to the Biacore buffer as a 
chloride salt would have elevated the salt concentration above physiological 
levels, as the buffer contained 150mM sodium chloride prior to addition of 
100mM magnesium chloride. Other similar salt-sensitive interactions involving 
integrins have been described, including the interaction of collagen and 
fibronectin by the α3β1 integrin 178.  
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3.3.5 Analysis of the structures of CD23 
Two structures of the soluble C-type lectin-like head of CD23, both of which 
contain the RKC motif, have been published in the literature 62, 63. Examination 
of the structures shows that the binding sites for the three CD23 ligands, CD21, 
IgE and integrins (RKC), are independent of each other (Figure 3-12A).  
Whereas a crystal structure gives a single set of coordinates, the NMR structure 
is an average of a number of structural coordinates, due to the dynamic nature 
of proteins in solution. It is possible therefore to isolate each individual 
structural file and analyse them individually. Figure 3-12B shows an image of the 
20 individual structure files that comprise the NMR structure of CD23 overlaid on 
each other using the Pymol graphics program (Delano Scientific, CA). The C-type 
lectin head is displayed as ribbons and the RKC motif rendered as sticks. The 
RKC motif is located on a solvent-exposed disulphide-bonded loop at the N-
terminal end of the C-lectin head domain, between the β0 and β1 strands. The 
Cys174RKC forms a disulphide bond with Cys163 and therefore is restricted and 
maintains its position in all of the 20 structures comprising the NMR average 
structure. Similarly, the Lys173RKC does not show much movement, other than a 
slight apparent rotation of the side chain. In contrast, the Arg172RKC side chain is 
shown to sample a number of positions in the different NMR structure files which 
make up the final structure. Comparison of the relative positions of the RKC 
motif in the averaged NMR structure and crystal structure indicates that in the 
crystal structure (Figure 3.12B) the Arg172 RKC and Lys173RKC appear less solvent-
exposed than in the averaged NMR structure (Figure 3-12A). However, as the 
crystal structure represents a single defined structure (“snapshot in time”), it is 
possible that this less solvent-exposed conformation is also observed during 
dynamic movements of the solution CD23. The fact that it is not reflected in the 
averaged CD23 NMR structure suggested that in solution this residue is more 
likely to be solvent exposed than not. This apparent flexibilty in the Arg172RKC 
may have important consequences for the binding of CD23 to its integrin ligands. 
It does not preclude the possibility of an induced-fit model for CD23 binding. The 
relevance of this to the interaction will rely on the solution of a structural model 
of the interaction prior to making any conclusions in this regard.  
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Data collected in this study suggested that the interaction between CD23-
derived peptides and αV integrins occurs via an RKC motif in CD23 and that this 
motif is bound at an alternate binding site to that which recognises the RGD 
motif. Attempts to identify this site during this investigation were hampered by 
technical problems and it remains to be identified. Work is continuing to extend 
the analysis of this interaction. Our priority is to identify the location of the 
basic site for ligand binding on the αV integrins and to analyse the substitutions 
of the RKC motif in the full length CD23 protein.  
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Figure  3-12 Analysis of RKC motif in CD23 crystal and NMR structures 
Crystal 94, 98 and NMR  62, 63 structures of the C-lectin like domain of CD23 have been solved. (A) 
The binding sites for IgE (blue), CD21 (red) and integrins/RKC (yellow) on CD23 are distinct from 
each other. (B) CD23 solution structure, showing the position of the RKC motif in the 27 individual 
coordinate files that comprise the NMR structure file. The RKC motif (shown as sticks) is located on 
a solvent-exposed loop at the base of the C-lectin like head domain of CD23. The LysRKC and 
CysRKC retain similar positions in all the files, while the ArgRKC is shown to sample a number of 
positions. RKC motif is shown in the NMR solution (C) and crystal (D) structures of CD23. Figures 
were generated using Pymol (DeLano Scientific); NMR structure PDB code is 1T8C and Crystal 
structure PDB code is 2H2R. 
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4 INTEGRIN-REGULATED CYTOKINE 
PRODUCTION BY MONOCYTIC CELLS 
 107 
4.1 Introduction 
4.1.1 CD23-Integrin interactions and cytokine production 
CD23 (Blast-2, FcεRII) is a 45 kDa, Type II transmembrane glycoprotein, which 
exists in both membrane bound and soluble forms 32. Membrane bound CD23 
(mbCD23) is cleaved by membrane-associated metalloproteases to yield soluble 
CD23 (sCD23) fragments of 37kDa, which are subsequently cleaved to yield CD23 
species of 33kDa, 29kDa, 25kDa and 16kDa 35, 179. These sCD23 species possess 
cytokine-like activities, which may be induced by interactions with partner 
proteins. Of particular interest in this thesis is the interaction between sCD23 
and integrins, which is important in the stimulation the production of cytokines 
by monocytes 40, 41, 83, 84, 180. Integrins are proteins that play a critical role in cell 
adhesion and signalling across membranes. They control cell-cell and cell-
extracellular matrix contacts and participate in signalling both from the 
cytoplasm to the exterior of the cell and vice versa. CD23 interacts with two 
classes of integrin (αV and β2) to induce cytokine synthesis in monocytes. 
4.1.1.1 CD23 and β2 integrins 
The ß2 integrins are exclusively expressed on leukocytes. They are 
heterodimeric αß integrins, formed by the non-covalent association of one of 4 α 
chains (αD, αL, αM or αX) with the ß2 integrin 88, 144. An absence of the ß2 
integrin results in impairment of a variety of immune functions, including 
reductions in macrophage oxidative burst and phagocytosis and lymphocyte 
proliferation 181. CD23 interacts with the alpha chains of the leukocyte integrins 
αMß2 (CD11b/CD18) and αXß2 (CD11c/CD18) 74. Membrane-bound CD23 
incorporated into liposomes has been shown to interact with αXß2 and αMß2 
expressed on the surface of monocytes. Soluble CD23 was demonstrated to 
induce the synthesis by monocytes of the pro-inflammatory cytokines IL-1ß, IL-6 
and TNF-α through interaction with αMß2 and αXß2 41, 74, 83, 84.   
4.1.1.2 CD23 and αV integrins 
The αV family of integrins, also known as the vitronectin receptors, include the 
αV subunit in complex with one of β1, β3, β5, β6 or β8 subunits. CD23 interacts 
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with the vitronectin receptors αVß3 and αVβ5, with αVβ3 having an important 
role in cytokine production in monocytes. Integrin αVβ3 is associated with CD47, 
a 50kDa tetraspan transmembrane protein, to form the αVβ3 integrin signalling 
complex 182, 183. The αVβ3 integrin plays a role in cytokine production through its 
interaction with sCD23, which leads to the production of TNF-α and IL-1 40. Our 
laboratory has recently identified an interaction between CD23 and αVß5, which 
is implicated in prevention of apoptosis of pre-B cells 75. The potential role of 
αVβ5 in cytokine production remains to be established.  
4.1.2 Hierarchy of integrin activity in cytokine production 
by monocytic cells 
The role of CD23 in initiating cytokine production by monocytic cells via an 
interaction with one or more of its integrin receptors has been described by a 
number of groups 40, 41, 83, 84. However, the relative importance of each of the 
individual integrin isoforms to this process has not been studied in detail. We 
aimed to extend the analysis of the role of individual integrins in cytokine 
production by monocytic cells and to identify any relative hierarchy of 
importance of the individual integrins with respect to cytokine production. This 
analysis included the first investigation of the role of the αVβ5 integrin in 
promoting cytokine synthesis by monocytic cells.  
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4.2 Results 
4.2.1 CD23 drives cytokine production by monocytic cells 
The interaction between CD23 and integrins expressed on monocytic cells has 
been shown to induce the synthesis of cytokines, including TNF-α, IL-1β, MIP-
1α/β and nitric oxide 40, 41, 83, 84, 180. We tested our model monocytic cell line, 
THP-1, for the ability to produce cytokines in response to treatment with CD23 
(Figure 4-1A). Supernatant from THP-1 cells stimulated overnight with CD23 was 
tested for the presence of RANTES, IL-8 and MIP-1β using ELISA. CD23 stimulated 
the production of all of these cytokines by THP-1 cells (Figure 4.1A), albeit to 
different extents.  
However, CD23 binds to four members of the integrin family of proteins (αVβ3, 
αVβ5, αMβ2 and αXβ2) and often more than a single integrin isoform will be 
expressed on the surface of monocytic cells at the same time. The cytokine 
output of a cell, therefore, will be the net result of the interaction of CD23 with 
the range of interacting integrins expressed on that particular cell. In order to 
assess the contribution of individual integrins to the cytokine output, we used 
antibodies against specific integrin isoforms to attempt to identify a hierarchy of 
importance amongst the different CD23-binding integrins with respect to 
monocyte stimulation (Figure 4-1B).  
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Figure  4.1 Cytokine production by CD23-integrin interaction in monocytes 
(A) THP-1 cells were incubated overnight alone (white bars) or with 5µg/mL sCD23 (grey bars) 
Cytokines released into the supernatant were detected by ELISA. (B) The response of a monocytic 
cell to CD23 treatment is due to the combined effect of binding to any of 4 possible CD23 binding 
integrins. The use of antibodies raised against specific integrins allowed identification of the 
contribution of individual integrin isoforms and/or subunits to the cytokine output of the monocyte. 
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4.2.2 Qualitative analysis of the cytokine output in 
response to integrin binding 
In order to investigate the global cytokine production profile induced by 
stimulating integrins on monocytic cells, we used a commercially available 
cytokine array technique (Figure 4-2). This method uses a combination of 
sandwich ELISA, Western blotting and chemiluminescent-based detection to 
simultaneously analyse a sample for the presence of 36 different cytokines in 
duplicate. The protein array itself comprises a nitrocellulose membrane with 
antibodies conjugated to it at defined locations in a grid (Figure 4-2B). This 
membrane was incubated with the sample (in our case cleared supernatant from 
stimulated cells) and then non-specific sites on the membrane were blocked 
with BSA. Cytokines in the sample/supernatant bound to their corresponding 
antibody on the membrane. The bound cytokines were then detected with a 
biotinylated primary antibody against that specific cytokine (to form the 
antibody “sandwich”). The binding of biotinylated primary antibody was 
detected using streptavidin-conjugated to HRP, the nitrocellulose membrane 
incubated with chemiluminescent substrate and a signal pattern recorded on X-
ray film. The membrane is orientated by the location of the positive and 
negative samples and the location of the signal relative to that identifies a 
particular cytokine, as indicated by the grid (Figure 4-2B and C). The global 
cytokine output for a particular stimulus can be determined semi-quantitatively 
using densitometry and standardisation of the signal strength of individual 
cytokines against the positive control signals (Figure 4-2D).  
We selected a specific cytokine array that would allow us to analyse the 
production of a range of inflammatory cytokines. We validated the use of this 
technique for our purposes by first investigating the response of THP-1 cells to 
stimulation with IgG1, LPS and CD23. LPS and CD23 are known inducers of 
cytokine production 41, 184-186 and IgG1 was used as a negative control for ligating 
(but not cross-linking) of Fcγ receptors (certain members of which are known to 
induce cytokine production in phagocytes). Figure 4-2C shows the cytokine array 
membrane for cleared supernatants from untreated THP-1 cells and THP-1 cells 
treated overnight with IgG1, LPS and CD23. All of these arrays displayed the 
expected patterns for the positive and negative control signals on the 
membranes. These are shown as a block of four signal dots at the top right and 
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bottom right of each of the blots (positive controls), separated by a space that 
shows no signal (negative control), indicating that the array had performed 
according to manufacturer’s instructions. 
The blot using the supernatant from untreated THP-1 cells showed positive 
signals in certain positions. These signals correspond to cytokines that are 
produced constitutively by the cell line, such as the chemokine RANTES. THP-1 
cells are derived from a patient suffering from acute myelogenous leukaemia 
and therefore the changes associated with this disease may be responsible for 
this constitutive production of certain cytokines. IgG1-treated THP-1 cells 
showed a similar profile in cytokine production as the untreated cells and in 
some cases lower levels of constitutive cytokine production. LPS and CD23, both 
known to induce cytokine production by monocytes, produced a number of 
positive signals, indicating the presence of a range of cytokines in the THP-1 
supernatant. Strong positive signals were obtained for RANTES, MIP-1α/β, IL-8, 
VEGF, IL-4 and IL-12p40 in response to LPS and sCD23 treatment.  
The array technique is, however, qualitative and therefore could only be used to 
illustrate the presence or absence of a certain cytokine but not to determine its 
concentration. Additionally, the chemiluminescent based signal detection meant 
that there was the potential for membrane-to-membrane variation in signal 
intensity due to exposure times. As such, the signal intensity for each cytokine 
was standardised against the positive control signals on each individual blot. The 
positive and negative control signal intensities are independent of concentration 
and therefore ideal for use as an internal standard to normalise cytokine signal 
intensity for exposure differences. This produced a set of data that could be 
used for comparison between different blots. The standardised data for the 
signal intensity of 36 cytokines produced in response to negative (untreated and 
IgG1) and positive (LPS and IgG1) treatments are shown in Figure 4-2D. This 
chart shows the cytokine signal intensity determined by densitometry and 
represented as a ratio relative to the signal intensity of the positive control 
signal intensity on that same membrane. The signal ratios of the 36 cytokines 
produced in response to a particular treatment are shown together on the chart. 
This gives a global view of the effect of the particular treatment; allowing 
identification of those treatments which are most stimulatory with respect to 
cytokine production. The chart shows that although there is some constitutive 
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production of cytokines observed in the untreated supernatant or the IgG1-
treated cells, there is a large increase in the number of positive signals when the 
THP-1 cells are treated with LPS or CD23.  
Using this semi-quantitative approach, we analysed the response of THP-1 cells 
to antibodies directed against individual CD23-binding integrins (Figures 4-3 and 
4-4). THP-1 cells express high levels of the αVβ3, αVβ5 and αXβ2 integrins but 
only low levels of the αMβ2 integrin. The difference in expression levels of the 
different CD23-binding integrins with respect to cytokine production is discussed 
later in the chapter (Figure 4-8). We selected pairs of antibodies against the four 
CD23-binding integrins (αVβ3, αVβ5, αMβ2 and αXβ2) and the two common 
integrin chains (αV and β2). The antibodies were selected to recognise the 
different families of integrin (αV or β2), distinct heterodimer isoforms within 
those families (αV, αVβ3 or αVβ5) or different epitopes on a specific heterodimer 
(Table 4-1). We used these antibodies to determine the difference in the 
cytokine response to binding of the αV integrins as opposed to the β2 integrins, 
to analyse the role of different isoforms within a particular family (αV or β2), 
and to investigate the role of different epitopes on a specific integrin.  
Figure 4-3 shows the global cytokine profile for THP-1 cells treated with 
antibodies against CD23-binding integrins from the αV family. The cytokine array 
membrane signal pattern is shown in Figure 4-3B and the associated 
densitometry data are displayed in the bar chart in Figure 4-3C. The untreated 
and IgG1-treated THP-1 supernatants did not produce significantly different 
signals, other than certain cytokines, such as RANTES, which were constitutively 
expressed by the THP-1 cell line. LPS treatment led to the expression of a 
number of cytokines, leading to a large change of signals represented in the 
densitometry chart. This indicated that LPS induced the production of a range of 
cytokines by THP-1 cells, including TNF-α, RANTES, IL-8 and MIP-1β. Comparing 
the cytokine arrays for the treatment of THP-1 cells with antibodies (Figure 4-
3Bii) showed that THP-1 cells produced cytokines, including RANTES, IL-8 and 
MIP-1β, in response to anti-αV antibodies. Stimulation of THP-1 cells with 
antibodies against αV (using AMF7) and αVβ3 (23C6) and αVβ5 (15F11) produced 
a similar qualitative cytokine profile, although αV and αVβ5 ligation were less 
effective than αVβ3. The anti-αVβ3 antibody was the most effective at 
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stimulating cytokine production by THP-1 cells and induced the greatest range of 
cytokines of the anti-αV antibodies (Figure 4-3C). 
Figure 4-4 shows the equivalent data for the global cytokine profile for THP-1 
cells treated with antibodies against CD23 binding integrins from the β2 family. 
Stimulation of THP-1 cells with antibodies to members of the β2 family of 
integrins resulted in the production of a range of cytokines. Ligation of the β2 
subunit using the antibody MEM48 did not produce a change in the profile 
compared with untreated or IgG1-treated THP-1 cells. Treatment with the anti-
αMβ2 antibody Clone44 and anti-αXβ2 antibody HC1.1 induced the production of 
a similar range of cytokines to that observed with LPS treatment. Of the two 
treatments, the anti-αXβ2 antibody produced the greater cytokine response and 
was most similar to the LPS induced response (Figure 4-4D).  
Analysis of the qualitative cytokine data collected for stimulation of the αV and 
β2 integrins indicated that a similar profile of cytokines is produced, irrespective 
of the family of integrin targeted. Rather than a change in the identity of the 
cytokines, the concentration of individual cytokines produced in response to 
stimulation of integrins was seen to vary. Using the qualitative information 
obtained from the global cytokine arrays, a number of cytokines that had been 
secreted as a consequence of integrin binding were selected for quantitative 
analysis. The chemokines MIP-1β, IL-8 and RANTES were selected for the 
majority of further analysis. In certain cases the production of other cytokines 
and growth factors, including but not limited to IL-4 or VEGF, were analysed.   
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Figure  4.2 Validation of cytokine arrays for the simultaneous detection of 36 
cytokines 
(A) Schematic diagram of the cytokine array process. Supernatant from stimulated cells was 
cleared by centrifugation and incubated with the cytokine array membrane. The nitrocellulose 
membrane has antibodies for specific cytokines attached at defined positions, as shown by the 
template guide. (B) The membrane was incubated with cleared supernatant for 2 hours, washed 
and incubated with biotinylated antibodies to specific cytokines. Binding of these biotinylated 
primary antibodies was detected using streptavidin conjugated to HRP. The blot was incubated 
with chemiluminescent substrate and the membrane exposed to x-ray film. (C) Cytokine arrays 
showing the global cytokine array responses for positive (LPS and CD23) and negative (Untreated 
cells and IgG1 stimulation) controls. The patterns were recorded and analysed using ImageJ 
software. Signal intensity was calculated as a ratio relative to the positive control signal intensity, to 
standardize for exposure differences (D). The response to IgG1 is included as a representative 
example. All antibody isotypes were tested (IgG1, IgG2a, IgG2b and IgG3) and gave responses 
equivalent to IgG1.  
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Table  4-1 Antibody pairs used to determine response to integrin binding 
 
INTEGRIN 
 
ANTIBODY 
 
EPITOPE* 
 
 
AMF7 
 
Non-RGD 
 
 
αV  
LM142 
 
Non-RGD 
 
 
23C6 
 
RGD 
 
 
αVβ3  
LM609 
 
RGD** 
 
 
P1F6 
 
RGD 
 
 
αVβ5  
15F11 
 
Non-RGD 
 
 
PAH9 
 
Non-RGD 
 
 
β2  
MEM48 
 
Non-RGD 
 
 
Clone44 
 
RGD 
 
 
αMβ2  
ICO-GMI 
 
Non-RGD 
 
 
Clone3.9 
 
RGD 
 
 
αXβ2  
HC1.1 
 
RGD 
 
 
*RGD signifies that the antibody inhibits or blocks the adhesive function of the integrin; Non-RGD 
indicates that the antibody does not inhibit adhesion 
** Blocks adhesion via an allosteric site, i.e. does not bind directly to the RGD site 
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Figure  4.3 Cytokine Arrays for THP-1 treated with antibodies to αV integrins  
(A) Cytokine array template showing location of antibodies to specific cytokines on the 
nitrocellulose membrane. (B) Cytokine array profile of the cleared supernatant from THP-1 cells 
treated with controls (Bi) or antibodies to members of the αV integrin family (Bii). The integrin 
isoform targeted in each array is indicated above the blot, while the clone name corresponding to 
the antibody used is detailed below the individual blots. Cytokines bound to the membrane were 
detected with specific biotinylated antibodies, which in turn were detected using HRP-congujated 
streptavidin and chemiluminescent based detection. (C) Densitometric analysis of cytokine array 
pattern, showing the ratio of all of the individual cytokine signal intensities to the positive control 
signal. All 36 cytokines are displayed together in the bar chart to yield a global, semi-quantitative 
representation of the response to each treatment. The response to IgG1 is included as a 
representative example. All antibody isotypes were tested (IgG1, IgG2a, IgG2b and IgG3) and 
gave responses equivalent to IgG1.  
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Figure  4.4 Cytokine Arrays for THP-1 treated with antibodies to β2 integrins 
(A) Cytokine array template showing location of antibodies to specific cytokines on the 
nitrocellulose membrane. (B) Cytokine array profile of the cleared supernatant from THP-1 cells 
treated with controls (Bi) or antibodies to members of the β2 integrin family (Bii). The integrin 
isoform targeted in each array is indicated above the blot, while the clone name corresponding to 
the antibody used is detailed below the individual blots. Cytokines bound to the membrane were 
detected with specific biotinylated antibodies, which in turn were detected using HRP-congujated 
streptavidin and chemiluminescent based detection. (C) Densitometric analysis of cytokine array 
pattern, showing the ratio of all of the individual cytokine signal intensities to the positive control 
signal. All 36 cytokines are displayed together in the bar chart to yield a global semi-quantitative 
representation of the response to each treatment. The response to IgG1 is included as a 
representative example. All antibody isotypes were tested (IgG1, IgG2a, IgG2b and IgG3) and 
gave responses equivalent to IgG1.  
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4.2.3 Quantitative analysis of the cytokine output in 
response to integrin binding 
ELISAs were used to detect the presence of MIP-1β, IL-8 and RANTES in the 
supernatant of THP-1 cells treated with antibodies against integrins (Table 4-1). 
The ELISAs were validated for our purpose using positive and negative 
stimulations in a dose-response experiment (Figure 4-5). The response of THP-1 
cells to treatment with an isotype control (IgG1), RGDS and vitronectin was 
tested. The positive control selected was the 23C6 antibody specific for αVβ3 
that gave a large signal in the global cytokine array. A dose-dependent increase 
in cytokine production was observed for 23C6 (anti-αV antibody) but not for any 
of the other stimulations. The THP-1 cultures did not produce a significant 
amount of IL-8 and MIP-1β in response to treatment with IgG1 or the RGDS 
peptide or the ECM protein, vitronectin, even at the highest concentrations of 
5µg/mL. A high constitutive level of RANTES production, as detected in the 
cytokine arrays, was observed with untreated THP-1 cells and was slightly 
enhanced by stimulation of THP-1 cells with anti-αVβ3 antibody but not with any 
of the other treatments (Figure 4-5). 
We used these ELISAs to evaluate the role of different integrin families, subunits 
and epitopes in cytokine production using specifically selected antibodies. Figure 
4-6 shows the production of IL-8, MIP-1β and RANTES by the model monocytic 
cell line THP-1 after stimulation with antibodies against individual integrins. The 
data are displayed as stimulation index, which represents the fold elevation of 
cytokine production over the untreated cells (accounting for any constitutive 
expression). A fold stimulation value below 1 indicates a decrease in the 
cytokine output in response to a specific stimulus compared to the untreated 
control, while a fold stimulation value above 1 indicates an increase in the 
cytokine output in response to a specific stimulus compared to the untreated 
cells. THP-1 cells constitutively produced RANTES, but not IL-8 or MIP-1β. The 
concentration ranges for cytokines produced in response to stimulations were as 
follows: RANTES 1 000-10 000 pg/mL; IL-8 100-1 000pg/mL and MIP-1β 200-2 
000pg/mL.  
Figure 4-6 shows the production of IL-8 (A), MIP-1β (B) and RANTES (C) by THP-1 
cell cultures in response to stimulation with anti-integrin antibodies (Table 4-1). 
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The responses of THP-1 cells to antibodies against the αV integrin family are 
shown in the left hand panel (labelled Ai, Bi and Ci) and those to antibodies 
against the β2 family are shown on the left hand panel (labelled Aii, Bii, and 
Cii). No stimulation of cytokine production was observed with any of the control 
treatments for THP-1. IgG1, RGDS peptide and vitronectin failed to induce 
cytokine production and therefore have a fold stimulation equal to or below 1.  
Figure 4-6Ai shows the production of IL-8 by THP-1 cells induced by antibodies 
directed against members of the αV integrin family. Treatment of THP-1 cells 
with antibodies AMF7 and LM142, which are directed against the common αV 
subunit, produced a statistically significant increase in the production of IL-8 
production. Both treatments induced a similar fold stimulation of ~8-fold and 
~11-fold for AMF7 and LM142, respectively. For the αVβ3 and αVβ5 integrins, 
only one of the pairs of antibodies induced a significant response from the THP-1 
cells. For the αVβ3 integrin, a fold stimulation of ~9-fold was obtained for 
treatment with the 23C6 antibody, whereas the LM609 clone did not produce a 
statistically significant increase in IL-8 production by THP-1 cells. For the αVβ5 
heterodimer, the P1F6 antibody induced an equivalent ~9-fold increase over 
baseline IL-8 levels, while the 15F11 antibody, whilst still producing a 
statistically significant increase in IL-8 secretion, induced a much lower response 
(~3-fold stimulation).  
Figure 4-6Aii shows the IL-8 responses of THP-1 cells following stimulation with 
antibodies against members of the β2 family of integrins. THP-1 cells did not 
show any increase in IL-8 concentration over baseline in response to antibodies 
directed against the common β2 subunit. Neither the P4H9 nor the MEM48 
antibody induced any production of IL-8. An increase in the levels of IL-8 
produced was observed for treatment of the THP-1 cells with the Clone44 
antibody (directed against αMβ2) and the Clone 3.9 antibody (directed against 
αXβ2). The fold stimulations were ~7-fold and ~22-fold, respectively. The other 
antibody directed against αMβ2 (ICO-GM1) did not induce a statistically 
significant increase in IL-8 production.  
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Figure 4-6B shows the data for the production of MIP-1β by THP-1 cells under 
exactly the same set of conditions. A striking similarity is observed for the fold-
stimulation pattern of THP-1 cells in response to αV and β2 antibodies for the 
production of IL-8 and MIP-1β (compare Figures 4-6A and B). Exactly the same 
trend in stimulation is observed for IL-8 and MIP-1β production by stimulated 
THP-1 cells. A large increase in MIP-1β production was observed when THP-1 
cells were treated with AMF7, LM142, 23C6 and P1F6 antibodies (~5-fold, ~9-
fold, ~6-fold and ~7-fold, respectively). THP-1 cells also significantly increased 
production of MIP-1β in response to Clone44 (~10-fold), and Clone3.9 (~28-fold). 
In this case, the response to ICO-GMI was determined to be statistically 
significant, although it was much lower than that observed for Clone44 or 
Clone3.9 treatment. Again, treatment of THP-1 cells with antibodies against β2 
integrins resulted in a greater response, although the range of response was 
more limited than that observed with the αV antibodies.  
Figure 4-6C shows the production of RANTES by THP-1 cells in response to 
integrin binding. No statistically significant increase in cytokine production was 
seen with any of the controls for THP-1 cells. THP-1 cells were shown previously 
to produce RANTES constitutively. There was no significant stimulation over this 
background level in response to stimulation with any of the negative controls- 
IgG1, RGDS or vitronectin. Treatment with the anti-αV antibodies, AMF7 and 
LM142, and the anti-αVβ3 antibody, 23C6, produced small yet significant 
increases in RANTES production. Treatment with the anti-αXβ2 integrin antibody 
Clone3.9 induced a small but significant increase in RANTES production. Analysis 
of RANTES production was complicated by the high constitutive production by 
THP-1 cells. 
Overall, treatment of THP-1 cells with anti-αXβ2 antibody Clone3.9 lead to the 
greatest increase in IL-8 and MIP-1β production (~22-fold and ~28-fold 
respectively), although the cells responded to a greater range of antibodies 
directed against the αV family of integrins than the β2 family of integrins. The 
THP-1 cells failed to produce IL-8 or MIP-1β in response to binding the common 
β2 chain of the β2 family of integrins, but ligation of the common αV subunit 
stimulates cytokine release to a level similar that noted following binding of 
antibodies to the heterodimers αVβ3 or αVβ5.  
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Figure 4-7 shows the data for the production of IL-8, MIP-1β and RANTES by U937 
cells treated in the same manner as the THP-1 cell experiments. U937 cells did 
not show a statistically significant increase in IL-8 levels in response to 
treatment with any of the anti-αV antibodies. A modest increase in IL-8 
production of approximately 2-fold was observed after treatment with the αXβ2 
antibody, Clone3.9. Treatment of U937 cells with the LM142 and 23C6 antibodies 
resulted in statistically significant increases in MIP-1β (2-fold and 4-fold 
respectively). U937 cells did not show a significant increase in RANTES 
production in response to treatment with antibodies against αV or β2 integrins. 
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Figure  4.5 Cytokine production by THP-1 cells is not induced by binding 
controls 
THP-1 cells were treated overnight as indicated below and the presence of RANTES (A), MIP-1β 
(B) and IL-8 (C) in the cleared supernatant determined by ELISA. Untreated cells:black bars; 
Vitronectin:white bars; RGDS:light grey bars; IgG1:dark grey bars; diagonal-striped bars:anti-αVβ3 
23C6 Statistical analysis was performed using Student’s t-test *p<0.05. Data are representative of 
at least 3 separate experiments. The error bars indicate standard deviations (SD). The response to 
IgG1 is included as a representative example. All antibody isotypes were tested (IgG1, IgG2a, 
IgG2b and IgG3) and gave responses equivalent to IgG1.  
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Figure  4.6 Cytokine production by THP-1 cells in response to integrin 
ligation 
Supernatants from THP-1 cells stimulated with anti-αV antibodies (Ai, Bi and Ci) or anti-β2 
antibodies (Aii, Bii and Cii) were tested for the presence of IL-8 (Ai and Aii; white bars), MIP-1β (Bi 
and Bii; grey bars) and RANTES (Ci and Cii; black bars) using ELISA. Fold-stimulation represents 
the ratio of the cytokine concentration produced by the integrin-stimulated sample after treatment 
with the differentiating agent relative to the integrin-stimulated untreated cells.  Unt:Untreated cells; 
IgG1:Isotype control; RGDS: RGDS peptide; VN:vitronectin; AMF7:anti-αV; LM142:anti-αV; 
23C6:anti-αVβ3; LM609: anti-αVβ3; 15F11:anti-αVβ5; P1F6:anti-αVβ5; P4H9:anti-β2; MEM48: 
anti-β2; Clone44:anti-αMβ2; ICO-GM1:anti-αMβ2; Clone3.9:anti-αXβ2. Statistical analysis was 
performed using Student’s t-test *p<0.05. Data are representative of at least 3 separate 
experiments. The response to IgG1 is included as a representative example. All antibody isotypes 
were tested (IgG1, IgG2a, IgG2b and IgG3) and gave responses equivalent to IgG1.  
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Figure  4.7 Cytokine production by U937 cells in response to integrin binding 
Supernatants from U937 cells stimulated overnight with anti-αV antibodies (Ai, Bi and Ci) or anti-β2 
antibodies (Aii, Bii and Cii) were tested for the presence of IL-8 (Ai and Aii; white bars), MIP-1β (Bi 
and Bii; grey bars) and RANTES (Ci and Cii; black bars) using ELISA. Fold-stimulation represents 
the ratio of the cytokine concentration produced by the integrin-stimulated sample after treatment 
with the differentiating agent relative to the integrin-stimulated untreated cells.  Unt:Untreated cells; 
IgG1:Isotype control; RGDS: RGDS peptide; VN:vitronectin; AMF7:anti-αV; LM142:anti-αV; 
23C6:anti-αVβ3; LM609: anti-αVβ3; 15F11:anti-αVβ5; P1F6:anti-αVβ5; P4H9:anti-β2; MEM48: 
anti-β2; Clone44:anti-αMβ2; ICO-GM1:anti-αMβ2; Clone3.9:anti-αXβ2. Statistical analysis was 
performed using Student’s t-test *p<0.05. Data are representative of at least 3 separate 
experiments. The response to IgG1 is included as a representative example. All antibody isotypes 
were tested (IgG1, IgG2a, IgG2b and IgG3) and gave responses equivalent to IgG1.  
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4.2.4 Effect of integrin expression levels on cytokine 
production by THP-1 and U937 cells 
THP-1 and U937 cells were tested for their cytokine responses to stimulation by 
CD23-binding integrins (Figures 4-6 and 4-7). Stimulation of different integrins 
induced distinct patterns of production of IL-8, RANTES and MIP-1β by the two 
cell lines. To establish whether this was due to the levels of these integrins on 
the cell lines we examined the integrin expression levels on THP-1 and U937 
cells and related this to the levels of cytokines produced in response to binding a 
specific heterodimer (Figure 4-9).  
Figure 4-9A shows the expression of the four CD23 binding integrin heterodimers 
on the surface of U937 (Figure 4-9Ai) and THP-1 cell lines (Figure 4-9Aii). THP-1 
and U937 cells express similar levels of these integrin heterodimers. There was 
no significant difference between the different cell lines. Within an individual 
cell line, the most highly expressed integins were the αVβ3, αVβ5 and αXβ2 
heterodimers, with only low levels of αMβ2 integrin expressed. However, the 
cytokine production in response to stimulation of a particular heterodimer was 
markedly different between the cell lines (despite the equivalent integrin 
expression levels). 
Figure 4-9B shows the relationship between the relative expression of the 
different integrins on THP-1 cells (Figure 4-9Bi) and the levels of cytokines 
produced by stimulating them (Figure 4-9Bii). Of the β2 integrins, the β2 subunit 
is expressed to the highest level on the surface of THP-1 cells (black line), 
followed by the αXβ2 isoform (blue line) and then the αMβ2 heterodimer (red 
line). The hierarchy of cytokine production indicated that stimulation of cells 
with anti-αXβ2 antibodies (Clone3.9, blue arrow) resulted in the highest level of 
MIP-1β release. Stimulation of the cells with anti-αMβ2 (Clone44, red arrow) 
induced a moderate level of MIP-1β production, while binding of the β2 subunit 
did not result in the production of detectable levels of MIP-1β (black arrows). 
Integrin expression level alone in this case was unlikely to be the major 
determinant of concentrations of cytokines produced in response to integrin 
stimulation, either between cell lines or within different integrin isoforms on the 
same cell line. 
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Figure  4.8 Integrin expression level alone does not determine cytokine output 
(A) Expression levels of integrins on U937 (Ai) and THP-1 cells (Aii) was determined by flow cytometry. (B)  Expression levels of different isoforms of β2 integrins on THP-1 
cells was determined by flow cytometry. Integrin staining is shown as a solid black line and isotype staining is shown as grey shading (Bi) and the corresponding levels of 
MIP-1β production by binding those isoforms was determined by ELISA (Bii). Red line/arrow:αMβ2; Blue line/arrow:αXβ2; Black line/arrow:β2.Data are representative of at 
least 3 separate experiments. The error bars indicate standard deviations (SD). 
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4.2.5 Cytokine response after differentiation of THP-1 cells  
A difference in cytokine production in response to the same stimulus was observed 
between the two cell lines THP-1 and U937. These two cell lines represent 
monocytic cell lines at different maturation stages. U937 is more similar to an early 
blood monocyte 166, whereas the THP-1 cell line is more monocyte/macrophage in 
nature 165. To investigate further the role of cell differentiation state on integrin-
mediated cytokine production, we treated THP-1 cells with differentiating agents 
and compared the cytokine response to antibody-mediated stimulation of specific 
integrins.  
THP-1 cells were treated for 3 days with macrophage colony stimulating factor (M-
CSF/CSF-1), granulocyte/macrophage colony stimulating factor (GM-CSF) and 
dibutryl-cyclic adenosine monophosphate (db-cAMP). The cells were washed and 
integrin expression and cytokine production in response to integrin binding 
determined (Figures 4-9, 4-10 and 4-11, respectively). Expression of integrins was 
determined by flow cytometry. The integrin staining observed for untreated cells is 
shown in grey shading and the equivalent staining for M-CSF, GM-CSF or db-cAMP-
differentiated cells is shown as a black line. The cytokine production was 
determined by ELISA and is represented as fold-stimulation. This represents the 
ratio of the cytokine (RANTES, IL-8 or MIP-1β) concentration produced by the 
integrin-stimulated sample after treatment with the differentiating agent relative 
to the integrin-stimulated untreated cells.  
Figure 4-9 shows the comparison of the integrin expression levels (Figure 4-9A) and 
cytokine production level (Figure 4-9B) from untreated and M-CSF-treated THP-1 
cells. THP-1 cells that were treated with 10ng/mL M-CSF for 3 days did not show 
any appreciable change in the expression levels of the αVβ3, αVβ5, αMβ2 or αXβ2 
integrins (Figure 4-9A). A slight, non-specific increase was observed for RANTES 
production by untreated cells and in response to all stimulations. There was no 
increase in the IL-8 levels in response to any of the stimulations.  An increase in the 
fold-stimulation for the production of MIP-1β was observed in response to 
stimulation with the anti-αMβ2 antibody, but not with any of the other stimulations.  
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Figure 4-10 shows the effect of treatment of THP-1 cells with 1ng/mL GM-CSF for 3 
days. Treatment of THP-1 cells with GM-CSF did not considerably alter the 
expression of any of the CD23-binding integrins compared to the untreated cells 
(Figure 4-10A). There was no substantiated increase in the production of RANTES, 
IL-8 or MIP-1β for any of the stimulations tested (Figure 4-10B). 
Figure 4-11 shows the expression levels and cytokine production characteristics of 
THP-1 cells that had been treated with db-cAMP for 3 days prior to stimulation.  An 
increase in the expression levels of the αXβ2 integrin upon treatment with db-cAMP 
was noted, while there was no change in expression of αVβ3, αVβ5 or αMβ2. A 
general reduction in the secretion of RANTES was observed for untreated cells and 
in response to all stimulations. There was an increase in the fold stimulation for   
IL-8 and MIP-1β production in response to αVβ5 binding, but not for stimulation with 
any other integrin-directed antibody.   
Differentiation of THP-1 cells with db-cAMP led to changes in expression levels of 
specific integrin heterodimers. This change in expression, however, did not 
necessarily correlate with the levels of cytokines produced as a consequence of 
integrin stimulation. For example, treatment of THP-1 cells with M-CSF did not 
influence the expression levels of integrins compared to untreated THP-1 cells, but 
led to an increase in the production of IL-8 in response to 23C6 treatment. Although 
the expression levels of αVβ5 did not change, treatment of the THP-1 cell line with 
db-cAMP led to an increase in the production of IL-8 and MIP-1β in response to 
stimulation with the anti-αVβ5 antibody. The cell line U937 had similar surface 
expression of integrins to the THP-1 line, but responded differently to integrin 
stimulation (i.e. did not produce cytokines).  
Integrins play an important role in modulating the effects of other surface receptors 
and so we analysed the expression of other surface receptors after treatment of 
THP-1 cells with M-CSF, GM-CSF or db-cAMP. We hypothesised that cytokine 
production involved an additional receptor (apart from the integrin) and that the 
levels of this receptor may explain the discrepancies between expression level and 
cytokine production. The Fcγ receptors are immunoreceptors that recognise the 
constant region of immunoglobulins and have an important role in cytokine 
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production by monocytes. We also assessed the levels of CD47 (integrin associated 
protein). CD47 is part of the αVβ3 signalling complex and therefore its expression 
levels might influence cytokine production.  
Figure 4-12 shows the expression of the Fcγ receptors, CD16, CD32, CD64 and the 
integrin associated protein CD47, on U937 cells and on THP-1 cells before and after 
treatment with M-CSF, GM-CSF or db-cAMP.  There was no change in the expression 
of CD16, CD32, CD64 or CD47 by THP-1 cells that had been treated with M-CSF 
(Figure 4-12B), GM-CSF (Figure 4-12C) or db-cAMP (Figure 4-12D) compared with 
untreated THP-1 cells (Figure 4-12A). There was, however, a difference in the 
expression levels of the Fcγ receptors on the U937 cell line compared with the THP-
1 cell line. U937 cells did not express CD16 or CD32 and only expressed low levels of 
CD64 and CD47, compared with the THP-1 cells. We also tested the primary blood 
monocytes for the expression of these receptors. The cells stained positive for all 4 
receptors, although at lower levels than found on THP-1 cells.  
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Figure  4.9 Integrin expression and cytokine profile of THP-1 cells after 
differentiation with M-CSF 
THP-1 cells were cultured with or without 10ng/mL M-CSF for 3 days before analysis of integrin 
expression and cytokine production. (A) Untreated cells (grey shading) and M-CSF treated cells (black 
line) were stained for integrin expression by flow cytometry. (B) The cytokine production was 
determined by ELISA and is represented as fold stimulation. This represents the ratio of the cytokine 
(RANTES, IL-8 and MIP-1β) concentration produced by the integrin-stimulated sample after treatment 
with the differentiating agent relative to the integrin-stimulated untreated cells. Statistical analysis was 
performed using Students t-test. Data are representative of at least 3 separate experiments. The 
response to IgG1 is included as a representative example. All antibody isotypes were tested (IgG1, 
IgG2a, IgG2b and IgG3) and gave responses equivalent to IgG1.  
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Figure  4.10 Integrin expression and cytokine profile of THP-1 cells after 
differentiation with GM-CSF 
THP-1 cells were cultured with or without 1ng/mL GM-CSF for 3 days before analysis of integrin 
expression and cytokine production. (A) Untreated cells (grey shading) and GM-CSF treated cells 
(black line) were stained for integrin expression by flow cytometry. (B) The cytokine production was 
determined by ELISA and is represented as fold stimulation. This represents the ratio of the cytokine 
(RANTES, IL-8 and MIP-1β) concentration produced by the integrin-stimulated sample after treatment 
with the differentiating agent relative to the integrin-stimulated untreated cells. Statistical analysis was 
performed using Students t-test. Data are representative of at least 3 separate experiments. The 
response to IgG1 is included as a representative example. All antibody isotypes were tested (IgG1, 
IgG2a, IgG2b and IgG3) and gave responses equivalent to IgG1.  
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Figure  4.11 Integrin expression and cytokine profile of THP-1 cells after 
differentiation with dibutryl-cyclic AMP (db-cAMP) 
THP-1 cells were cultured with or without 100mM db-cAMP for 3 days before analysis of integrin 
expression and cytokine production. (A) Untreated cells (grey shading) and db-cAMP treated cells 
(black line) were stained for integrin expression by flow cytometry. (B) The cytokine production was 
determined by ELISA and is represented as fold stimulation. This represents the ratio of the cytokine 
(RANTES, IL-8 and MIP-1β) concentration produced by the integrin-stimulated sample after treatment 
with the differentiating agent relative to the integrin-stimulated untreated cells. Statistical analysis was 
performed using Students t-test. Data are representative of at least 3 separate experiments. The 
response to IgG1 is included as a representative example. All antibody isotypes were tested (IgG1, 
IgG2a, IgG2b and IgG3) and gave responses equivalent to IgG1.  
 134 
 
Figure  4.12 Expression of integrin associated receptors on monocytic cells 
THP-1 cells (with or without treatment with differentiating agents), U937 and CD14+PBMC were 
assessed for their expression of Fcγ receptors (CD16, CD32 and CD64) and CD47 (integrin associated 
protein) by flow cytometry. Isotype control staining is shown as grey shading and antibody staining is 
shown as a solid black line. The identity of the protein detected is indicated above the individual 
histograms. A: THP-1 cells in OptiMEM, B: THP-1 cells in OptiMEM with M-CSF, C: THP-1 cells in 
OptiMEM with GM-CSF D: THP-1 cells in OptiMEM with db-cAMP, E: U937 in OptiMEM, F: CD14+ 
blood monocytes. 
 135 
4.2.6 Cooperation between different integrin heterodimers 
The data in Figures 4-2 to 4-11 have shown that specific integrins can regulate 
cytokine production by monocytic cells when stimulated with antibodies against 
specific integrin isoforms, subunits and epitopes. Cross-talk amongst different 
integrins has been reported and so we investigated the response of monocytes to 
simultaneous stimulation with antibodies against multiple integrins. The production 
of RANTES, MIP-1β and IL-8 was monitored by ELISA after overnight stimulation with 
multiple antibodies as indicated in figure legends.  
We selected the anti-αVβ3 antibody 23C6 and the anti-αXβ2 antibody Clone3.9 for 
these analyses as they had induced high levels of cytokine production in the 
previous experiments. We examined the ability of the two antibodies to influence 
the cytokine production of the other when supplied at a suboptimal concentration. 
Figure 4-13A shows the response of THP-1 cells to incubation with increasing 
concentrations of Clone3.9 (0.2 – 1.0 µg/mL) in the absence (white bars) or 
presence (black bars) of a fixed suboptimal concentration of 23C6 (0.4µg/mL). The 
sub-optimal concentration of 23C6 was titrated in a dose-response experiment. The 
concentration of 23C6 at which cytokine production was half of the maximum 
concentration of cytokine produced by the cell line, was selected as the sub-
optimal concentration (data not shown). A dose-dependent increase in the levels of 
RANTES, IL-8 and MIP-1β was observed with the increasing Clone3.9 concentration. 
Cytokine production was enhanced at all concentrations by the addition of 
0.4µg/mL 23C6 antibody. Figure 4-13B shows the data for the reverse situation, 
where THP-1 cells were stimulated with increasing concentrations of 23C6 antibody 
alone (white bars) or in the presence of concentration of Clone3.9 (0.4µg/mL; black 
bars) and tested for the production of RANTES, IL-8 and MIP-1β. A dose-dependent 
increase in the production of all of these cytokines was observed with increasing 
23C6 concentration. The levels of RANTES, IL-8 and MIP-1β produced at all 
concentrations of 23C6 were enhanced by the addition of suboptimal concentrations 
of Clone3.9. These data indicated that simultaneous binding of the αVβ3 and αXβ2 
integrins enhanced cytokine production, and so we tested if any of the other 
integrins could influence the levels of cytokines produced in response to 23C6 or 
Clone3.9 stimulation.  
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Figure 4-14 shows the effect of incubation of THP-1 cells with the 23C6 antibody 
(0.2µg/mL) and increasing concentrations of antibodies against other αV integrins 
(anti-αV antibodies AMF7 and LM142 and anti-αVβ5 antibody P1F6). Figure 4-15 
shows the response of THP-1 cells to stimulation with 23C6 (anti-αVβ3 antibody) in 
conjunction with antibodies against members of the β2 integrin family (anti-αβ2 
antibodies Clone44 and ICO-GMI and anti-β2 antibody P4H9). The data are 
represented as stimulation index (SI). The stimulation index is the fold-stimulation 
of cytokine production when using 23C6 and another antibody together, over the 
level of cytokine produced by treatment with 23C6 alone. There was no statistically 
significant enhancement or inhibition of the levels of RANTES, IL-8 or MIP-1β 
produced by THP-1 cells in response to 23C6 when co-incubated with any of the 
antibodies AMF7 (αV), LM142 (αV) or P1F6 (αVβ5). Similarly, there was no 
statistically significant increase or decrease in stimulation index for the production 
of RANTES, IL-8 and MIP-1β when cells were treated with 23C6 (αVβ3) and the β2 
family antibodies, ICO-GMI (αMβ2), Clone44 (αMβ2) and P4H9 (β2). The co-
stimulation of THP-1 cells with 23C6 and the anti αMβ2 antibody ICO-GMI did appear 
to cause a modest, dose-dependent increase in the stimulation index for the 
production of IL-8, although these data were outside the confidence interval to be 
statistically significant (p=0.055 using Student’s t-test).  
Figure 4-16 and Figure 4-17 show the equivalent data for the treatment of THP-1 
cells with Clone 3.9 (αXβ2) and other antibodies against αV and β2 integrins, 
respectively.  THP-1 cells were treated with the Clone3.9 antibody (0.2µg/mL) and 
increasing concentrations of antibodies against αV integrins (anti-αV antibodies 
AMF7 and LM142 and anti-αVβ5 antibody P1F6) and β2 integrins (anti-αMβ2 
antibodies Clone44 and ICO-GMI and anti-β2 antibody P4H9). The data are 
represented as stimulation index (SI). The stimulation index is the fold stimulation 
of cytokine concentration determined when treating cells with Clone3.9 in 
conjunction with another antibody over the concentration of cytokine produced by 
treatment with Clone3.9 alone. There was no statistically significant change in the 
stimulation index for IL-8, RANTES or MIP-1β when THP-1 cells were stimulated with 
Clone3.9 in conjunction with any of the antibodies tested (Figures 4-16 and 4-17).   
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Figure  4.13 Cytokine production in response to simultaneous ligation of αVβ3 
and αXβ2 
THP-1 cells were stimulated overnight with (A) 0.4µg/mL 23C6 (anti αVβ3 antibody) alone (white bars) 
or with varying concentrations of Clone3.9 (anti-αXβ2 antibody) (black bars) or (B) 0.4µg/mL of 
Clone3.9 (anti αXβ2 antibody) alone (white bars) or varying concentrations of 23C6 (anti-αVβ3 
antibody) (black bars). Cleared supernatants were tested for the presence of cytokines by ELISA. 
Statistical analysis was performed using Student’s t-test *p<0.05. Data are representative of at least 3 
separate experiments.  The error bars indicate standard deviations (SD). 
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Figure  4.14 Effect of simultaneous ligation of αVβ3 and other αV integrins on cytokine production by THP-1 cells 
THP-1 cells were incubated overnight with 23C6 (0.2µg/mL) alone or in conjunction with increasing concentrations of (A) AMF7 (anti-αV antibody), (B) LM142 
(anti αV antibody) or (C) P1F6 (anti-αVβ5 antibody). Cytokine production was analysed by ELISA. Statistical analysis was performed using Student’s t-test. 
Data are representative of at least 3 separate experiments  
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Figure  4.15 Effect of simultaneous ligation of αVβ3 and β2 integrins on cytokine production by THP-1 cells 
THP-1 cells were incubated overnight with 23C6 (0.2µg/mL) alone or in conjunction with increasing concentrations of (A) ICO-GMI (anti-αXβ2 antibody), (B) 
Clone44 (anti αMβ2 antibody) or (C) P4H9 (anti-β2 antibody). Cytokine production was analysed by ELISA. Statistical analysis was performed using Student’s t-
test. Data are representative of at least 3 separate experiments. 
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Figure  4.16 Effect of simultaneous ligation of αXβ2 and αV integrins on cytokine production by THP-1 cells 
THP-1 cells were incubated overnight with Clone3.9 (0.2µg/mL) alone or in conjunction with increasing concentrations of (A) AMF7 (anti-αV antibody), (B) 
LM142 (anti αV antibody) or (C) P1F6 (anti-αVβ5 antibody). Cytokine production was analysed by ELISA. Statistical analysis was performed using Student’s t-
test. Data are representative of at least 3 separate experiments. 
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Figure  4.17 Effect of simultaneous ligation of αXβ2 and other β2 integrins on cytokine production by THP-1 cells 
THP-1 cells were incubated overnight with Clone3.9 (0.2µg/mL) alone or in conjunction with increasing concentrations of (A) ICO-GMI (anti-αXβ2 antibody), (B) 
Clone44 (anti αMβ2 antibody) or (C) P4H9 (anti-β2 antibody). Cytokine production was analysed by ELISA. Statistical analysis was performed using Student’s t-
test. Data are representative of at least 3 separate experiments. 
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4.2.7 Effect of serum on cytokine production by integrin 
stimulation 
All of the integrin stimulation experiments described thus far have been conducted 
in serum-free, OptiMEM medium. Given the role of integrins in cell adhesion and 
the presence of adhesive integrin ligands (such as vitronectin) in serum, we tested 
the effect of serum on cytokine production by 23C6 (αVβ3) and Clone3.9 (αXβ2).  
Figure 4-18 shows the production of RANTES, IL-8, MIP-1β and VEGF by THP-1 cells 
stimulated with increasing concentrations of 23C6 in OptiMEM alone (white bars) or 
OptiMEM supplemented with 5% serum (white bars). Serum does not negatively 
affect cytokine production by THP-1 cells in response to 23C6 treatment. In most 
cases, except for the production of RANTES, serum has a positive effect on cytokine 
production, leading to a slight but statistically significant increase in the levels of 
IL-8, MIP-1β and VEGF.  
Figure 4-19 shows the corresponding data for the stimulation of THP-1 cells with 
increasing concentrations of Clone3.9 in OptiMEM alone (white bars) or OptiMEM 
supplemented with FCS (grey bars). The presence of serum does not inhibit the 
production of RANTES, IL-8, MIP-1β and VEGF by THP-1 cells in response to Clone3.9 
stimulation. In the case of MIP-1β and VEGF, inclusion of serum in the reaction 
leads to a statistically significant increase in concentration in response to 
stimulation by Clone3.9. 
 
 143 
 
Figure  4.18 Effect of serum on αVβ3 induced cytokine production 
THP-1 cells were stimulated with increasing concentrations of 23C6 (anti-αVβ3 antibody) in the presence (grey bars) and absence (white bars) of 5% FCS and 
cytokine production detected by ELISA. Statistical analysis was performed using Student’s t-test *p<0.05. Data are representative of at least 3 separate 
experiments. The error bars indicate standard deviations (SD). 
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Figure  4.19 Effect of serum on αXβ2 induced cytokine production 
THP-1 cells were stimulated with increasing concentrations of Clone3.9 (anti-αXβ2 antibody) in the presence (grey bars) and absence (white bars) of FCS and 
cytokine production detected by ELISA. Statistical analysis was performed using Student’s t-test *p<0.05. Data are representative of at least 3 separate 
experiments. The error bars indicate standard deviations (SD). 
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4.2.8 Analysis of the responses to integrin stimulation in 
primary human monocytes 
The THP-1 and U937 cells are cell lines derived from patients with leukaemia 165, 166. 
The changes associated with these diseases may influence the cytokine responses of 
the cells. To confirm that integrin stimulation results in cytokine production under 
non-diseased, physiological conditions, we tested the responses of primary human 
CD14+ monocytes and human primary bone marrow monocytes. Primary CD14+ 
human monocytes from peripheral blood (CD14+PBMC) and bone marrow-derived 
monocytes (BMDM) were cultured in RPMI-1640 medium supplemented with 1% 
serum and 10ng/mL M-CSF for 3 days before staining for surface expression of 
integrins and determination of integrin-induced cytokine production.  
Figure 4-20 shows the expression of CD23-binding integrins on primary BMDM and 
CD14+PBMC as determined by flow cytometry. The BMDM and the CD14+PBMC both 
expressed the αVβ3, αMβ2 and αXβ2 integrins, while CD14+PBMC also expressed the 
αVβ5 integrin. 
Figures 4-21 and 4-22 show the responses of primary human BMDM and CD14+PBMC 
to integrin stimulation. The primary cells were stimulated under the same 
conditions used for stimulation of THP-1 cells and cytokines released into the 
supernatant quantified by ELISA. The cytokine production is shown as fold 
stimulation over the untreated sample, where a fold stimulation of 1 indicates that 
there was no cytokine produced over constitutive levels (BMDM and CD14+PBMC 
constitutively produced high levels of IL-8).   
Integrin stimulation had no effect on the levels of RANTES and IL-8 produced by 
CD14+PBMC. There was a statistically significant increase in the TNF-α production 
by CD14+PBMC in response to stimulation with Zymosan and with antibodies against 
the β2 heterodimers, αMβ2 (Clone44) and αXβ2 (Clone3.9). The CD14+PBMC did not 
produce TNF-α in response to stimulation with an antibody against the common β2 
chain (P4H9). There was no TNF-α response observed for CD14+PBMC stimulated 
with any of the anti-αV antibodies.   
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The BMDM showed a similar IL-8 profile to the CD14+PBMC; there was no effect on 
IL-8 levels by any of the integrin treatments. A statistically significant increase in 
the levels of RANTES, MIP-1β and TNF-α was observed for BMDM treated with the 
anti-αVβ3 antibody (23C6) and the anti-αXβ2 antibody (Clone3.9). αMβ2 stimulation 
with the ICO-GMI antibody also led to a statistically significant increase in the 
production of MIP-1β. The BMDM were the most similar to the THP-1 cell line in 
their cytokine responses to integrin stimulation.  
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Figure  4.20 Expression of integrins on primary human bone marrow and CD14+ 
blood monocytes 
Primary human monocytes from bone marrow (A) or peripheral blood (B) were incubated with anti-
integrin antibodies on ice and binding of these primary antibodies was detected by binding of a 
secondary antibody conjugated to PE. The integrin heterodimer targeted is indicated in the top right 
corner of the plot. Isotype control is shown as grey shading and the antibody binding is shown as a 
black line. 
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Figure  4.21 Production of cytokines by primary human bone monocytes in response to integrin stimulation  
Primary human bone marrow monocytes were stimulated overnight with antibodies against integrins. The cytokine production was detected by ELISA and is 
represented as fold stimulation. This represents the ratio of the cytokine (TNF-α, RANTES, IL-8 and MIP-1β) concentration produced by the integrin-stimulated 
sample relative to the unstimulated/untreated cells. IgG1:Isotype control; RGDS:RGDS peptide; VN:vitronectin; AMF7:anti-αV; LM142:anti-αV; 23C6:anti-αVβ3; 
LM609:anti-αVβ3; 15F11:anti-αVβ5; P1F6:anti-αVβ5; P4H9:anti-β2; MEM48:anti-β2; Clone44:anti-αMβ2; ICO-GM1:anti-αMβ2; Clone3.9:anti-αXβ2. Statistical 
analysis was performed using Student’s t-test *p<0.05. The response to IgG1 is included as a representative example. All antibody isotypes were tested (IgG1, 
IgG2a, IgG2b and IgG3) and gave responses equivalent to IgG1.  
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Figure  4.22 Cytokine production by primary CD14+ blood monocytes 
Primary human CD14+ peripheral blood monocytes were stimulated overnight with antibodies 
against integrins. The cytokine production was detected by ELISA and is represented as fold 
stimulation. This represents the ratio of the cytokine (TNF-α, IL-8 and MIP-1β) concentration 
produced by the integrin-stimulated sample relative to the unstimulated/untreated cells. 
IgG1:Isotype control; RGDS:RGDS peptide; VN:vitronectin; AMF7:anti-αV; LM142:anti-αV; 
23C6:anti-αVβ3; LM609:anti-αVβ3; 15F11:anti-αVβ5; P1F6:anti-αVβ5; P4H9:anti-β2; MEM48:anti-
β2; Clone44:anti-αMβ2; ICO-GM1:anti-αMβ2; Clone3.9:anti-αXβ2. Statistical analysis was 
performed using Student’s t-test *p<0.05. The response to IgG1 is included as a representative 
example. All antibody isotypes were tested (IgG1, IgG2a, IgG2b and IgG3) and gave responses 
equivalent to IgG1.  
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4.3 Discussion 
CD23 induces cytokine production by monocytic cells through an interaction with 
integrins 40, 41, 84. There are four integrins which bind CD23, two from the αV 
family, namely αVβ3 and αVβ5, and two from the β2 family, namely αMβ2 and 
αXβ2. We have investigated the individual contribution of these integrins to 
cytokine production by monocytes, using antibodies directed against these 
integrins. This approach has been used to a limited extent by some laboratories 
to investigate the role of the β2 integrins 41, 84, but has not been previously 
performed for the role of CD23-binding αV integrins.  
Antibodies were selected to investigate the role of the different integrin families 
(e.g. αV vs β2 integrins); to analyse the role of different heterodimer isoforms 
(e.g. αV vs αVβ3 vs αVβ5); and to investigate the role of specific epitopes within 
a particular isoform (e.g. different antibody clones against the same 
integrin/subunit) (Table 4-1). We used two monocytic cell lines to address the 
role of cell differentiation state on cytokine production.  
The preliminary analysis was conducted using a global cytokine array technique. 
This allowed the detection of 36 different cytokines in one supernatant in a 
simultaneous assay. We selected the particular cytokine array based on previous 
investigations into the types of cytokines produced by monocytes in response to 
CD23. Although this technique was qualitative, it was possible to use 
densitometry to produce standardised data that allowed comparison of the 
responses of different stimulating antibodies. Visual observation alone of the 
arrays could be misleading due to exposure differences between individual blots, 
which influenced signal intensity. The positive control signals on each blot are 
independent of integrin treatment and therefore were used to standardise the 
signal intensity between blots.  
At the outset of the analysis, we were uncertain whether each treatment would 
result in a very different cytokine profile. We therefore used the cytokine arrays 
to perform the preliminary qualitative analysis and assess the production of a 
wide range of cytokines, from which we could subsequently select specific 
cytokines for quantitative analysis. Analysis of the cytokine array profiles from 
THP-1 cells treated with antibodies against CD23-binding integrins indicated that 
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the cytokine profile produced did not differ significantly between different 
integrin families or isoforms. We did not find that one family regulated a 
particular group or groups of cytokines, as we may have hypothesised. Our 
analyses suggested that, although the cytokine profile may be similar, the 
concentration of cytokines produced was influenced by integrin family, integrin 
isoform and integrin epitope targeted.  
We selected three chemokines RANTES, IL-8 and MIP-1β for the quantitative 
analysis. These chemokines were selected on the basis of the qualitative arrays 
and also because they have similar roles in the biology of the immune system. 
They are all chemotactic cytokines involved in the recruitment and activation of 
immune cells to the site of infection and, in the case of RANTES and MIP-1β, 
they share a common receptor (CCR5). We attempted to define a hierarchy of 
importance for the CD23 binding integrins in the production of these cytokines 
by monocytic cells.  
Using the quantitative ELISAs, we determined that cytokine production by THP-1 
cells in response to integrin binding results in the production of physiologically-
relevant levels of cytokines. The concentrations of cytokines detected in our 
analyses were similar to the concentrations observed in human serum in 
physiological and pathological conditions (Table 6-2). The interaction was 
specific and influenced by the integrin family, the subunit composition of the 
heterodimer and by the epitope bound on the heterodimer. It was not simply 
sufficient to have a high level of expression of a particular heterodimer to 
induce cytokine production; a precise signal was required.  
4.3.1 Role of integrin family on cytokine production 
Both CD23-binding members of the αV and β2 family of integrins induced 
cytokine synthesis by THP-1 cells. Cytokine production in response to binding of 
αVβ3, αMβ2 and αXβ2 have been published previously by other groups 40, 74. Our 
group has recently identified the αVβ5 integrin as a new receptor for CD23 75. 
This thesis is the first to identify cytokine production by monocytic cells in 
response to stimulation with antibodies against the αVβ5 integrin. Stimulation of 
THP-1 cells with an antibody against αVβ5 (P1F6) induced synthesis of RANTES, 
IL-8 and MIP-1β.  
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Using antibodies against different isoforms within the αV and β2 families we 
investigated the role of individual heterodimer isoforms in cytokine production. 
Within the αV family of integrins, both antibodies selected against the αV 
subunit (AMF7 and LM142) were able to induce synthesis of RANTES, IL-8 and 
MIP-1β. Antibodies 23C6 and P1F6 directed against αVβ3 and αVβ5, respectively, 
were able to induce cytokine synthesis. Similarly, antibodies against the αMβ2 
and αXβ2 integrins induced cytokine production (antibodies Clone44 and 
Clone3.9, respectively). However, stimulation of THP-1 cells with antibodies 
against the common β2 subunit using antibodies MEM48 or P4H9 failed to induce 
synthesis of cytokines. Taken together, these data suggest that the important 
determinant of integrin-mediated cytokine production could be the integrin α 
subunit. All of the stimulations involving the α subunit of the heterodimer 
resulted in cytokine production, even if only the α subunit (i.e. not the 
heterodimer) was targeted. Ligation of the α subunit alone was sufficient to 
induce cytokine production, while the β subunit alone was not. The binding site 
for CD23 on integrins remains to be identified, although a number of groups have 
suggested that the binding site for CD23 on integrins and thus the site 
responsible for inducing cytokine production, is located on the α chains of the 
integrins 40, 83. This may be important in regulating the signalling pathways that 
arise from integrin ligation, as both the α and β subunits contact cytoplasmic 
signalling molecules and are capable of inducing signalling cascades in the 
cytoplasm. In the case of αVβ3, the phosphorylation of the β3 tail relies on the 
presence of the αV subunit 187.  
It was interesting to find two distinct families of integrins (αV and β2) both 
influencing cytokine production by monocytic cells. The production of cytokines 
is specific and therefore it is possible that these different families of integrin 
regulate cytokine production under different conditions or environments. For 
example, the β2 integrin family is expressed exclusively on leukocytes and not 
on other cell types in the body. As such, β2-mediated cytokine production may 
be important for processes that are specific to leukocytes, such as extravasation 
and oxidative burst. The αV integrins, however, are expressed by a variety of 
cell types, such as fibroblasts, in addition to leukocytes. Therefore, their role in 
cytokine production will not be limited to those functions related to leukocytes. 
The αV-mediated cytokine production may substitute for β2 integrins on other 
cell types. The expression pattern of particular integrins is developmentally 
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regulated and specific to certain cell types. Therefore, the ability of individual 
integrins to induce cytokine production may be regulated at the level of integrin 
expression. Additionally, integrins are known to cooperate with other receptors, 
including other integrins, as we have shown with the αVβ3 and αXβ2 integrins 
(See Figures 4-12 to 4-16). Stimulation of cells with antibodies against both 
integrins led to an increase in cytokine production over the levels produced by 
stimulation of a single integrin. Therefore, the cytokine output of a particular 
cell will also be influenced by the different types of integrins expressed on the 
cell surface.  
4.3.2 Role of integrin isoform 
Cytokine output was influenced by the heterodimer within the integrin family 
that was targeted. Stimulation of the cells with antibodies against the αVβ3 and 
αVβ5 integrins induced similar cytokine responses by monocytic cells. The αVβ3 
and αVβ5 integrins were expressed at comparable levels and induced a similar 
increase in the fold stimulation of cytokine production by THP-1 cells. In 
contrast, the αMβ2 integrin induced lower levels of cytokines than the αXβ2 
integrin. THP-1 cells express significantly lower levels of αMβ2 than αXβ2, 
although the expression level alone of a particular integrin was not sufficient to 
influence the production of cytokines. In the presence of the correct signal to 
induce cytokine production, however, expression levels may influence the 
concentration of cytokines released. This may account for the difference 
observed in the concentrations of cytokine produced by stimulation of αMβ2 
versus αXβ2. Although treatment of the THP-1 cells with GM-CSF led to an 
increase in the expression of αMβ2, we did not observe an increase in αMβ2-
mediated cytokine production. This may indicate, again, that expression levels 
of an integrin are not the major determinant of its ability to induce cytokine 
production. We cannot exclude the possibility though that there may have been 
changes other than in αMβ2 expression in the cell line after GM-CSF treatment 
that we did not observe, but which would explain the discrepancy between 
integrin level and cytokine production.  
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4.3.3 Role of integrin epitope 
We investigated the role of the integrin epitope on the production of cytokines 
by integrin stimulation using paired antibodies against the same heterodimer. 
We observed that there was an epitope effect, since for both the αV and β2 
heterodimers, only one of the paired antibodies elicited a response. Therefore, 
the site at which the integrin is bound is important for inducing cytokine 
production. This comparison is independent of concentration as both antibodies 
bind the same heterodimer and gives an indication of the specificity of the 
interaction. For the αVβ3 integrin, the 23C6 antibody induced high levels of 
cytokine synthesis by THP-1 cells. The other αVβ3 antibody used in the analysis, 
LM609, failed to induce the production of the cytokines studied. This suggests 
that the 23C6 clone may recognise the site on the heterodimer required to 
activate this integrin to induce cytokine production, while LM609 did not. The 
mechanism of this interaction will need to be determined; 23C6 may activate 
αVβ3 by binding to the critical site or through an allosteric mechanism. This 
remains to be determined. In addition, an analysis of the affinities of the 
individual antibodies should be undertaken, to ensure that the responses 
observed are not solely due to the strength of the interaction.  
4.3.4 Role of cell differentiation status 
We tested two monocytic cells lines, THP-1 and U937, for their ability to 
produce cytokines in response to integrin binding. THP-1 cells are derived from 
the peripheral blood of a patient suffering with acute myeloid leukaemia 165. 
U937 cells were derived from a patient with histiocytic lymphoma 166. Both cell 
lines are routinely used as model cell systems for analysis of 
monocytic/macrophage responses.  
The two lines expressed similar levels of CD23-binding integrins, but responded 
differently to equivalent stimulation. This suggests that cell differentiation state 
may influence cytokine production in response to integrin stimulation. These 
data were supported by the studies involving the differentation of THP-1 cells 
using M-CSF, GM-CSF and db-cAMP. In these cases, a change in the expression 
level of the integrins did not correlate with an increase in cytokine production in 
response to integrin binding. It may be however, that THP-1 cells are already too 
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differentiated to observe any changes in response to treatment with the 
different agents. These experiments should have rather been conducted on the 
less differentiated U937 cell line.  
It is possible that there was an increase in integrin activation without a change 
in expression levels that led to the increases in cytokine production. This is a 
difficult parameter to measure in the context of this interaction. The integrin 
stimulation in these experiments was performed using soluble ligands with cells 
in suspension and therefore it is difficult to define integrin activation under 
these conditions. Most analyses define integrin activation in terms of adhesion, 
and consequently the reagents available for the study of integrin activation 
(conformational antibodies), are based on the adhesive/RGD-binding abilities of 
integrins. We anticipate that the site on the integrin that modulates cytokine 
production is independent of the RGD site, although we have yet to identify it. It 
seems unlikely therefore, that activation of an integrin in the “classical 
adhesion-based” sense would enhance cytokine production. Our hypothesis is 
supported by the fact that the inclusion of FCS (which contains RGD-containing 
ligands) does not inhibit or dampen the cytokine response. Inclusion of FCS in 
the medium led to a statistically significant increase in cytokine production. 
Chemokines are known to activate integrins, this may lead to RGD binding and 
enhancement of the cytokine response. ECM proteins alone cannot induce 
cytokine response in solution. Alternatively, it may simply be due to the fact 
that the cells are better adapted and less stressed in media containing serum. 
The possible interplay between adhesive and non-adhesive integrin signalling 
will be addressed as more information regarding the role of integrins in non-
adhesion based signalling becomes available. 
4.3.5 Cooperation between integrins and other receptors 
The role of integrins as modulators of the activity of other surface receptors is 
an example of adhesion-independent integrin-based signalling. Integrins are 
signalling molecules in their own right, but have also been shown to show 
synergy with other surface receptors. Cell differentiation is often associated 
with changes in activity and changes in the expression levels of surface proteins. 
The production of cytokines by integrins, therefore, may rely on the expression 
of an additional surface receptor that is developmentally regulated.  
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We analysed the expression of the Fcγ receptors, a family of immunoreceptors 
which play a key role in cytokine production by monocytes 188. Three Fcγ 
receptors are expressed on monocytes, CD16, CD32 and CD64. CD64 is the high 
affinity receptor, which is capable of binding monomeric IgG, while the CD16 
and CD32 receptors only bind IgG as part of an immune complex. Fc receptors 
have an important role in a number of integrin-mediated immune functions 189-
192, which might influence cytokine production. As we were using antibodies, it 
was plausible that Fcγ receptors may be involved in the interaction.  
We did not find any change in the levels of Fcγ receptors on the differentiated 
THP-1 cells that could explain the discrepancies between integrin expression 
levels and cytokine production. Interestingly, U937 cells, which did not produce 
significant quantities of cytokines in response to integrin binding, did not 
express CD16 or CD32 and only expressed low levels of CD64. The precise role of 
the Fcγ receptors in integrin-induced cytokine production would need to be 
addressed using the corresponding Fab fragments that lack the Fc portion of the 
antibody, as opposed to whole immunoglobulin molecule. Isotype controls were 
used to control for the contribution of Fcγ receptors, although they are not 
necessarily a true representation of the immune complexes required to induce 
cytokine production by Fcγ receptors. A better approach would have been to use 
Fcγ receptor blockers in conjunction with the specific antibodies.  However, 
even if Fcγ receptors are involved in the mechanism of integrin-mediated 
cytokine production, the interaction was still specific, as it was only observed in 
specific cases (such as 23C6), not with any antibody (such as LM609).  
We also analysed the expression of CD47 on the differentiated THP-1 cells. CD47 
is a component of the αVβ3 signalling complex and therefore an increase in CD47 
levels may lead to an increase in αVβ3-mediated signalling without altering αVβ3 
levels. There was no change in the expression of CD47 on the differentiated 
THP-1 cells or U937 cells that could explain the differences between change in 
expression level and cytokine production. It is still possible, however, that an 
additional, as yet unidentified, receptor is regulating integrin-mediated cytokine 
production.  
We did not observe cooperativity between different integrins during cytokine 
production. Co-stimulation of THP-1 cells with the 23C6 and Clone3.9 antibody 
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led to higher levels of cytokine production, than when used alone at equivalent 
concentrations. This indicates that the pathways that lead from αVβ3 and αXβ2 
integrins during cytokine production are not opposing and lead to a similar 
outcome. We would anticipate that both integrins activate the same pathway, 
possibly via a common co-receptor, although we do not currently have the data 
to support this conclusion. To observe cooperativity between the integrins, we 
would have expected an antibody that did not normally induce cytokine 
production (such as P4H9) to enhance the cytokine production of a suboptimal 
level of 23C6 or Clone3.9. We did not observe a statistically significant effect 
with any of the co-stimulations tested.  
4.3.6 Integrin-mediated cytokine production by primary 
cells 
Although used as a model for monocytic cells, the THP-1 cell line is derived from 
a patient suffering from acute myeloid leukaemia and carries the MLL-AF9 
mutation 165. It may be a better model for integrin-mediated cytokine production 
during pathology than in physiological conditions. We analysed the cytokine 
responses of primary cells (BMDM and CD14+PBMC) to integrin stimulation. The 
CD14+PBMC produced cytokines upon β2 ligation, but did not produce cytokines 
in response to stimulation with antibodies against αV integrins. The BMDM gave 
the most similar response to THP-1 cells and produced cytokines in response to 
both αV and β2 antibodies. This was unexpected as THP-1 cells are routinely 
used as a model for macrophage/monocytic cells and therefore it was 
anticipated that the CD14+PBMC would be the most similar in response to THP-1. 
These data would suggest that in fact, THP-1 cells are more similar to BMDM in 
their integrin-mediated cytokine responses. These data further suggest that 
differentiation state is crucial for integrin-mediated cytokine synthesis.  
We have analysed the importance of stimulation of different CD23-binding 
integrins in cytokine production by monocytic cells. This analysis has indicated 
that integrin-mediated cytokine production is specific and influenced by integrin 
family, isoform and epitope targeted. The production of these chemokines may 
have a role in the biology of the immune system and the monocytes themselves. 
CD23 itself also induces maturation/activation of monocytes via its interactions 
with β2 integrins 74, 193.  
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5 ROLE OF αVβ3 INTEGRIN IN MONOCYTE 
DIFFERENTIATION 
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5.1  Introduction 
5.1.1 The αVβ3 integrin 
The αVβ3 integrin is a member of the vitronectin receptor family, integrins 
which all contain the αV subunit in a non-covalent association with one of 5 β 
chains, namely β1, β3, β5, β6 or β8, and have the capacity to bind vitronectin 
194. The αVβ3 integrin is expressed at low levels in most normal tissues including 
intestinal, vascular and smooth muscle, although in general, the other αV 
isoforms are more widely expressed in normal tissues. High levels of αVβ3 
expression in vivo are observed in bone, placenta, inflammatory sites and 
invasive malignancies (including melanoma, glioma, ovarian and breast 
tumours). Specifically, cell types which express high levels of the αVβ3 integrin 
are mature osteoclasts (bone resorbing cells), activated macrophages, 
angiogenic endothelial cells and migrating smooth muscle cells 195.  
The aVβ3 integrin is one of the most well studied of the integrins, with the 
recent information on the general structure and conformational regulation of 
integrin activation being based on the published crystal structures of the 
extracellular domain of the αVβ3 integrin 94, 98. The αVβ3 integrin plays an 
important role in adhesion and non-adhesion based interactions in cells.  As a 
cell adhesion receptor it binds a wide range of ECM proteins in addition to 
vitronectin, including fibronectin, fibrinogen, osteopontin and thrombospondin. 
These interactions are mediated via recognition of the RGD motif in the various 
ECM proteins. These adhesive interactions are important during 
osteoclastogenesis and in the case of metastatic cancers. The αVβ3 integrin also 
functions as a receptor for a number of viruses during entry into cells. These 
interactions are both RGD-dependent and RGD-independent (Table 6-1). 
In addition to its role in cell adhesion and migration processes, αVβ3 associates 
with and modulates the activity of a number of growth factor receptors, 
including the platelet-derived growth factor (PDGF) receptor 196-198, basic 
fibroblast growth factor (BFGF) receptor 137, 199-203, transforming growth factor-β 
(TGFβ) receptor 204-206, insulin growth factor (IGF) receptor140, 207 and vascular 
endothelial growth factor (VEGF) receptor 137, 196, 197, 208. The αVβ3 integrin has 
also been shown to associate with the M-CSF receptor, c-FMS, during osteoclast 
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development and macrophage activation 142, 209, 210. The combined expression 
patterns and functions of αVβ3 make it an attractive target for therapies against 
a number of inflammatory disorders, rheumatic diseases and cancers 194, 211-216.   
5.1.2 Macrophage differentiation and activation  
Macrophages are a highly heterogeneous population that fulfil a range of 
functions in the immune system. They are the precursors for a number of 
terminally differentiated cells with specialised functions in the body, including 
osteoclasts and dendritic cells. Macrophages develop when blood monocytes 
move into the tissues in response to cues from the local environment. 
Macrophages can be activated by a number of different stimuli, each of which 
results in a macrophage that is polarised to exhibit specific characteristics. 
Activated macrophages can be classified as having undergone either a classical 
or alternative programme of activation.  
5.1.2.1 Classically Activated Macrophages (M1) 
Classically activated macrophages develop in response to treatment with IFN-γ 
and TNF-α. These macrophages are pro-inflammatory and produce high levels of 
pro-inflammatory cytokines, including TNF-α, IL-1 and IL-6 217. This type of 
macrophage is traditionally associated with Th1 responses that result in 
inflammation and the destruction and clearance of intracellular pathogens and 
tumour cells 217.  
5.1.2.2 Alternatively Activated Macrophages (M2) 
Alternatively activated macrophages are generally classed as anti-inflammatory 
and are usually identified due to their high expression of IL-10 and lack of IL-12 
expression 6. M2 macrophages can be further sub-classified into M2a (also known 
as alternatively activated), M2b (also known as type II activated) and M2c (also 
known as deactivated) macrophages, according to the activating signals under 
which they arise and their subsequent cytokine production profiles. M2a 
macrophages develop in response to treatment with agents including IL-4, IL-13 
and glucocorticoids, while M2b develop in response to TLR or IL-1R ligation and 
immune complexes, and M2c macrophages develop in response to IL-10 
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treatment. M2 macrophages are associated with anti-inflammatory, tissue 
remodelling and pro-cancer activity. M2b macrophages are distinct in that they 
continue to produce the pro-inflammatory cytokine TNF-α, in addition to the 
anti-inflammatory IL-10 16.   
5.1.3 Activated macrophages and disease 
Activated macrophages play an important role in the development and 
progression of a number of diseases 2. Both pro-inflammatory M1 activated 
macrophages and anti-inflammatory M2 macrophages can contribute to human 
disease. Pro-inflammatory M1 activated macrophages are a hallmark of a number 
of inflammatory diseases, including rheumatoid arthritis 194, 217. The production 
of cytokines (such as TNF-α, IL-6 and IL-1) by M1 macrophages is responsible for 
inflammation observed during these diseases. Anti-inflammatory M2 
macrophages also have a role in human pathology, most likely as tumour-
associated macrophages (TAM) 218. TAMs are a M2 population of activated 
macrophages recruited to tumour sites, which do not destroy tumours, but 
rather contribute to their survival and development. TAMs aid in the 
establishment of a favourable tumour microenvironment by the release of pro-
tumourgenic and pro-angiogenic mediators, including factors like VEGF and IL-8 
219.  
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5.2  Results 
5.2.1 Integrin signalling during cytokine production  
Stimulation of THP-1 cells with an anti-αVβ3 antibody 23C6 led to the production 
of high levels of cytokines. We examined the early signalling events that 
occurred in the THP-1 cells after integrin stimulation with 23C6. Activation of 
the β3 integrin has been shown to induce phosphorylation of the cytoplasmic tail 
at different sites 220-224. To test if 23C6 was inducing cytoplasmic signalling by 
the αVβ3 (i.e., 23C6 was activatory as opposed to inhibitory), we examined the 
phosphorylation state of the β3 tail in THP-1 cells after treatment with 
increasing concentrations of 23C6. Figure 5-1 shows Western blots for the 
phosphorylation of the β3 cytoplasmic domain at residues Tyr773 or Tyr785. In 
the absence of treatment, there was no phosphorylation of the β3 tail at either 
residue (Tyr773 or Tyr785). Ligation of αVβ3 with the 23C6 antibody led to 
detectable phosphorylation of the β3 tail at Tyr773 at concentrations ranging 
from 0.25µg/mL – 5µg/mL antibody. There was no detectable phosphorylation of 
Tyr785 of the β3 cytoplasmic tail at any concentration of 23C6 treatment.  
Integrins are known to activate the mitogen-activated protein kinase (MAPK) 
pathway in many cell lineages 84, 225-228. We tested if treatment of THP-1 cells 
with the anti-αVβ3 antibody 23C6 in solution led to activation of the MAPK 
pathway and subsequent phosphorylation of extracellular signal-regulated kinase 
(ERK). Figure 5-2 shows the Western analysis for the phosphorylation of ERK in 
THP-1 cells treated with 23C6. Actin was used as a loading control and 
densitometry was performed using the ImageJ program, although using total ERK 
levels as a loaded control would have been more accurate. Figure 5-2A shows 
the phosphorylation of ERK in THP-1 cells treated with increasing concentrations 
of 23C6 for 30 min. Figure 5-2B shows the response of THP-1 cells treated with 
1µg/mL of 23C6 at different time points. Phosphorylation of ERK was observed 
when THP-1 cells were stimulated with 23C6.  
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We analysed the importance of ERK activation in integrin-mediated production 
of cytokines using the mitogen-activated ERK-kinase (MEK) inhibitor U0126. MEK 
directly phosphorylates ERK during MAPK signalling 229. THP-1 cells were 
stimulated to induce cytokine production using LPS (positive control), 23C6 
(anti-αVβ3 integrin) or Clone3.9 (anti-αXβ2) in the absence and presence of the 
MEK inhibitor U0126, and cytokines (RANTES, MIP-1β and IL-8) released into the 
supernatant were detected by ELISA (Figure 5-3). THP-1 cells stimulated with 
LPS, 23C6 or Clone3.9 in the absence of U0126 produced high levels of RANTES 
(Figure 5-3A white bars), IL-8 (Figure 5-3B white bars) and MIP-1β (Figure 5-3C 
white bars). THP-1 cells were stimulated with the same treatments in the 
presence of the MEK inhibitor, U0126. Inclusion of the MEK inhibitor in the 
reaction lead to a statistically significant reduction in the concentrations of 
RANTES (Figure 5-3A grey bars), IL-8 (Figure 5-3B grey bars) and MIP-1β (Figure 
5-3C grey bars) produced in response to integrin stimulation with either 23C6 or 
Clone3.9. LPS-induced RANTES production was statistically reduced by U0126 
treatment, while LPS-induced IL-8 and MIP-1β concentrations did not differ 
significantly in the presence or absence of U0126. The MEK inhibitor did not 
completely inhibit cytokine production, as low levels of RANTES, IL-8 and MIP-1β 
were still released in the presence of U0126. In general, αXβ2-stimulated 
cytokine production was inhibited to a greater degree than the αVβ3-mediated 
cytokine production. Interestingly, treatment of cells with U0126 also inhibted 
the constitutive expression of RANTES observed previously with THP-1 cells.  
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Figure  5.1 Phosphorylation of β3 tail in response to binding of anti-αVβ3 
antibody to THP-1 cells 
THP-1 cells were incubated with increasing concentrations of 23C6 (anti-αVβ3) antibody for 
30mins. Lysates prepared were resolved by SDS-PAGE and probed for the presence of specific 
phosphorylation of the β3 integrin using antibodies to residues phosphotyrosine 773 and 
phosphotyrosine 785. Actin was used as a loading control. Data are representative of at least 3 
separate experiments. 
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Figure  5.2 Integrin binding induces ERK phosphorylation 
 (A) THP-1 cells in OptiMEM were stimulated with increasing concentrations of 23C6 (anti-αVβ3 
antibody) for 30mins. (B) THP-1 cells in OptiMEM were incubated with 1µg/mL of 23C6 (anti-αVβ3 
antibody) and samples taken at specific time points. Cell lysates were analysed for expression of 
phosphorylated ERK and actin (loading control) by SDS-PAGE and Western blotting. Signal 
intensity was quantified by densitometry and represented as a ratio of pERK:Actin to standardise 
for loading inaccuracies. Data are representative of at least 3 separate experiments. 
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Figure  5.3 Inhibition of MEK blocks integrin-mediated cytokine production 
Cytokine production by THP-1 cells was determined in the presence (grey bars) and absence 
(white bars) of the MEK inhibitor U0126 (10 µM). Cytokines released into the supernatant were 
detected by ELISA. Unt:untreated; IgG1:isotype control; LPS:positive control; 23C6:anti-αVβ3 
antibody; 3.9:anti-αXβ2 antibody. Statisitical analysis was performed using Student’s t-test*p<0.05. 
Data are representative of at least 3 separate experiments. The response to IgG1 is included as a 
representative example. All antibody isotypes were tested (IgG1, IgG2a, IgG2b and IgG3) and 
gave responses equivalent to IgG1.  
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5.2.2  Analysis of the effects of cytokines produced by 
integrin ligation upon migration of THP-1 cells 
RANTES, IL-8 and MIP-1β are all involved in migratory responses of leukocytes in 
vivo and in vitro 12, 230-234. We therefore analysed the chemotactic ability of the 
supernatant containing chemokines produced by THP-1 cells in response to 
integrin binding.  
THP-1 cells were treated with different agents overnight and cleared 
supernatants collected. These supernatants were subsequently used as the 
chemotactic stimulus in transwell migration assays using unstimulated THP-1 
cells. The concentrations of IL-8, RANTES, VEGF and MIP-1β in the supernatants 
were quantified prior to use in the transwell assays. Consistent levels of 
cytokines were detected in all supernatants used in the analysis (data not 
shown). The transwell migration assays are conducted in multiwell plates that 
contain an upper and lower chamber separated by a polycarbonate membrane. 
Supernatants from THP-1 cells treated with stimulating agents (LPS, 23C6 or 
Clone3.9) were cleared by centrifugation and filtration and the levels of 
RANTES, IL-8 and MIP-1β quantified by ELISA. Untreated THP-1 cells in OptiMEM 
were placed in the upper chamber of the transwell plate and cleared 
supernatants in the lower chamber. The plate was incubated for 3 hours at 370C 
and cells that had migrated from the upper chamber across the membrane into 
the lower chamber were collected and quantified by flow cytometry.  
The migration of unstimulated THP-1 cells across the transwell membrane was 
tested in response to OptiMEM or supernatant from stimulated THP-1 cells 
(Figure 5-4). A small number of cells migrated in response to OptiMEM. This can 
be considered due to random migration. There was a statistically significant 
increase in the number of migratory cells when cleared supernatant from 23C6-
stimulated or Clone3.9-stimulated cells was used instead of OptiMEM (Figure 5-
4A). There was no statistically significant increase in migration observed with 
cleared supernatant from LPS-stimulated supernatants over OptiMEM alone. 
23C6-stimulated supernatant induced the greatest migration of THP-1 cells.  
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To determine if the increase in migration was due to the concentration of 
chemokines in the supernatant, we analysed the migratory response of THP-1 
cells to serial dilutions of the cleared supernatant from 23C6-stimulated THP-1 
cells. Cleared supernatant from 23C6-treated THP-1 cells was diluted (1 in 2, 1 
in 5 and 1 in 10) with fresh OptiMEM and used in transwell migratory assays. 
Figure 5-4B shows that THP-1 cells migrated in response to undiluted 
supernatant from 23C6-treated cells (dilution factor=1). The dilution of the 
cleared supernatant in the transwell assay led to a statistically significant, dose-
dependent decrease in migration of THP-1 cells.  The greater the dilution of the 
supernatant, the fewer cells migrated across the membrane, although, even at 
10-fold dilution, an increase in migration over the background (OptiMEM) was 
observed. 
As migration across the membrane is an active process involving adhesion 
reactions, we measured the effect of coating the transwell polycarbonate 
membrane with proteins on the migration of THP- 1 cells to the same stimulus 
(Figure 5-4C). The transwell plate was incubated with the coating proteins at 
370C for 1 hour. The chambers were washed with OptiMEM and used in transwell 
migration assays using cleared supernatant from 23C6-treated cells as the 
chemotactic stimulus. Bovine serum albumin (BSA) was used to control for the 
presence of non-specific protein on the membrane. This was compared with the 
migration of THP-1 cells across polycarbonate membranes coated with foetal 
calf serum (FCS), vitronectin (VN) or fibrinogen (FBGN). A statistically significant 
increase in migration was observed for membranes coated with FCS and VN, 
compared to BSA. The membrane coated with FBGN did not lead to a 
statistically significant increase in cell migration across the membrane compared 
with BSA (Figure 5-4C).  
We tested the ability of the supernatants to influence the migration of other 
cells in the immune system. We compared the migration of THP-1 cells with the 
T cell line, Jurkat, and the B cell line, IB4. Figure 5-5 shows that cleared 
supernatant from THP-1 cells treated with 23C6 could positively influence the 
migration of Jurkat and IB4 cell lines in addition to THP-1 cells (Figure 5-5A). 
Although the greatest number of migratory cells was observed with THP-1 cells 
compared to Jurkat or IB4 cells, the fold stimulation over the number of 
randomly migrating cells was similar for all the cell lines (Figure 5-5B).  
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Figure  5.4 Migration of THP-1 cells in transwell assays 
(A) Migration of cells towards Optimem (OPT) or cleared supernatants from LPS, 23C6 (anti-αVβ3) 
or 3.9 (anti-αXβ2) treated cells. (B) Effect of dilution of 23C6 (anti-αVβ3) supernatant on cell 
migration. (C) Effect of coating of transwell polycarbonate membrane with proteins on cell 
migration. Wells were coated with bovine serum albumin (BSA), foetal calf serum (FCS), vitronectin 
(VN) or fibrinogen (FBGN) for at least 1 hour at 370C prior to migration assays. Cells (1x10-5) were 
placed in the upper transwell chamber and cleared supernatant from treated THP-1 cultures was 
placed in the lower chamber of transwell plates. The plates were incubated at 370C, in 5% CO2 for 
3 hours, whereupon cells that had migrated across the membrane into the lower chamber were 
collected by centrifugation, washed and resuspended in equivalent volumes of PBS/formalin. Cell 
counts in duplicate were determined by flow cytometry.  Data represent mean of at least 3 
independent experiments. Statistical analysis was performed using Students t-test, *p<0.05. The 
error bars indicate standard deviations (SD). 
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Figure  5.5 Comparison of migration of different cell types in transwell assay 
(A) Migration of THP-1 (black bars), Jurkat (white bars) and IB4 (grey bars) cell lines to untreated 
Optimem medium (OPT) or cleared supernatant (SN) from 23C6 (anti-αVβ3) treated THP-1 
cultures. (B) The migration index, representing fold-stimulation of migration in response to 23C6 
(anti-αVβ3) supernatant relative to migration in response to Optimem. Migration of cells was 
measured using transwell plate assays. Cells that had migrated across the membrane into the 
lower chamber were collected by centrifugation, washed and resuspended in equivalent volumes of 
PBS/formalin. Cell counts in duplicate were determined by flow cytometry. Data represent mean of 
at least 3 separate experiments. Statistical analysis was performed using Students t-test, *p<0.05. 
The error bars indicate standard deviations (SD). 
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5.2.3  αVβ3-mediated monocyte differentiation/activation 
Monocytic cells are the precursors for a number of essential cells in the body. 
Monocytes develop into cells such as macrophages, dendritic cells and 
osteoclasts when treated with different stimuli. CD23 has been shown to 
mediate monocyte activation via an interaction with β2 integrins 74, 193.  
We had previously analysed the response of THP-1 cells to acute (<24 hours) 
stimulation with anti-integrin antibodies. Stimulation of THP-1 cells with specific 
antibodies led to the production of cytokines over this time period. We were 
therefore interested in investigating the potential activation of THP-1 cells in 
response to chronic stimulation with these antibodies (>3 days).  
Monocyte activation requires multiple signals, one of which is often a priming 
step induced by cytokines such as M-CSF. We tested the ability of selected 
antibodies to induce monocyte activation in conjunction with the myeloid 
growth factor, M-CSF (Figure 5-6). THP-1 cells were incubated in OptiMEM 
supplemented with 10ng/mL M-CSF and selected antibodies for 5 days and 
observed for changes in morphology associated with monocyte activation (such 
as increases in size and adherence).  Any changes in cell morphology associated 
with monocyte differentiation were recorded by phase contrast microscopy 
(Figure 5-6).  
Unstimulated cells cultured in OptiMEM/M-CSF retained a small, rounded 
morphology, although there was a minor increase in the degree of adherence to 
the plastic culture dish observed (Figure 5-6A). LPS treatment was used as a 
positive control for monocyte activation. LPS-stimulated THP-1 cells cultured in 
OptiMEM/M-CSF displayed an altered morphology characterised by a larger, 
adherent phenoytpe with a number of spiky cytoplasmic extensions 
characterisitc of activated macrophages (Figure 5-6B).  There was no change in 
morphology for THP-1 cells treated with IgG1, MEM48 (β2) or P1F6 (αVβ5) in the 
presence of M-CSF (Figure 5-6C, D and F, respectively). The cells treated in this 
manner appeared similar to the untreated cells (Figure 5-6A). Treatment of THP-
1 cells with the anti-integrin antibodies Clone44 (αMβ2) and Clone3.9 (αXβ2) 
induced a degree of change in THP-1 morphology that was similar but less 
extreme than that observed for the LPS-treated THP-1 cells (Figure 5-6 G and H, 
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respectively).  By contrast, 23C6 induced a significant change in the morphology 
of THP-1 cells. These changes were more pronounced than those observed for 
LPS-treated THP-1 cells. The THP-1 cells became adherent and increased 
significantly in size, with a large number of spiky cytoplasmic extensions. In 
certain cases, 23C6/M-CSF-treated cells were observed to have multiple nuclei 
by Giemsa staining.  Given this pronounced phenotype, we elected to analyse 
further the 23C6-mediated activation of THP-1 cells.  
We investigated whether 23C6 could mediate this activation in the absence of 
the M-CSF growth factor. THP-1 cells in OptiMEM were incubated with 23C6 
alone or in conjunction with the cytokine M-CSF for 3-7 days and observed for 
any changes in morphology (Figure 5-7). Stimulation of THP-1 cells with anti-
αVβ3 antibody alone led to the distinct changes in morphology. The THP-1 cells, 
which are usually small, rounded suspension cells (Figure 5-7A) formed clumps in 
solution and a number of cells became adherent and enlarged, with significant 
spiky processes. Treatment with 23C6 alone was sufficient to induce this change 
in morphology of THP-1 cells (Figure 5-7C), although the number of cells showing 
the differentiated morphology and the extent of the differentiation was 
enhanced by the presence of M-CSF (Figure 5-7D). Equivalent concentrations of 
M-CSF alone caused changes in morphology of the cells associated with 
maturation of monocytic cells to a more macrophage-like phenotype. Cells 
became slightly larger and adherent, but lacked the large number of spiky 
protuberances observed with the 23C6-treated cells. The 23C6-treated cells 
(with and without M-CSF) were significantly larger, more adherent and had a 
greater number of spiky extensions compared to those treated with M-CSF alone. 
The cytoplasm appeared to be highly granular or vesicular in nature (Figure 5-7).  
We investigated the effect of 23C6 and M-CSF on the morphology of primary 
human monocytes derived from peripheral blood (CD14+PBMC) or bone marrow 
(BMDM). Figure 5-8 shows the differentiation of BMDM in response to M-CSF (A 
and B), 23C6 and M-CSF (C and D) and LPS and M-CSF (E and F). Treatment of 
BMDM with M-CSF led to a change in morphology associated with a more 
macrophage-like phenotype, with cells being adherent, rounded and flattened in 
appearance. Treatment of BMDM with 23C6 in conjunction with M-CSF led to a 
similar adherent phenotype, together with the development of numerous spiky 
processes. A similar change in morphology was observed with BMDM treated with 
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LPS and M-CSF, although in this case, the LPS treated cells had fewer spiky 
processes than the 23C6-treated cells. 
Figure 5-9 shows the differentiation of CD14+PBMC in OptiMEM alone (Figure 5-
9A) or supplemented with M-CSF (Figure 5-9B), 23C6 (Figure 5-9C) or 23C6 and 
M-CSF (Figure 5-9D). The difference in morphology is less obvious, as CD14+PBMC 
are adherent even when unstimulated. However, closer observation of cultures 
suggested a change in morphology when CD14+PBMC were treated with 23C6, 
either in the presence or absence of M-CSF. Treatment with 23C6 in the 
presence or absence of M-CSF induced a change in morphology, where the cells 
became enlarged, with a stellate morphology and a number of projections. A 
number of cells appeared to have multiple nuclei. Cells treated with M-CSF 
alone generally had an enlongated morphology.     
Monocytic cells are known to differentiate into a number of different cell types, 
including but not limited to macrophages, dendritic cells and osteoclasts. The 
morphological changes observed in the THP-1 cells upon treatment with 23C6 
and M-CSF were potentially consistent with the differentiation of the monocytic 
cells into one of these cell types. Each of these cell types has a characteristic 
set of surface markers and cytokine outputs that are defined by their nature.  
We first investigated whether the THP-1 cells were acquiring an osteoclast-like 
phenotype. Osteoclasts are large, adherent, multinuclear cells derived from 
macrophages. The αVβ3 integrin and the cytokine M-CSF are associated with 
osteoclast development in vivo and in vitro. Therefore, given the morphology of 
the 23C6/M-CSF-treated cells (large, adherent, multinucleated), and the 
stimulus used to induce differentiation (anti-αVβ3 antibody and M-CSF), we 
hypothesised that the THP-1 cells may developing into osteoclasts. Osteoclasts 
can be identified by staining for the osteoclast marker, tartrate-resistant acid 
phosphatase (TRACP), which should give a pink colour due to the activity of the 
TRACP enzyme. Figure 5-10 shows the TRACP staining for 23C6/M-CSF-treated 
cells. The cells stained yellow with the TRACP assay. No pink colour was 
observed, even with the large, multinucleated cells (Figure 5-10B). This 
suggested that the stimulated THP-1 cells did not acquire an osteoclast-like 
nature, as defined by TRACP staining.  
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In light of the above result, we proposed that the change in morphology of the 
THP-1 cells was an indication of macrophage activation. Macrophages are a 
naturally heterogeneous population and there are multiple mechanisms which 
lead to macrophage activation 7, 8, 235. Each of these mechanisms defines a 
specific type of macrophage, each of which has a characteristic expression of 
surface markers and cytokine profiles (summarised in Table 5-1). To investigate 
whether 23C6/M-CSF treatment of THP-1 cells was initiating a specific 
programme of activation, we analysed the changes in surface marker expression 
and monitored the cytokine profile of the differentiated cells during a 5-day 
stimulation. 
After stimulation with M-CSF and 23C6 for 5 days, the THP-1 cells were assessed 
for the presence of specific cell surface markers by flow cytometry (Figure 5-
11). These markers have been correlated with a specific type of macrophage 
activation mechanism (Table 5-1) 7. The expression levels of selected markers on 
untreated THP-1 cells cultured in OptiMEM for 5 days (Figure 5-11A) was 
compared to the expression of the same markers after treatment of cells with 
23C6 and M-CSF for 5 days (Figure 5-11B). A general increase in the background 
staining was observed for 23C6/M-CSF-treated cells compared to untreated cells. 
There was no significant change in the expression levels of CD86, HLA-DR, CD23 
or CD14 between untreated THP-1 cells and 23C6/M-CSF stimulated THP-1 cells. 
There was also no change in the expression level of CD25, IFNγ-R1, TLR-2, CD64 
or CD47. 23C6/M-CSF-stimulated THP-1 cells expressed lower levels of the Fcγ 
receptors CD16 and CD32, but slightly upregulated expression of the chemokine 
receptor CCR5. Figure 5-12 shows the expression of integrins on unstimulated 
and 23C6/M-CSF-stimulated THP-1 cells. THP-1 cells treated with 23C6/M-CSF 
expressed lower levels of the αV subunit and the individual αVβ3 and αVβ5 
heterodimers. The expression of the β1 integrin, β2 integrin, αMβ2 and αXβ2 
were roughly equivalent between the stimulated and unstimulated THP-1 cells  
Figure 5-13 shows the production of RANTES, MIP-1β, IL-8, TNF-α, IFN-γ, IL-
12p40, IL-10, IL-4 and VEGF by the 23C6/M-CSF-treated THP-1 cultures over the 
5 day stimulation period. THP-1 cells in OptiMEM were treated for 5 days with 
23C6 and M-CSF and supernatant samples were analysed for the presence of 
cytokines by ELISA at specific time points.The cytokines IL-12p40 and IL-4 were 
not detected in the cell supernatant at any time during the stimulation.  The 
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stimulated THP-1 cells produced high levels of RANTES, MIP-1β, IL-8, TNF-α and 
VEGF during differentiation. For all these cytokines, there was a sustained 
proportional increase in cytokine production with the length of stimulation. The 
stimulated cultures transiently released IFN-γ and IL-10. A peak in IFN-γ and IL-
10 levels was observed after 24 hours, but levels were reduced to zero after 48 
hours after stimulation and did not increase later in the experiment.  
The data from the above analyses are summarised in Table 5-1, along with the 
corresponding data collected for specific types of macrophage activation. Table 
5-1 indicates the details determined for different mechanisms of macrophage 
activation, classical (M1) and alternative (M2 which can be sub-divided in M2a, 
M2b and M2c). The cytokine profile and surface marker expression of 23C6/M-
CSF-treated THP-1 cells did not correlate significantly with any of the specific 
macrophage activation mechanisms. However, the upregulation of other 
markers, such as CCR5, and the production of cytokines, suggests that the 
stimulated THP-1 cells may still be classified as activated macrophages.  
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Figure  5.6 Screen of antibodies for monocyte activation 
Antibodies known to induce cytokine production were screened for their ability to induce monocyte 
activation in the presence of M-CSF. Monocyte activation was measured by morphological 
changes, including increased size and adherence. THP-1 cells were treated with 10ng/mL M-CSF 
along with A: untreated, B: LPS, C: IgG1, D: MEM48, E: 23C6, F: P1F6, G: Clone44, H: Clone3.9. 
Data are representative of at least 3 separate experiments. The response to IgG1 is included as a 
representative example. All antibody isotypes were tested (IgG1, IgG2a, IgG2b and IgG3) and 
gave responses equivalent to IgG1.  
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Figure  5.7 Integrin-mediated activation of THP-1 cells 
THP-1 cells were grown for 5 days in Optimem medium (A) without supplementation, (B) with 
10ng/mL M-CSF, (C) with 1µg/mL 23C6 (anti-αVβ3) antibody or (D) 10ng/mL M-CSF and 1µg/mL 
23C6 (anti-αVβ3) antibody. Phase contrast photomicrographs (magnification x320) of cell 
morphology were taken using the Zeiss Axiovert microscope. Data are representative of at least 3 
independent experiments. 
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Figure  5.8 Differentiation of bone marrow derived monocytes in response to 
treatment with 23C6 and M-CSF 
Bone marrow monocytes were stimulated with 5ng/mL M-CSF (A and B), 5ng/mL M-CSF and 23C6 
(C and D) and LPS (E and F). Pictures A, C and E are 200x magnification and B, D and F are 320x 
magnification.  Cells were fixed and stained with Giemsa stain and images captured using a Canon 
EOS300 digital camera attached to a Zeiss Axiovert S100 microscope. 
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Figure  5.9 Differentiation of CD14+ blood monocytes in response to 
treatment with 23C6 and M-CSF 
CD14+ peripheral blood monocytes were cultured in OptiMEM with 1% FCS (A) or OptiMEM with 
1% FCS supplemented with 10ng/mL M-CSF (B) or 23C6 1µg/mL (C) or a combination of 10ng/mL 
M-CSF and 1µg/mL 23C6 (D). Phase contrast photomicrographs (magnification x320) of cell 
morphology were taken using the Zeiss Axiovert microscope. 
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Figure  5.10 Staining of 23C6/M-CSF treated THP-1 cells for the osteoclast 
marker TRACP 
THP-1 cells were treated with 23C6 and M-CSF for 5 days before being fixed and stained for the 
osteoclast marker, TRACP. Images at different magnifications (A is x200 and B is x320) were 
captured using a Canon EOS300 digital camera attached to a Zeiss Axiovert S100 microscope.  
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Figure  5.11 Analysis of THP-1 cells for surface markers of macrophage 
activation 
THP-1 cells were grown in OptiMEM (A) or OptiMEM supplemented with 23C6 and M-CSF for 5 
days (B) and then analysed for the expression of markers characteristic of macrophage activation 
by flow cytometry.  Isotype control staining is shown as grey shading and antibody staining as a 
black line. The antigen targeted is indicated above the individual plots. Data are representative of 
at least 3 separate experiments. 
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Figure  5.12 Analysis of expression of integrins on THP-1 cells before and 
after treatment with 23C6 and M-CSF 
THP-1 cells were grown in OptiMEM (A) or OptiMEM supplemented with 23C6 and M-CSF for 5 
days and then analysed for the expression of integrins by flow cytometry.  Isotype control staining 
is shown as grey shading and antibody staining as a black line. The antigen targeted is indicated 
above the individual plots. Data are representative of at least 3 separate experiments. 
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Figure  5.13 Cytokine production during THP-1 differentiation/activation by M-CSF and 23C6 
THP-1 cells were stimulated with M-CSF and 23C6 for 5 days. Supernatant samples were collected at intervals and assessed for the production of cytokines by 
ELISA. Data are representative of at least three independent experiments.  
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Table  5-1 Characteristics of activated macrophages (adapted from6, 7, 16, 236) 
 
ALTERNATE (M2) 
 
 
DETAIL 
 
 
 
CLASSICAL 
(M1) 
 
 
 
M2a 
 
M2b 
 
M2c 
 
INTEGRIN 
MEDIATED 
 
Activating 
signals 
 
IFN-γ 
TNF-α 
 
IL-4  
glucocorticoids 
 
Immune 
complexes/ 
TLR/IL-1R 
ligands 
 
 
IL-10 
 
αVβ3 binding 
M-CSF 
 
Cytokines 
secreted 
 
TNF-α 
IL-12 
IL-1 
IL-6 
 
IL-1RA 
IL-10 
 
TNF-α 
IL-10 
IL-6 
 
 
TGF-β 
IL-10 
 
TNF-α 
Transient IL10 
Transient IFN-γ 
 
Growth 
factors 
  
VEGF*** 
 
VEGF*** 
 
 
VEGF*** 
 
VEGF 
 
 
Markers 
 
 
UP: 
 
MHC-II 
CD86 
 
 
 
 
DOWN: 
 
Mannose 
receptor 
 
 
UP: 
 
MHC-II 
Mannose 
receptor 
Scavenger 
receptor 
CD23 
 
DOWN: 
 
CD14 
CD163 
MS-1 
 
 
UP: 
 
MHC-II 
CD86 
 
 
 
 
DOWN: 
 
Mannose 
receptor 
 
 
UP: 
 
SLAM 
Mannose 
receptor 
 
 
 
DOWN: 
 
CD14 
CD163 
MS-1 
 
 
 
UP 
 
CCR5 
 
UNCHANGED: 
 
CD86 
CD14 
CD23 (not 
expressed) 
HLA-DR 
 
NOT 
ANALYSED: 
 
Mannose 
receptor 
Scavenger 
receptor 
CD163 
MS-1 
 
 
Killer 
molecules 
 
 
NO, O2
- 
 
NONE 
 
None/*NO, 
O2
- 
 
NONE 
 
NONE 
 
 
Chemokines 
 
MCP-1 
MIP-1 
IP-10 
 
AMAC 
 
**ND 
 
AMAC 
 
IL-8 
RANTES 
MIP-1β 
 
* High levels of IL-10 block radicals 
**ND - not determined  
***in the context of tumour associated macrophages (TAM)236-238 
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5.2.4 Role of the receptors αVβ3, c-FMS and TLR-2 during 
macrophage activation 
Toll-like receptors (TLRs) are immunoreceptors that play in important role in the 
innate immune response, particularly with respect to detection of pathogens. 
Binding of TLRs on macrophages can lead to their activation, either directly or 
via TLR-induced cytokine production. These TLRs often associate with other 
surface receptors, including integrins, to achieve these functions. The LPS 
signalling complex, for example, is composed of CD14, TLR-4 and the CD18 
integrin. We hypothesised that the αVβ3-mediated macrophage activation and 
cytokine production involved a similar signalling complex that included TLR-2 
and the M-CSF receptor c-FMS. 
THP-1 cells were shown to be activated by stimulation of the αVβ3 integrin with 
the 23C6 antibody (Figure 5-1). This activation was enhanced by the presence of 
the cytokine M-CSF. M-CSF is known to exhibit its effects by binding to its 
receptor, c-FMS. We had previously shown that THP-1 cells express the αVβ3 
integrin and so we examined the cells for the expression of the M-CSF receptor 
c-FMS. Figure 5-14 shows the western blot and densitometric analysis using actin 
as a loading control of the expression of c-FMS in THP-1 and U937 whole cell 
lysates. THP-1 was shown to express the c-FMS receptor, as indicated by a band 
at ~170 kDa. The U937 cell lysate did not express the c-FMS receptor. U937 cells 
failed to differentiate under treatment conditions similar to those causing the 
morphology changes in THP-1 cells. U937 cells did not respond with an altered 
morphology, but instead the cultures failed to survive for the 3-7 day treatment 
with 23C6 and M-CSF (data not shown).  
The stimulatory effect of 23C6 and M-CSF on THP-1 cells was determined to be 
dose-dependent, with respect to both 23C6 concentration and M-CSF 
concentration (Figure 5-15). Figure 5-15 shows the dose-dependent 
differentiation of the THP-1 cells in response to changing concentrations of 23C6 
and a constant M-CSF concentration (Ai), and to changing concentrations of M-
CSF and a fixed concentration of 23C6 (Bi). Cells were treated with the indicated 
concentrations of 23C6 and M-CSF and the number of cells exhibiting the altered 
morphology per microscope field was counted. Three fields were randomly 
selected and the number of differentiated cells counted in duplicate wells 
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(Figure 5-15 A and B ii). An increase in either 23C6 concentration at a fixed M-
CSF concentration (Figure 5-15A) or M-CSF at a fixed 23C6 concentration (Figure 
5-15B) led to an increase in the number of differentiated cells per field and an 
increase in the degree of change of morphology.  
We continued to examine the relationship between 23C6 and M-CSF in the 
processes of cytokine production and activation of the THP-1 cells. The 23C6 
antibody was previously shown to induce high levels of cytokines in THP-1 cells, 
which could be responsible for the morphological changes and monocyte 
differentiation phenotype. We observed a dose-dependent enhancement of THP-
1 differentiation as measured by changes in cell morphology in response to 
suboptimal concentrations of 23C6 or M-CSF by M-CSF and 23C6, respectively. 
We therefore examined the effect of M-CSF on 23C6-mediated cytokine 
production (Figure 5-16) and ERK phosphorylation (Figures 5-17 and 5-18).  
Figure 5-16 shows the enhancement of 23C6-mediated RANTES, IL-8 and MIP-1β 
production stimulated by increasing concentrations of M-CSF (Figure 5-16A, B 
and C respectively). M-CSF alone (white bars) did not induce release of RANTES, 
IL-8 or MIP-1β by THP-1 cells at any concentration tested. Cytokine production 
by THP-1 cells treated with a suboptimal level of 23C6 (when M-CSF is absent) 
was enhanced by the addition of M-CSF (5-25ng/mL), in a dose-dependent 
manner (black bars). Increasing concentrations of M-CSF led to an increase in the 
cytokine output for the fixed concentration of 23C6.  
The enhancement of cytokine production was associated with an enhancement 
of 23C6-mediated ERK phosphorylation by the presence of M-CSF. We previously 
determined that 23C6 induces a signalling pathway that involves ERK 
phosphorylation in THP-1 cells. Figures 5-17 and 5-18 show data collected to 
examine the effect of M-CSF on this ERK phosphorylation.  
Figure 5-17 shows the western blot (A) and densitometry analysis (B) for the 
effect of increasing M-CSF concentrations on ERK phosphorylation. THP-1 cells 
were treated with increasing concentrations of M-CSF with or without 23C6 for 
30 min and lysates probed for the phosphorylation of ERK by Western blotting. 
M-CSF treatment alone led to phosphorylation of ERK at a concentration of 
50ng/mL, but not at the lower concentrations (0-20ng/mL). Treatment of THP-1 
cells with 23C6 alone at a concentration of 0.5µg/mL induced ERK 
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phosphorylation. This 23C6-mediated ERK phosphorylation was enhanced by 
addition of M-CSF, even at the lower concentrations of 10ng/mL and 20ng/mL, 
where M-CSF alone failed to induce ERK phosphorylation.  
We analysed the kinetics of ERK phosphorylation in response to 23C6 and M-CSF 
treatment (Figure 5-18). THP-1 cells were incubated with M-CSF alone, 23C6 
alone or a combination of 23C6 and M-CSF for different time periods. Lysates 
were probed for phosphorylation of ERK by Western blot using actin as a loading 
control. Treatment of THP-1 cells with M-CSF alone led to phosphorylation of 
ERK that was observed after 10 min of treatment and peaked at 60 min after 
stimulation. Treatment of THP-1 cells with 23C6 led to weak phosphorylation of 
ERK that was observed after 5 min of treatment and peaked at 60 min after 
stimulation. Treatment of THP-1 cells with 23C6 and M-CSF led to a stronger 
phosphorylation of ERK that was observed after 5min of treatment and peaked at 
30 min after stimulation.  
We next examined the expression of TLR-2 on THP-1 and U937 cell lines. Both 
THP-1 and U937 expressed high levels of TLR-2 (Figure 5-19). We compared the 
morphology of the 23C6/M-CSF-treated THP-1 cells with THP-1 cells activated by 
a TLR-2 ligand, yeast zymosan. Figure 5-20 shows the morphology of untreated 
THP-1 cells (A and B), compared with THP-1 cells treated with zymosan (C and 
D) and 23C6/M-CSF treated THP-1 cells (E and F). Untreated THP-1 cells were 
small, non-adherent and rounded in culture. Zymosan and 23C6/M-CSF treated 
cells both acquired a similar morphology, large and adherent, with spiky 
projections.  The 23C6/M-CSF treatment appeared to induce larger cells with a 
greater number of projections than zymosan-treated cells. We assessed the 
ability of the TLR-2 ligand zymosan to induce cytokine production by THP-1 cells 
(Figure 5-21). Zymosan-treated cells produced high levels of MIP-1β and IL-8, as 
observed with 23C6 and 23C6/M-CSF treatment. This suggested that a TLR-2-
induced response was consistent with the activation and cytokine profile 
observed for 23C6 treated THP-1 cells.  
We had previously established that the M-CSF receptor was essential for the 
23C6-mediated THP-1 activation, as U937 cells which did not express c-FMS did 
not activate/differentiate in response to 23C6 or 23C6/M-CSF treatment (data 
not shown). We attempted to identify the role of TLR-2 in cytokine production 
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using a blocking antibody. THP-1 cells were pre-treated with a neutralising 
antibody against TLR-2 or an RGDS peptide and then stimulated with the 23C6 
antibody. Cytokines released into the supernatant were quantified by ELISA 
(Figure 5-22). The production of MIP-1β, RANTES, IL-8 and VEGF was not 
inhibited by the pre-incubation and inclusion of the RGDS peptide. The inclusion 
of the neutralising TLR-2 antibody, however, led to a statistically significant 
reduction in the production of all four cytokines. This supported a role for TLR-2 
in the 23C6-mediated cytokine production by THP-1 cells.  
TLRs are capable of two signalling mechanisms, one dependent on the MyD88 
(myeloid differentiation factor 88) molecule and the other independent of this 
protein. TLR-2-based signalling is dependent on MyD88; no MyD88-independent 
signalling pathway has been identified for TLR-2. We therefore investigated the 
effect of blocking MyD88 signalling on cytokine production by THP-1 cells in 
response to 23C6 binding (Figure 5-23). THP-1 cells were incubated with the 
MyD88 inhibitory peptide239 or control peptide for 24 hours or anti-TLR-2 
antibody for 1 hour prior to stimulation with 23C6 or the TLR-2 ligand zymosan. 
Treatment of the THP-1 cells with the control peptide did not inhibit release of 
IL-8, RANTES or MIP-1β produced in response to 23C6 or zymosan treatment 
(Figure 5-23, black bars). Pre-incubation of THP-1 cells with the neutralising 
TLR-2 antibody led to a statistically significant reduction in RANTES, IL-8 and 
MIP-1β concentrations in response to stimulation with either 23C6 or zymosan 
(Figure 5-23, white bars). Treatment of THP-1 cells with the MyD88 inhibitory 
peptide caused a statistically significant reduction in the levels of IL-8 and MIP-
1β, but not RANTES, produced in response to zymosan treatment. MyD88 
inhibition did not affect the production of IL-8, MIP-1β or RANTES in response to 
23C6 stimulation (Figure 5-23, grey bars).  
We extended this analysis to test the effect of the anti-TLR-2 antibody and the 
MyD88 peptide on the transcription of the cytokine genes. Using IL-8 as a model, 
we investigated the production of mRNA in response to 23C6-mediated 
stimulation using semi-quantitative PCR. Total RNA was extracted from THP-1 
cells that had been stimulated with 23C6 or zymosan after being incubated with 
the anti-TLR-2 antibody or the MyD88 inhibitory peptide. The RNA was used in 
semi-quantitative RT-PCR reactions for the detection of IL-8 transcripts, using 
GAPDH as an internal standard (Figure 5-24). RNA from untreated THP-1 cells did 
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not contain any detectable IL-8 transcript. Transcripts for IL-8 were observed in 
cells treated with the control peptide and the MyD88 inhibitory peptide, and 
stimulated with 23C6 or zymosan. The signal for the IL-8 transcript was not 
reduced compared to the control cells treated with zymosan. Pre-treatment of 
THP-1 cells with the anti-TLR-2 antibody prior to stimulation with 23C6 or 
zymosan led to a decrease in the expression of the IL-8 transcript relative to the 
GAPDH signal. These data were consistent with the reduction in cyoktine 
production by inhibition of TLR-2, but not by inhibition of MyD88, observed in 
the ELISA analysis (Figure 5-23). 
As TLR signalling leads to activation of the NFκB transcription factors, we 
investigated whether 23C6/M-CSF treatment could lead to activation of this 
pathway. We performed gel shift assays (EMSAs) to detect the presence of 
activated transcription factors in nuclear extracts from THP-1 cells treated with 
23C6. Nuclear extracts were prepared from untreated THP-1 cells, THP-1 cells 
treated with 23C6, and THP-1 cells treated with 23C6 and anti-TLR-2 antibody. 
These extracts were assessed for their ability to bind the radioactively labelled 
NFκB consensus oligonucleotide in electrophoretic mobility shift assays/EMSAs 
(Figure 5-25A). Untreated THP-1 nuclear extract did not bind the NFκB oligo. 
Nuclear extracts from THP-1 cells treated with 23C6 or 23C6 and M-CSF antibody 
bound the radioactively-labelled NFκB consensus oligonucleotide, as indicated by 
the presence of a low mobility band on the autoradiogram (Figure 5-25A, arrow). 
This was deemed to be a specific interaction, as it could be prevented by 
competition with a cold/unlablled NFκB consensus oligonucleotide. We were 
unable to identify the member of the NFκB family by supershift analysis, but we 
attempted to analyse the translocation of p65 to the nucleus using 
immunofluorescence staining and confocal microscopy (Figure 5-25B). There was 
no difference observed for the expression levels or subcellular localisation of p65 
in untreated or 23C6/M-CSF-treated THP-1 cells (Figure 5-25B).   
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We next examined the activation of the signalling pathway leading to activation 
of the NFκB transcription factors. The TLR-mediated pathway involves signalling 
factors such as TRAF-6 and IRAK-1. We examined the expression of IRAK-1 in 
response to 23C6, M-CSF and zymosan treatment by confocal microscopy. 
Untreated THP-1 cells or THP-1 cells treated with M-CSF alone did not express 
detectable levels of IRAK-1. Treatment of THP-1 cells with 23C6 induced low 
levels of IRAK-1, which was enhanced by the addition of M-CSF. The IRAK-1 
staining for 23C6 and M-CSF was similar to that observed for the TLR-2 ligand 
zymosan, which induced a strong IRAK signal in THP-1 cells (Figure 5-26).   
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Figure  5.14 Expression of c-FMS by THP-1 and U937 cell lines 
Expression of the M-CSF receptor c-FMS in THP-1 and U937 cell lines as determined by western 
blotting. Whole cell lysates from THP-1 and U937 cells were resolved by SDS-PAGE and c-FMS 
detected by Western blotting (A) and the signal quantified by densitometry against an actin loading 
control using the ImageJ program (B). The data are representative of at least 3 independent 
experiments.  
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Figure  5.15 Integrin-mediated differentiation and activation of THP-1 is dose-
dependent 
THP-1 cells were grown for 5 days in Optimem medium (A) with M-CSF (10ng/mL) and increasing 
concentrations of 23C6 (anti-αVβ3) antibody or (B) with 23C6 (anti-αVβ3) antibody at 0.5µg/mL 
and increasing concentrations of M-CSF. Numbers in the top right corners indicate concentrations 
of 23C6 (anti-αVβ3) antibody in µg/mL (A) or M-CSF in ng/mL (B). (A)i and (B)i show 
photomicrographs of cell morphology and (A)ii and (B)ii show the quantitation of the numbers of 
differentiated cells with increasing concentration of 23C6 (anti-αVβ3) antibody and M-CSF, 
respectively. Data shown are representative of at least three independent experiments. Statistical 
analysis was performed using Students t-test, *p<0.05. The error bars indicate standard deviations 
(SD). 
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Figure  5.16 Enhancement of 23C6-mediation cytokine production by M-CSF  
Cells were incubated with increasing concentrations of M-CSF alone (white bars) or M-CSF with a 
fixed concentration of 0.5µg/mL of 23C6 (anti-αVβ3) antibody (black bars) overnight at 370C. 
Cytokines released into the supernatant were quantified by ELISA. Data are representative of at 
least 3 independent experiments. Statistical analysis was performed using Students t-test, *p<0.05. 
The error bars indicate standard deviations (SD). 
  
194 
  
 
 
 
 
Figure  5.17 Enhancement of ERK phosphorylation by M-CSF for a given 
concentration of 23C6. 
Cells were incubated with increasing concentrations of M-CSF alone or M-CSF with a fixed 
concentration of 0.5µg/mL of 23C6 (anti-αVβ3) antibody for 30min at 370C. ERK phosphorylation 
was detected by SDS-PAGE and Western blotting, with actin as a loading control. Band intensity 
was quantified by densitometry using ImageJ graphics software. Data are representative of at least 
3 independent experiments.  
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Figure  5.18 Kinetics of ERK phosphorylation in 23C6/M-CSF-treated cells 
Cells were incubated with M-CSF alone (50ng/mL), 23C6 alone (0.5µg/mL) or a combination of M-
CSF (50ng/mL) and 23C6 (0.5µg/mL) at 370C. Samples were collected at time points indicated and 
ERK phosphorylation was detected by SDS-PAGE and Western blotting, with actin as a loading 
control. Band intensity was quantified by densitometry using ImageJ graphics software. Data are 
representative of at least 3 independent experiments.  
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Figure  5.19 Expression of TLR-2 by THP-1 and U937 cell lines 
THP-1 and U937 cells were incubated with anti-TLR-2 antibody (black line) or isotype matched 
control (grey shading). Primary antibody binding was detected by secondary antibody conjugated 
to the fluorescent label PE. The data are representative of at least 3 independent experiments.  
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Figure  5.20 Comparison of morphologies of zymosan-treated and 23C6/M-
CSF-treated THP-1 cells 
THP-1 cells were grown for 5 days in Optimem medium (A and B) without supplementation, (C and 
D) with 10µg/mL Zymosan A (E and F) with 10ng/mL M-CSF and 1µg/mL 23C6 (anti-αVβ3) 
antibody. Phase contrast photomicrographs (magnification x320) of cell morphology were taken 
using the Zeiss Axiovert microscope. Data are representative of at least 3 independent 
experiments.  
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Figure  5.21 Cytokine responses of THP-1 cells to the TLR-2 ligand, Zymosan  
THP-1 cells (1x106/mL) in Optimem were exposed to increasing concentrations of yeast zymosan 
A and incubated overnight at 370C in 5% CO2. Cytokines released into the supernatant were 
quantified by ELISA. The data are representative of at least 3 independent experiments. The error 
bars indicate standard deviations (SD). 
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Figure  5.22 Reduction in 23C6 induced cytokine levels in response to anti-
TLR-2 antibody, but not RGDS peptide 
THP-1 cells were incubated with increasing concentrations of anti-TLR-2 antibody or β3 blocking 
peptide for 30min prior to stimulation with 23C6 (anti-αVβ3) antibody (1µg/mL) overnight at 370C 
and 5% CO2. Cytokines released into the supernatant were quantified by ELISA. Data are 
representative of at least 3 independent experiments. Statistical analysis was performed using 
Students t-test, *p<0.05. The error bars indicate standard deviations (SD). 
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Figure  5.23 Cytokine production in cells treated with anti-MyD88 peptide 
THP-1 cells were incubated with control peptide (black bars), anti-TLR2 antibody (white bars), anti-
MyD88 signalling peptide (grey bars) before being stimulated with zymosan or 23C6. MIP-1β (A), 
IL-8 (B) and (C) RANTES released into the supernatant were detected using ELISA. Data are 
representative of at least 3 independent experiments. Statistical analysis was performed using 
Students t-test, *p<0.05. The error bars indicate standard deviations (SD). 
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Figure  5.24 Reduction in integrin induced IL-8 mRNA expression by blocking  
TLR-2, but not MyD88 
(A) THP-1 cells were untreated or treated with either anti-MyD88 peptide or TLR-2 blocking 
antibody prior to stimulation with 23C6 (anti-αVβ3) antibody or TLR-2 ligand, zymosan for 6 hours 
at 370C. Total RNA was Trizol extracted and used in semi-quantitative RT-PCR reactions to detect 
the presence of IL-8 and GAPDH mRNA. Densitometric analysis of bands was acheived using 
ImageJ software. The data are representative of at least 2 independent experiments.  
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Figure  5.25 Analysis of NFκB activation in 23C6-treated THP-1 cells 
(A) Nuclear extracts were prepared from untreated THP-1 cells, THP-1 cells treated overnight with 
23C6 and THP-1 cells treated overnight with 23C6 and M-SF and assessed for the activation of 
NFκB by EMSA. (B) Localisation and expression of p65 before and after 23C6 /M-CSF treatment 
was analysed by confocal microscopy. Primary anti-p65 was detected using Secondary antibody 
conjugated to FITC. DAPI was used to stain nuclei and images captured using the Zeiss LSM 510 
Microscope (magnification x320).  
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Figure  5.26 IRAK-1 expression in response to anti-αVβ3 integrin and M-CSF 
treatment 
THP-1 cells were treated with agents indicated in left panel for 3 hours at 370C, prior to being fixed 
with acetone/methanol and stained for the presence of IRAK-1. Primary anti-IRAK-1 was detected 
using Secondary antibody conjugated to FITC. DAPI was used to stain nuclei and images captured 
using the Zeiss LSM 510 Microscope (magnification x320).  
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5.3  Discussion 
Treatment of THP-1 cells with the αVβ3 antibody 23C6 was shown to induce high 
levels of cytokine release by these cells. We analysed further the role of the 
23C6 antibody in monocyte differentiation. We observed that 23C6 ligation led 
to the phosphorylation of the β3 cytoplasmic tail and activation of the ERK 
signalling pathway in THP-1 cells during cytokine production. Chemokines 
produced by αVβ3 ligation with 23C6 were capable of inducing monocyte 
migration in vitro and possibly contributed to 23C6-mediated monocyte 
activation. Treatment of THP-1 cells with the 23C6 antibody was enhanced by 
the addition of M-CSF and led to distinct changes in cell morphology, consistent 
with a more macrophage-like phenotype. The 23C6/M-CSF-activation and 
cytokine production of THP-1 cells was influenced by the presence of the M-CSF 
receptor c-FMS and partially inhibited by the blockage of the TLR-2 receptor 
using an anti-TLR-2 antibody, but not an inhibitor of MyD88-dependent 
signalling.  
5.3.1  23C6 treatment of THP-1 cells induces signalling  
The 23C6 antibody induced the production of high levels of cytokines by THP-1 
cells. Antibodies may be defined as neutralising if they block the function of the 
antigen receptor to which they bind, or activating if they stimulate the function 
of their target antigen. We analysed the signalling events induced by αVβ3 
ligation by 23C6.  
Binding of the anti-αVβ3 integrin antibody 23C6 to THP-1 cells was shown to 
induce phosphorylation of the β3 cytoplasmic domain on the Tyr773 residue. 
Phosphorylation of this residue activates the integrin and is required for firm 
adhesion of αVβ3 to vitronectin 220-222. This is considered to be an early event in 
the adhesion of leukocytes and is associated with the activation of the Rho 
signalling pathway and reorganisation of the actin cytoskeleton to form adhesive 
contacts. The phosphorylation of the β3 tail at this residue is consistent with the 
morphological changes associated with long term exposure of THP-1 cells to 
23C6. Under these conditions, the THP-1 cells became enlarged and adhered to 
the plastic tissue culture dish. The stimulation of THP-1 cells with 23C6 was 
conducted in a short time period (30 min), during which the cells were still in 
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suspension and had not acquired an adherent morphology. This indicated that a 
soluble ligand for αVβ3, namely the 23C6 antibody in solution, was capable of 
activating the adhesive function of the integrin. Phosphorylation of β3 on this 
site is known to activate the Rho/ROCK signalling pathway, which would account 
for the morphological changes observed 222, although further analysis would be 
required to conclusively link 23C6 ligation with an activation of the Rho/ROCK 
pathway. However, these data suggest that the effects of ligation of αVβ3 are 
due to direct signalling via this integrin, as opposed to indirect activation of 
other signalling pathways (i.e. where neutralisation of αVβ3 allows signalling via 
an alternative pathway to proceed). 
Ligation of αVβ3 by the 23C6 antibody in THP-1 cells led to the activation of the 
MAPK pathway and ERK phosphorylation. An increase in ERK phophorylation was 
observed with increasing concentrations of 23C6 and with increased length of 
stimulation. Cytokine production by THP-1 cells in response to 23C6 binding 
required ERK phosphorylation, as treatment of cells with the MEK inhibitor 
U0126 reduced cytokine production in response to stimulation with this 
antibody. Cytokines also induce activation of MAPK pathways via interactions 
with their receptors on cells, although, the ERK phosphorylation assays were 
conducted over a 30 time period, prior to any detectable cytokine release in the 
supernatant. This indicated that the ERK phosphorylation observed was not a 
result of cytokine activation of THP-1 cells but rather due to direct integrin 
ligation by 23C6.  
Integrin-mediated activation of ERK can occur by activation of the 
Ras/Raf/MEK/ERK pathway. This pathway can be activated either by FAK-
dependent activation of SFKs in focal adhesions or by activation of Grb2 and Sos 
directly by SFK, such as Fyn and Shc. Both pathways are involved in the 
activation of genes controlling cell differentiation and cytokine production and 
are linked to the integrin-mediated phosphorylation of focal adhesion kinase 
(FAK). We attempted to detect FAK phosphorylation in the 23C6-stimulated THP-
1 cells. Although we were unable to identify any phosphorylated FAK upon 
treatment of THP-1 cells with the 23C6 antibody, it is possible that activation of 
FAK did occur upon αVβ3 ligation with 23C6 and that the levels of FAK were 
below our detection limits, due to low expression levels in suspension cells 
which lack focal adhesions. Phosphorylated FAK can also activate Src which can 
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activate p190RhoGAP and inactivates its GAP function. P190RhoGAP catalyses 
the conversion of active RhoGTP to inactive RhoGDP and thus its inactivation 
could lead to an increase in active RhoGTP pools. This RhoGTP activates ROCK, 
which subsequently leads to reorganisation of the cytoskeleton, integrin 
clustering and adhesion. This mechanism would explain the signalling events 
from β3 phosphorylation by the binding of 23C6 to the activation of the ERK 
pathway in THP-1 cells.  
Other pathways, such as the JNK, p38 MAPK and PI3K pathways have been 
implicated in cytokine production by integrin ligation 240-244. We are currently 
analysing the potential role of these pathways in the signalling from the αVβ3 
integrin in this system. Preliminary investigations suggest that signalling via the 
PI3K pathway is not as important during integrin-mediated production of 
cytokines by THP-1 cells, as we have been unable to detect phosphorylated Akt 
in response to 23C6 treatment of THP-1 cells or to inhibit 23C6-mediated 
cytokine production by THP-1 cells using an inhibitor of PI3K (data not shown). 
Further analysis of these signalling events is underway.  
5.3.2  The role of αVβ3-induced cytokines in monocyte 
migration 
Treatment of THP-1 cells with 23C6 led to the production of a range of cytokines 
(as detailed in the previous chapters). A number of these cytokines, including IL-
8, RANTES and MIP-1β, are chemotatic cytokines known as chemokines.  
Chemokines are cytokines capable of influencing the migration of immune cells 
and are used in the body to recruit cells to specific sites at which they are 
required. This suggested a possible role for αVβ3-induced cytokines in the 
regulation of migration of immune cells. However, different chemokine isoforms, 
concentrations and combinations will have different chemotactic abilities. 
Therefore, it was necessary to analyse the chemotactic ability of 23C6-
stimulated THP-1 supernatants and not to merely assume that the presence of a 
specific chemokine equates to a high chemotactic effect. The ability of 
supernatants from 23C6-treated THP-1 cells to influence the migration of 
virgin/unstimulated cells was analysed in vitro using transwell migration assays. 
Cleared supernatants from THP-1 cells stimulated with 23C6 were capable of 
inducing the migration of unstimulated THP-1 monocytic cells, Jurkat T-cells and 
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IB4 B-cells.  Chemokines are known to activate integrins to lead to adhesion and 
extravasation. Therefore, it is possible that the soluble signalling via the αVβ3 
integrin induces the production of chemokines which are subsequently capable 
of activating the adhesive functions of other integrins, as indicated by an 
increase in the migration of THP-1 cells across FCS or VN coated membranes 
transwells, as opposed to BSA-coated membranes. The increased migration of 
THP-1 cells on vitronectin to 23C6-treated supernatant suggests activation of the 
adhesive functions of αV integrins. The use of neutralising antibodies against 
different chemokines should have been included in the analysis. This would have 
allowed identification of the chemokine responsible for mediating cell migration 
under these conditions.  
The ability of chemokines produced by αVβ3 ligation to induce migration of 
immune cells may be important in vivo in physiological immune system function 
during infections and pathological states in which inflammation and infiltration 
of immune cells contributes to the pathology of inflammatory diseases, such as 
rheumatoid arthritis and certain cancers.  
5.3.3  The role of αVβ3 and c-FMS during monocyte 
differentiation/ activation 
CD23 stimulation of monocytic cells leads to the production of cytokines in 
response to interaction with its integrin receptors (αVβ3, αVβ5, αMβ2 and αXβ2). 
Acute stimulation (< 24 hours) with antibodies against these integrins can mimick 
the effect of CD23 and induce cytokine production in monocytic cells (Chapter 4) 
40, 41, 84. CD23 is also known to induce monocyte activation via its interactions 
with the β2 integrins, αMβ2 and αXβ2 74, 193. The ability of selected anti-integrin 
antibodies in conjunction with M-CSF to induce monocyte activation was tested 
over a 5 day assay period (chronic stimulation).  
Long-term exposure of THP-1 to the anti-β2 antibodies, Clone44 and Clone3.9, 
led to changes in the THP-1 morphology to a more macrophage-like phenotype. 
The cells, originally small, rounded and in suspension, became enlarged and 
adherent with a number of spiky processes/extensions. A similar morphology was 
observed with LPS-treated THP-1 cells. CD23 is known to stimulate monocyte 
activation via an interaction with the β2 integrins, αMβ2 and αXβ2 74, 193. 
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Therefore the morphological changes associated with treatment of THP-1 cells 
with the anti-β2 antibodies (and LPS) may have mimicked the effects of CD23 
and led to activation of the THP-1 cells. LPS also binds to β2 integrins, as part of 
the LPS signalling complex 143, 245, 246.  
Treatment of THP-1 cells with the 23C6 antibody led to similar distinct 
morphological changes to those observed with anti-αXβ2, anti-αMβ2 and LPS 
treatment. However, the changes in the morphology of 23C6-treated cells were 
more pronounced than those observed with either LPS-stimulation or treatment 
with the anti-β2 heterodimer antibodies. The 23C6-treated cells were larger and 
had a greater number and degree of cytoplasmic extensions than THP-1 cells 
treated with LPS, Clone3.9 or Clone44. Indeed, 23C6 alone (without M-CSF) was 
sufficient to induce the morphological changes in THP-1 cultures, while M-CSF 
was required for LPS and β2-mediated activation of THP-1 cells. It is possible 
that the cytokines produced in response to integrin ligation contributed to the 
development of the activated phenotype, especially considering THP-1 cells 
express at least some of the receptors for those cytokines (i.e., CCR5 and IFNγR) 
and that cytokine production preceded monocyte activation. However, it seems 
likely that there are other events controlling these morphological changes in the 
monocytic cells, as antibodies that induced a similar cytokine release profile did 
not induce the same level of monocyte activation. For example, the 23C6 and 
Clone3.9 antibodies induced the release of high levels of cytokines by THP-1 
cells, but the 23C6-treated THP-1 cells acquired a more severe phenotype than 
the Clone3.9-treated cells. These morphological changes were associated with 
the continued synthesis of cytokines (TNF-α) and chemokines (IL-8, RANTES and 
MIP-1β), which indicated that the cells continued to be viable during the 5 day 
period. 
There are few reports in the literature of the role of the αVβ3 integrin in the 
activation of monocytic/macrophage cells. The αVβ3 integrin is important in the 
development of osteoclasts, terminally differentiated bone-resorbing cells that 
arise from macrophages. Osteoclasts upregulate αVβ3 as they develop from 
macrophages under the influence of M-CSF and receptor activator for NFκB 
ligand (RANKL). Osteoclast can be identified as large, adherent, multinuclear 
cells that express high levels of the osteoclast marker, TRACP. The 
morphological changes observed with 23C6-treatment of THP-1 cells were 
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consistent with the development of osteoclasts (a number of cells with multiple 
nuclei were also observed in the THP-1 cells stained with Giemsa stain). 
However, 23C6-treated THP-1 cells were consistently negative for the osteoclast 
marker TRACP and, as opposed to upregulating αVβ3 as would be expected for 
developing osteoclasts, the cells appeared to downregulate this heterodimer 
during the 5 day assay period. However, TRACP staining can be technically 
difficult and in the absence of a positive control it is not possible to state 
conclusively that the cells are not osteoclasts. Measurement of the levels of IL-6 
and TGF-β produced by these cells would also have aided in their identification.   
An alternative hypothesis was that these morphological changes were an 
indication of the activation of the THP-1 cells into an activated macrophage 
phenotype in response to 23C6/M-CSF treatment. Monocyte/macrophage 
activation can occur via a number of mechanisms, each of which leads to a 
macrophage of a particular function and phenotype. These macrophages can be 
identified by the surface markers they express and their characteristic cytokine 
profiles. We analysed the expression of specific surface markers and the 
cytokine production profiles of 23C6/M-CSF-treated THP-1 cells, to identify the 
nature of this 23C6-mediated activation of THP-1 cells with reference to 
published markers of macrophage activation7, 8, 247, 248. Table 5-1 shows a 
summary of the cytokine profile and surface marker expression of THP-1 cells 
treated with 23C6 and M-CSF, compared with characteristics of specific 
populations of activated macrophages. The expression of selected surface 
markers on THP-1 cells did not correlate with the surface marker profile for a 
particular type of macrophage activation.  
Specific cytokine profiles are also associated with macrophage activation 
mechanisms. Classical activation of macrophages (M1) is induced by treatment 
with IFN-γ and TNF-α and is characterised by the production of pro-inflammatory 
cytokines such as TNF-α and IL-12. Alternative activation of macrophages (M2) is 
characterised by the production of high levels of IL-10 and not IL-12 or TNF-α in 
response to exposure to stimuli such as IL-4, IL-10 and glucocorticoids. M2 
macrophages can be further sub-divided into M2a, M2b and M2c sub-populations 
of alternatively activated macrophages (Table 5-1). M2a and M2c are similar in 
that they both produce high levels of anti-inflammatory agents, such as IL-10 
and IL-1RA. M2b macrophages are a distinct population that develop in response 
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to exposure to immune complexes and to TLR ligation, and produce TNF-α in 
conjunction with high levels of IL-10 and low levels of IL-12.  
THP-1 cells treated with 23C6 and M-CSF for 5 days produced a range of 
cytokines. High levels of TNF-α, RANTES, IL-8, MIP-1β and VEGF were 
continuously released during the 5 day assay period. There was a transient 
release of IFN-γ and IL-10 detected after 24 hours, which had declined to zero 
after 48 hours. It is possible that this decline to zero was a result of autocrine 
uptake of these cytokines by the stimulated THP-1 cells. THP-1 cells express the 
receptor for IFN-γ (data not shown). Other authors have reported some 
morphological changes in THP-1 cells after treatment with IFN-γ and M-CSF 249. It 
is also possible that release of IFN-γ and IL-10 was inhibited after 24 hours due 
to changes associated with the activation of THP-1 cells by 23C6 and M-CSF. No 
IL-4 or IL-12p40 was detected at any time during the 5 day assay.  
The cytokine profiles, similar to the cell surface markers, did not correlate 
absolutely with a specific mechanism of macrophage activation.  The cytokines 
produced in response to 23C6/M-CSF may provide autocrine activating signals for 
the cells or may be the consequence of a specific programme of macrophage 
activation.  
It seems unlikely that the 23C6/M-CSF-treated THP-1 cells had undergone an M2a 
or M2c programme of alternative macrophage activation. The lack of IL-4 
production, the transient IL-10 production and the levels of TNF-α produced by 
23C6/M-CSF-treated THP-1 cells suggested that these are not M2a or M2c 
alternatively activated macrophages. Similarly, although the 23C6/M-CSF 
treated THP-1 cells produced IFN-γ (albeit transiently) and TNF-α, there was no 
production of IL-12, reactive nitrogen species (RNS) or reactive oxygen species 
(ROS) as would be expected of a classically activated macrophage (M1) 
population.  
Based on the data, it was hypothesised that the 23C6/M-CSF-activated THP-1 
cells were most similar in their profile to M2b activated macrophages.  The 
levels of TNFα, lack of production of ROS and RNS, transient IL-10 production 
and lack of IL-12 production suggested this was the most likely macrophage 
activation phenotype for the 23C6/M-CSF treated THP-1 cells. These data were 
supported by the fact that M2b macrophage activation is induced by IgG 
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complexes and TLR ligands. It is possible that 23C6 antibody binding involved a 
TLR receptor (discussed later). In addition, the production of VEGF and IL-8 by 
the 23C6/M-CSF-treated THP-1 cells is also observed with tumour-associated 
macrophages (TAM), which are defined as an M2 macrophage population. TAM 
are a major component of many tumours and are proposed to actively contribute 
to the development, survival and metastasis of cancers.  
Further analysis will be required to conclusively identify if these cells are indeed 
an activated macrophage population and that αVβ3-ligation in conjunction with 
M-CSF leads to macrophage activation. The data herein have tentatively 
identified 23C6/M-CSF-differentiated THP-1 cells as most similar to M2b 
macrophages. However, macrophages are a highly heterogenous population and 
it is plausible that not all the mechanisms leading to their activation have been 
described and that integrin-mediated activation represents a new type of 
macrophage activation mechanism. Similarly, it is equally possible that these in 
vitro experiments are lacking specific (unknown) factors that would result in the 
development of surface markers and cytokine profiles for 23C6/M-CSF-treated 
THP-1 cells identical to a specific type of activated macrophage. It may also be 
that these 23C6/M-CSF-treated THP-1 cells are arrested at a particular 
developmental point (such as a pre-osteoclast or osteoclast-like cell that has yet 
to express the TRACP osteoclast marker) and therefore, would differentiate 
further given the correct in vivo or in vitro environment. This, however, does 
not take away from the fact that ligation of the αVβ3 integrin by the 23C6 
antibody in the presence or absence of the myeloid growth factor M-CSF has a 
profound effect on the morphology and activity of THP-1 cells. 
5.3.4  Role of TLR-2 and c-FMS during αVβ3-mediated 
cytokine production by THP-1 cells 
Chronic stimulation of THP-1 cells with the anti-αVβ3 antibody, 23C6, led to 
morphological changes within the THP-1 cells. This 23C6-mediated activation in 
THP-1 cells was enhanced by simultaneous addition of M-CSF. This was reflected 
in the increased degree of the morphological changes induced by the presence of 
M-CSF. In addition, 23C6-mediated signalling via the MAPK pathway and cytokine 
production by THP-1 cells was enhanced by the addition of M-CSF.  Treatment of 
THP-1 cells with 23C6 alone did not induce the expression of M-CSF mRNA as 
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measured by semi-quantitative RT-PCR (data not shown). This enhancement of 
ERK phosphorylation and cytokine production by the combination of suboptimal 
concentrations of 23C6 and M-CSF suggests a synergistic relationship between 
the αVβ3 integrin and the M-CSF receptor c-FMS. 
The importance of the c-FMS receptor (even in the absence of exogenously 
supplied M-CSF) was revealed by the fact that U937 cells, which express 
equivalent levels of the αVβ3 integrin to THP-1 cells but do not express c-FMS, 
failed to differentiate in response to 23C6 or 23C6/M-CSF treatment.  The αVβ3 
integrin and c-FMS receptors have been shown to associate with each other 
during osteoclast development from macrophages. It is possible that αVβ3 and c-
FMS also associate during other macrophage differentiation events, such as 
macrophage activation.  
The authors who identified the interaction between αVβ3 and c-FMS proposed 
that the αVβ3/c-FMS association is part of a larger signalling complex which 
includes other, as yet unidentified, receptors. Data presented herein suggest 
that the 23C6/M-CSF-treated THP-1 cells acquired a phenotype most similar to 
M2b activated macrophages. The mechanism of activation of M2b activated 
macrophage involves binding of TLR ligands (Table 5-1). Thus, it was 
hypothesised that one of the unidentified receptors in the αVβ3/c-FMS signalling 
complex was one of the TLR family of receptors. The LPS signalling complex is 
comprised of a similar group of receptors. This complex contains the LPS 
receptor, CD14, the αXβ2 integrin and the TLR-4 isoform. β2 integrins contain 
binding sites for LPS. Therefore, given the existence of this complex, it is 
plausible to suggest the existence of other integrin/TLR complexes. 
Zymosan, a yeast-derived ligand for TLR-2, also binds β2 integrins. Treatment of 
THP-1 cells with zymosan induced the production of similar cytokines to those 
observed with 23C6/M-CSF treatment of THP-1 cells. We observed similarities 
between the morphology of 23C6/M-CSF-treated cells and THP-1 cells treated 
with the TLR-2 ligand, zymosan, which led us to hypothesise that TLR-2 might be 
involved. A neutralising antibody against TLR-2 reduced the levels of 23C6/M-
CSF-induced RANTES, IL-8, MIP-1β and VEGF to approximately half of those 
observed in the absence of the TLR-2 antibody, although the anti-TLR-2 antibody 
did not completely abolish cytokine production. Production of RANTES, IL-8 and 
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MIP-1β by THP-1 cells in response to 23C6/M-CSF treatment was inhibited by 
treatment of the cells with anti-TLR-2 but was not inhibited by the inclusion of 
an inhibitor of MyD88-based signalling. This was unexpected, as all TLR-2 
signalling pathways described to date are dependent on the MyD88 molecule. 
The production of IL-8 and MIP-1β by THP-1 cells in response to zymosan was 
inhibited by the anti-TLR-2 antibody and by the inhibitor of MyD88 signalling 
(albeit to a lesser extent than the inhibition observed with the antibody). The 
levels of IL-8 mRNA detected in THP-1 cells treated with 23C6/M-CSF or zymosan 
were not inhibited by the MyD88 inhibitor but were inhibted by the anti-TLR-2 
antibody.  
Treatment of THP-1 cells with 23C6 or 23C6/M-CSF led to the activation of NFκB 
transcription factor, as indicated by EMSA analysis. We were unable to detect a 
supershift using an anti-p65 antibody and also failed to observe translocation of 
p65 to the nucleus after 23C6/M-CSF treatment. Therefore, it was not possible 
to identify the individual NFκB protein involved in the analysis, although it was 
unlikely to be p65. We were able to detect increases in the levels of the TLR 
signalling molecule IRAK-1 in the cytoplasm of 23C6, 23C6/M-CSF and zymosan 
treated THP-1 cells compared with M-CSF-treated or untreated THP-1 cells. 
The data described above suggest that cytokine production by THP-1 cells in 
response to 23C6 and M-CSF treatment was reduced by binding of the exterior of 
the TLR-2 receptor but not by blocking the MyD88 molecule at the top 
(upstream) of the cytoplasmic TLR-2 signalling pathway. This may be due to the 
antibody blocking an association between αVβ3, c-FMS and TLR-2. However, 
increases in the expression of the IRAK-1 protein downstream of MyD88 in this 
pathway and activation of NFκB transcription factors were observed in 23C6/M-
CSF and zymosan-treated cells, suggesting that signalling was proceeding via the 
TLR-2 pathway, despite the lack of dependence on MyD88.  
Taken together, these data might suggest the possibility of a MyD88-independent 
pathway from TLR-2, which may function together with the MyD88-dependent 
pathway. In some cases, blockage of MyD88 appeared to increase the levels of 
cytokines produced, although these were not quantified and therefore no 
comment can be made on their significance.  There have been reports of cross-
talk between the FAK (integrin-mediated) and MyD88 (TLR-mediated) pathways. 
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The mechanism is poorly understood at present, but it has been suggested that 
FAK can mediate the phosphorylation-dependent activation of MyD88 and other 
TLR signalling intermediates 133. It may be that integrin-dependent activation of 
TLR signalling intermediates (such as TIRAP/Mal) exist, although this still needs 
to be determined 129.  
Alternatively, it could be hypothesised that TLR-2 plays a minor role in this 
complex and is important in external recognition and not internal signalling. 
Thus, the inclusion of TLR-2 in this complex may activate a signalling pathway 
other than that originating from TLR-2 itself, leading to the activation of similar 
transcription factors (NFκB). In this case, the signalling events may originate 
from the αVβ3 and c-FMS receptors and therefore could be modulated by the 
external complex which contains TLR-2 but would be independent of MyD88 
signalling. A recent study suggested that the αMβ2 integrin was capable of 
signalling via the TLR pathway, by hijacking the signalling intermediates IRAK 
and TRAF, in a MyD88-independent process 250. TLR-2 has also been shown to act 
as a scaffold for other signalling complexes. It is unfortunate that there are no 
data available from this analysis on the effect of the anti-TLR-2 antibody on the 
activation of NFκB transcription factors or the levels of IRAK-1 in THP-1 cells 
treated with 23C6 and M-CSF. Further analysis is underway to confirm the 
existence of and to investigate this potential complex, including 
immunoprecipitaion and co-localisation studies on these three receptors.  
The reduction in cytokine production due to the blockage of TLR-2 was not 
associated with a complete change in the cell morphology in response to 
23C6/M-CSF treatment. The 23C6/M-CSF treated cells still displayed a degree of 
change in morphology associated with 23C6 stimulation (data not shown), 
although these experiments need to be repeated to confirm the accuracy of 
these data. This suggests that the pathways leading to cytokine production and 
macrophage activation are distinct, although they may be overlapping, as 
indicated by synergy in cytokine production and differentiation phenotype upon 
addition of M-CSF. This is supported by the fact that antibodies that induce high 
levels of cytokine production do not necessarily induce the morphological 
changes in the THP-1 cells.  
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The data presented in this chapter suggest that the αVβ3 integrin may have an 
important role in the function of monocytic cells in the immune systems, both by 
regulating the production of inflammatory species such as cytokines and 
chemokines which may affect other cells in the body but also by directly 
influencing the biology of the monocyte itself. 
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6 DISCUSSION 
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6.1  CD23-Integrin Interaction 
CD23 interacts with four integrins, αVβ3, αVβ5, αMβ2 and αXβ2. The data in this 
thesis describe the analysis of the in vitro interaction between CD23/CD23-
derived peptides and the αV integrins, αVβ3 and αVβ5. We mapped the 
recognition site in CD23 for αVβ3 and αVβ5 to a set of peptides which all 
contained a common tripeptide motif RKC 75. The classical recognition site for 
integrins is the RGD motif, which mediates adhesive reactions and is bound at 
the interface of the α and β integrin subunits 101. The interaction between the 
integrin and RKC containing peptides was determined to be cation-independent, 
salt-sensitive and occurred even in the presence of RGD-containing integrin 
ligands. In addition, the RKC peptide is basic in nature whereas the RGD-binding 
site of integrins mediates binding of acidic motifs. These combined features of 
the CD23-integrin interaction suggest that the binding site for the RKC 
containing peptides on the integrin is not the RGD-binding site. While the RGD 
sequence is a highly conserved recognition sequence, it is plausible to propose 
the existence of alternative sites on integrins for other ligands. This suggests 
that the RKC motif is a novel motif for integrins and that it binds to an 
alternative site to the binding of RGD. This alternative site may be more 
important in non-adhesion based, integrin signalling in response to soluble 
ligands.  
Integrins are important receptors in adhesion reactions, but they also participate 
in complexes that could be considered “non-adhesive” signalling. There is now a 
growing body of evidence suggesting an alternative site for the binding of non-
RGD based, soluble ligands in integrins, such as that observed between CD23-
derived peptides and the αV integrins. These data support the findings of a 
number of studies that have proposed the existence of an alternative site on 
integrins for ligand recognition. In all of these cases, the interaction is between 
a soluble ligand and occurs at a site distinct from the RGD-binding site 75, 109, 114, 
115.  
The potential existence of an alternative integrin recognition site for soluble 
ligands will be important for the design of anti-integrin based drugs, especially 
since most drugs will be in solution in vivo. The majority of studies on integrins 
have been performed in adherent cells, although there is now a growing 
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appreciation of the participation of integrins in alternative modes of signalling. 
Most studies on the biological roles of integrins have been performed in adherent 
cell types. It is possible that the conclusions based on studies in adherent cells 
are not applicable to integrin-mediated signalling in suspension cells. The 
possibility of an alternative mode of signalling is particularly interesting in the 
context of haematopoietic cells, including monocytes, which are non-adherent, 
suspension cells, but nonetheless express a wide range of integrins and are the 
precursors of a number of adherent, terminally differentiated cells, such as 
macrophages and osteoclasts. Monocytes, therefore, are a model for the study of 
integrin-based signalling in soluble and adherent situations. Chronic treatment 
of THP-1 cells with the anti-αVβ3 antibody 23C6 in solution led to a change in 
morphology of the model cell line THP-1. The untreated THP-1 cells were small 
and rounded cells in suspension, which became enlarged and adherent after 
treatment with a soluble ligand, 23C6. This indicated that a soluble stimulus 
resulted in the activation of signalling pathways related to adhesion or that the 
pathways that have been previously described relating to adhesion are actually 
not exclusively reserved for adhesion based signalling. This further supports the 
suggestion that integrins participate in two different modes of signalling, and 
that it may or may not be possible to completely separate the adhesive and non-
adhesive based functions of integrins.  
6.2 A potential Integrin/Growth Factor Receptor/ 
TLR Complex 
Integrins are well known modulators of signalling from other receptors, often 
being components of larger signalling complexes, such as the endotoxin 
signalling complex that is comprised of TLR-4/β2/CD14. We hypothesise that the 
αVβ3 integrin may form a similar complex with the M-CSF receptor, c-FMS, and 
TLR-2 and that this is one example of a range of complexes that involve 
integrins, TLRs and growth factor receptors. 
Macrophages activate in response to the presence of pathogens, often through 
the binding of TLRs. TLRs are a group of evolutionarily conserved receptors that 
form an important part of the innate immune response via their recognition of 
conserved pathogen associated molecular patterns (PAMPs). A number of 
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pathogens that interact with TLRs, have also been shown to bind integrins as 
receptors for entry into the cell (Table 6-1). Many pathogen receptors 
incorporate an RGD sequence which they use to interact with integrins, although 
a number of pathogens also gain entry to cells by interactions with integrins that 
do not involve an RGD (or related) sequence and cannot be blocked by RGD 
containing ligands 251-255. In this manner, these RGD-independent reactions with 
the integrins could be considered similar to the nature of the interaction 
observed with the interaction between CD23/CD23-derived peptides and the 
integrins in vitro.  
Therefore, the existence of a pathogen response complex including a TLR and an 
integrin, along with additional macrophage activation receptors such as c-FMS, 
would couple the innate sensing mechanism (TLRs) with a mechanism for 
inducing activation of the cell and cytokine production (integrins and growth 
factor receptors). Indeed, such a complex exists for endotoxin sensing. This 
complex is composed of the LPS receptor, CD14, TLR-4 and β2 integrins and in 
this case LPS contains binding sites for β2 integrins, TLR-4 and CD14 (Figure 6-1). 
It is possible that the formation of this complex is one example of a group of 
similar complexes which associate in response to different stimuli. Just as there 
are known specific pairings between different TLRs, it may be that specific 
integrins form partnerships with particular TLRs and GFRs. Indeed, both LPS and 
zymosan have the ability to bind both integrins and TLRs 256, 257.   
Our signalling data suggested that pathways activated by our proposed 
αVβ3/TLR-2/c-FMS complex during cytokine production are MyD88 independent.  
This indicates that in this case, the signalling is mediated not by the TLR-2 but 
rather by the integrin or indeed by integrin-mediated enhancement of c-FMS 
signalling. Therefore, both the integrin and the TLR are accessory proteins that 
provide the mechanism to sense and enhance the response to a potential 
pathogen. The most likely candidate for controlling the signalling pathways that 
connect ERK phosphorylation (from c-FMS and/or αVβ3) to NFκB (from the TLR-
based signalling) is FAK, although this still needs to be determined conclusively. 
In certain cases, integrin signalling pathways have resulted in the activation of 
intermediates of other signalling pathways, including TLR pathways. This may 
represent a novel mechanism for integrin-mediated synergy with other existing 
cellular signalling pathways, which will become clear as investigations continue.  
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Table  6-1 Pathogens that bind TLRs and Integrins  
 
Pathogen 
 
TLR 
 
Integrin 
 
Reference 
 
 
Adenovirus 
 
 
TLR-9 
 
 
 
αVβ3** 
αVβ5 
 
 
 
258-261 
 
 
Coxackievirus A9 
 
 
 
 
ND 
 
 
αVβ3* 
 
 
253, 262 
 
 
HIV 
 
 
TLR-7/8 (ssRNA) 
TLR-4 
 
 
 
αVβ3* 
 
263-266 
 
 
Hantavirus 
 
 
 
ND 
(potentially 3, 7, 9) 
 
 
αVβ3 
αIIbβ3 
 
 
252 
 
 
Rotavirus 
 
 
 
 
ND 
 
 
αVβ3* 
 
 
254 
 
 
Candida albicans 
 
 
 
 
TLR-2 
TLR-4 
 
 
αVβ3 
β2 
 
 
 
267-272 
 
 
Bacterial LPS 
 
 
 
 
TLR-4 
 
 
β2 
 
 
143, 273, 274 
 
 
Fungal Zymosan 
 
 
 
 
TLR-2 
 
 
β2 
 
 
256, 275, 276 
 
*Entry is RGD-dependent 
** RGD-dependent and RGD-independent strains identified 
ND not determined 
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Figure  6-1 Potential Integrin/TLR/GFR receptor signalling complexes 
(A) Proposed TLR, integrin and growth factor complexes involved in the control of innate immune 
responses. (B) Examples of specific integrin/TLR/GFR complexes with defined functions, such as 
the endotoxin signaling complex containing CD14/TLR-4 and β2 integrin and the complex of TLR-
2/αVβ3/c-FMS proposed by this study. (C) Potential signalling pathways from the TLR/integrin/GFR 
complexes, connected by FAK.  
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6.3  Integrin-mediated cytokine production and the 
Immune System 
The role of soluble CD23 in the production of cytokines by monocytic cells 
through interactions with the integrins aVβ3, αMβ2 and αXβ2 is well established. 
This study included the first analysis of the role of the newly defined CD23-
binding integrin receptor, αVβ5 on monocytic cells. The data conclude that αVβ5 
is similar to the other integrin receptors for CD23 and is also involved in the 
regulation of production of cytokines by monocytic cells. Taken together, the 
data indicate that both the αV and β2 families of CD23-binding integrins control 
the production of the same types of cytokines in response to specific ligation. It 
therefore appears that there is no relative hierarchy between the different CD23 
binding integrins during cytokine production. It may be that the response of a 
particular cell to CD23 treatment will therefore be controlled by the relative 
expression levels of the different integrins. This hypothesis could be addressed 
by evaluating the cytokine responses of cells with targeted depletion of specific 
integrin isoforms using techniques such as RNAi.  
6.3.1  Induction of cytokine production is specific 
Although no hierarchy between the different integrin families was observed, it 
was determined that cytokine production was specific with respect to the site on 
the individual integrin subunit. Only those antibodies that recognised a specific 
epitope were effective at inducing cytokine production. This again highlights the 
importance of specific, distinct epitopes during the regulation of integrin 
interactions and function. For example, ligation of the αVβ3 integrin with the 
23C6 antibody led to the release of high levels of cytokines, whereas ligation of 
the same integrin with the LM609 antibody did not induce cytokine production. 
Both 23C6 and LM609 inhibit adhesion-dependent reactions of αVβ3, but the 
antibodies recognise different sites on the integrin. Integrins are associated with 
a range of different diseases, ranging from inflammatory diseases to certain 
cancers. The specificity of the different integrin recognition sites is especially 
relevant in the case where integrins are targeted as therapies for diseases 195, 277, 
278.  
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Table  6-2 Cytokine levels detected in serum during human diseases 
 
Disease 
 
Chemokine and Concentration Range 
(pg/mL) 
 
Ref 
 
Normal/control levels 
 
IL-8 
MIP-1β 
RANTES 
TNF-α 
IL-10 
VEGF 
 
16.0  
60  
7900  
1-12  
44  
170  
 
279 
 
280 
 
 
Infectious disease 
 
Toxoplasmic retinochoroiditis 
(with vasculitis) 
 
IL-8        
 
 
35  
 
 
279 
 
Lyme Borreliosis 
 
IL-8 
MIP-1β 
 
 
100-800  
100-300  
 
281 
 
Viral infection (HCV) 
 
 
 
IL-8 
TNF-α 
 
10-10000  
10-100  
 
280 
 
Inflammatory disease 
 
Multiple sclerosis 
 
 
IL-8 
RANTES 
 
40-200  
100-600  
 
282 
 
Rheumatoid Arthritis and 
Osteoarthritis * 
 
IL-8 
MIP-1β 
RANTES 
 
80-150  
80-120  
8000-12000  
 
283 
 
Systemic lupus erthymatosis * 
 
 
IL-8 
IL-10 
TNF-α 
IFN-γ 
 
40 
10 
10-300  
10 
 
284 
285 
 
Sjogren’s Syndrome * 
 
 
IL-8 
RANTES 
MIP-1β 
TNF-α 
 
3  
1300  
20  
32  
 
286 
 
Inflammatory bowel disease/ 
Crohn’s Disease 
 
IL-10 
VEGF 
 
140  
440  
 
287 
288 
 
 
*Diseases associated with high serum levels of CD23 
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LM609 is the clone name for the anti-αVβ3 integrin antibody-based therapeutic 
known as Vitaxin 289. This humanised anti-αVβ3 antibody was developed by the 
company MedImmune as a treatment for inflammatory diseases and certain 
cancers 194, 290-292.  However, Vitaxin failed to prove effective in clinical trials for 
inflammatory diseases (such as rheumatoid arthritis and psoriasis). MedImmune 
have subsequently discontinued the development of Vitaxin as an anti-
inflammatory treatment, although it is still in trials for use as an anti-cancer 
agent 293. In light of our data, it is tempting to speculate that the reason Vitaxin 
is ineffective as an anti-inflammatory agent is that, while it targets the correct 
integrin, αVβ3, it is directed against the wrong epitope on the integrin. From the 
data presented herein, the critical site that governs cytokine production by αVβ3 
ligation is bound by 23C6 and not LM609. LM609 still inhibts adhesion and this 
may explain its continued potential to be effective in the prevention of cancer 
metastasis. This suggests that there are distinct sites on the integrin- one that 
mediates adhesive reactions and one that mediates cytokine production. These 
conclusions are consistent with the potential existence of distinct RGD and non-
RGD based binding sites on the integrins, as observed with the interaction of the 
αV integrins and CD23-derived peptides. It is also interesting to note that the 
inflammatory disorders (such as rheumatoid arthritis and psoriasis) in which αVβ3 
is being targeted are those which are correlated with high serum levels of 
soluble CD23 294.  
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6.3.2  Role of cytokines in physiological and pathological 
immune function 
Specific ligation of selected integrins led to the production of high levels of 
cytokines and chemokines by monocytic cells and the subsequent activation of 
these cells to develop a more macrophage-like phenotype. The chemokines 
produced were capable of inducing the migration of THP-1 cells, Jurkat T cells 
and IB4 B cells across a membrane in an in vitro assay for migration. The 
concentrations of cytokines observed during these experiments are similar to 
concentrations observed in a number of infectious and inflammatory challenges 
observed in vivo (Table 6-2).These combined functions are all important during 
the immune response under both physiological and pathological conditions.  
Figure 6-2 suggests how the combined functions of integrin ligation could 
contribute in vivo to the establishment of inflammation during pathogen invasion 
and in inflammatory disease such as RA. The process can be considered as stages 
A-D which encompass the onset of cytokine production by specific ligation of the 
integrin (A), the recruitment and activation of immune cells from the 
bloodstream to the site of stimulation (B), autocrine signalling leads to 
activation of the resident macrophage population (C), and when the 
inflammatory environment is established (D), which may also lead to a change in 
the cytokine profile from the original stimulus. 
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Figure  6-2 Schematic representation of the role of integrins in a model of inflammatory disease/infection 
(A) Ligation of macrophage integrin by sCD23 or pathogen at the correct epitope triggers cytokine production. (B) Cytokines and chemokines have paracrine effects on 
surrounding cells and recruit immune cells from the bloodstream to the tissue. (C) Cytokines have autocrine effect on macrophage and lead to macrophage activation (D) 
Recruited cells and activated macrophages lead to establishment and maintenance of inflammation 
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Specific ligation of the integrin/integrin signalling complex on a macrophage 
induces high levels of cytokine release. In the case of an infection, this binding 
would be mediated by a pathogen receptor, such as LPS or zymosan, whereas in 
an inflammatory disorder, such as rheumatoid arthritis, the stimulus for cytokine 
production could be induced by the high levels of CD23 detected in serum. The 
production of TNF-α, IL-8, RANTES and MIP-1β can be considered as pro-
inflammatory cytokines, which lead to the establishment of an inflammatory 
state.  
The cytokines produced in response to integrin ligation will induce both 
paracrine and autocrine effects. The concentrations of cytokines and 
chemokines induced by integrin ligation are similar to the concentration ranges 
observed in the serum of patients with infectious and inflammatory diseases 
(Table 6-2).  The chemokines diffuse into the surrounding tissues and recruit 
cells to the site of stimulation by activating integrins and inducing extravasation 
of immune cells from the bloodstream into the tissue. The integrin ligation and 
cytokines produced also have an autocrine effect on the original macrophage, 
which leads to activation and continued production of cytokines, to establish the 
inflammatory state. The activation of the macrophage by the initial stimulus 
may lead to a change in the cytokine profile. For example, under the conditions 
of our experiments, high levels of VEGF production were observed 48 hours after 
stimulation, suggesting that this may be a consequence of a change in the 
monocyte/macrophage biology. The initial stimulus will determine if the 
inflammation is productive, in the case of a pathogenic infection, or non-
productive, in the case of an auto-immune/auto-inflammatory disorder such as 
rheumatoid arthritis.  
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6.4 Conclusion 
This study has examined the interaction between CD23 and the αVβ3 and αVβ5 
integrins and attempted to define the individual roles of individual CD23-binding 
integrins (αVβ3, αVβ5, αMβ2 and αXβ2) in the production of cytokines by 
monocytic cells and the activation of these cells. Further analysis of integrin-
mediated signalling is challenging our view of these interesting receptors as 
mere adhesive structures. It is clear that integrins participate in a range of other 
modes of signalling in addition to those traditionally associated with adhesive or 
migratory functions. It is possible that these interactions will be mediated by an 
alternative site on the integrin that remains to be identified.  
 
 229 
 References 
 
1. Janeway, C., Travers, P., Walport, M. & Shlomchik, M. J. Imunobiology, the immune 
system in health and disease (Garland Science Publishing, New York, 2005). 
2. Gordon, S. The macrophage: past, present and future. Eur J Immunol 37 Suppl 1, S9-17 
(2007). 
3. Delneste, Y. et al. Interferon-gamma switches monocyte differentiation from dendritic 
cells to macrophages. Blood 101, 143-50 (2003). 
4. Chomarat, P., Dantin, C., Bennett, L., Banchereau, J. & Palucka, A. K. TNF skews 
monocyte differentiation from macrophages to dendritic cells. J Immunol 171, 2262-9 
(2003). 
5. Fujikawa, Y., Quinn, J. M., Sabokbar, A., McGee, J. O. & Athanasou, N. A. The human 
osteoclast precursor circulates in the monocyte fraction. Endocrinology 137, 4058-60 
(1996). 
6. Gordon, S. Alternative activation of macrophages. Nat Rev Immunol 3, 23-35 (2003). 
7. Mosser, D. M. The many faces of macrophage activation. J Leukoc Biol 73, 209-12 (2003). 
8. Ma, J. et al. Regulation of macrophage activation. Cell Mol Life Sci 60, 2334-46 (2003). 
9. Elenkov, I. J., Iezzoni, D. G., Daly, A., Harris, A. G. & Chrousos, G. P. Cytokine 
dysregulation, inflammation and well-being. Neuroimmunomodulation 12, 255-69 (2005). 
10. Woo, P. Cytokine polymorphisms and inflammation. Clin Exp Rheumatol 18, 767-71 
(2000). 
11. Hanada, T. & Yoshimura, A. Regulation of cytokine signaling and inflammation. Cytokine 
Growth Factor Rev 13, 413-21 (2002). 
12. Cinamon, G. et al. Novel chemokine functions in lymphocyte migration through vascular 
endothelium under shear flow. J Leukoc Biol 69, 860-6 (2001). 
13. Taub, D. D. & Oppenheim, J. J. Chemokines, inflammation and the immune system. Ther 
Immunol 1, 229-46 (1994). 
14. Mantovani, A. The chemokine system: redundancy for robust outputs. Immunol Today 20, 
254-7 (1999). 
15. Perretti, M. & Getting, S. J. Migration of specific leukocyte subsets in response to 
cytokine or chemokine application in vivo. Methods Mol Biol 225, 139-46 (2003). 
16. Mantovani, A. et al. The chemokine system in diverse forms of macrophage activation 
and polarization. Trends Immunol 25, 677-86 (2004). 
17. Bleul, C. C., Wu, L., Hoxie, J. A., Springer, T. A. & Mackay, C. R. The HIV coreceptors 
CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. 
Proc Natl Acad Sci U S A 94, 1925-30 (1997). 
18. Zaitseva, M. et al. Expression and function of CCR5 and CXCR4 on human Langerhans 
cells and macrophages: implications for HIV primary infection. Nat Med 3, 1369-75 
(1997). 
19. Lu, Z. et al. Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 
and CXCR4 domains. Proc Natl Acad Sci U S A 94, 6426-31 (1997). 
20. De Clercq, E. & Schols, D. Inhibition of HIV infection by CXCR4 and CCR5 chemokine 
receptor antagonists. Antivir Chem Chemother 12 Suppl 1, 19-31 (2001). 
21. D'Apuzzo, M. et al. The chemokine SDF-1, stromal cell-derived factor 1, attracts early 
stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol 27, 1788-93 
(1997). 
22. Bauer, J. W. et al. Elevated serum levels of interferon-regulated chemokines are 
biomarkers for active human systemic lupus erythematosus. PLoS Med 3, e491 (2006). 
23. Vergunst, C. E., van de Sande, M. G., Lebre, M. C. & Tak, P. P. The role of chemokines in 
rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 34, 415-25 (2005). 
24. Allavena, P., Garlanda, C., Borrello, M. G., Sica, A. & Mantovani, A. Pathways connecting 
inflammation and cancer. Curr Opin Genet Dev (2008). 
25. Barton, G. M. A calculated response: control of inflammation by the innate immune 
system. J Clin Invest 118, 413-20 (2008). 
26. Kiyono, H., Kweon, M. N., Hiroi, T. & Takahashi, I. The mucosal immune system: from 
specialized immune defense to inflammation and allergy. Acta Odontol Scand 59, 145-53 
(2001). 
27. Bodolay, E., Koch, A. E., Kim, J., Szegedi, G. & Szekanecz, Z. Angiogenesis and 
chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. 
J Cell Mol Med 6, 357-76 (2002). 
 230 
28. Szekanecz, Z., Szucs, G., Szanto, S. & Koch, A. E. Chemokines in rheumatic diseases. 
Curr Drug Targets 7, 91-102 (2006). 
29. Mossalayi, M. D., Arock, M. & Debre, P. CD23/Fc epsilon RII: signaling and clinical 
implication. Int Rev Immunol 16, 129-46 (1997). 
30. Dugas, B., Mencia-Huerta, J. M. & Braquet, P. The low affinity receptor for IgE (CD23) in 
human: a multifunctional receptor/cytokine? Eur Cytokine Netw 3, 35-41 (1992). 
31. Gordon, J. et al. CD23: a multi-functional receptor/lymphokine? Immunol Today 10, 153-
7 (1989). 
32. Bonnefoy, J. Y. et al. Structure and functions of CD23. Int Rev Immunol 16, 113-28 
(1997). 
33. Weskamp, G. et al. ADAM10 is a principal 'sheddase' of the low-affinity immunoglobulin E 
receptor CD23. Nat Immunol 7, 1293-8 (2006). 
34. Lemieux, G. A. et al. The low affinity IgE receptor (CD23) is cleaved by the 
metalloproteinase ADAM10. J Biol Chem 282, 14836-44 (2007). 
35. Marolewski, A. E. et al. CD23 (FcepsilonRII) release from cell membranes is mediated by 
a membrane-bound metalloprotease. Biochem J 333 ( Pt 3), 573-9 (1998). 
36. Arock, M. et al. Soluble CD23 increases IL-3 induction of histamine synthesis by human 
bone marrow cells. Int Arch Allergy Appl Immunol 96, 190-2 (1991). 
37. Mossalayi, M. D. et al. Cytokine effects of CD23 are mediated by an epitope distinct from 
the IgE binding site. Embo J 11, 4323-8 (1992). 
38. Armant, M., Ishihara, H., Rubio, M., Delespesse, G. & Sarfati, M. Regulation of cytokine 
production by soluble CD23: costimulation of interferon gamma secretion and triggering 
of tumor necrosis factor alpha release. J Exp Med 180, 1005-11 (1994). 
39. Herbelin, A., Elhadad, S., Ouaaz, F., de Groote, D. & Descamps-Latscha, B. Soluble CD23 
potentiates interleukin-1-induced secretion of interleukin-6 and interleukin-1 receptor 
antagonist by human monocytes. Eur J Immunol 24, 1869-73 (1994). 
40. Hermann, P. et al. The vitronectin receptor and its associated CD47 molecule mediates 
proinflammatory cytokine synthesis in human monocytes by interaction with soluble 
CD23. J Cell Biol 144, 767-75 (1999). 
41. Rezzonico, R., Imbert, V., Chicheportiche, R. & Dayer, J. M. Ligation of CD11b and 
CD11c beta(2) integrins by antibodies or soluble CD23 induces macrophage inflammatory 
protein 1alpha (MIP-1alpha) and MIP-1beta production in primary human monocytes 
through a pathway dependent on nuclear factor-kappaB. Blood 97, 2932-40 (2001). 
42. Sutton, B. J. & Gould, H. J. The human IgE network. Nature 366, 421-8 (1993). 
43. Schwarzmeier, J. D. et al. The role of soluble CD23 in distinguishing stable and 
progressive forms of B-chronic lymphocytic leukemia. Leuk Lymphoma 43, 549-54 (2002). 
44. Saka, B. et al. Prognostic importance of soluble CD23 in B-cell chronic lymphocytic 
leukemia. Clin Lab Haematol 28, 30-5 (2006). 
45. Kalil, N. & Cheson, B. D. Management of chronic lymphocytic leukaemia. Drugs Aging 16, 
9-27 (2000). 
46. Hamblin, T. J. Achieving optimal outcomes in chronic lymphocytic leukaemia. Drugs 61, 
593-611 (2001). 
47. Wagner, S. D. & Cwynarski, K. Chronic lymphocytic leukaemia: new biological markers 
for assessing prognosis. Hematol J 5, 197-201 (2004). 
48. Chomarat, P., Briolay, J., Banchereau, J. & Miossec, P. Increased production of soluble 
CD23 in rheumatoid arthritis, and its regulation by interleukin-4. Arthritis Rheum 36, 
234-42 (1993). 
49. Fernandez-Gutierrez, B., Hernandez-Garcia, C., Banares, A. A. & Jover, J. A. CD23 
hyperexpression in rheumatoid arthritis: evidence for a B cell hyperresponsiveness to 
cognate and noncognate T-cell signals. Clin Immunol Immunopathol 72, 321-7 (1994). 
50. Rezonzew, R. & Newkirk, M. M. Impaired release of sCD23 by activated B-cells from RA 
patients. Clin Immunol Immunopathol 71, 156-63 (1994). 
51. Bansal, A. S. et al. Increased levels of sCD23 in rheumatoid arthritis are related to 
disease status. Clin Exp Rheumatol 12, 281-5 (1994). 
52. Massa, M. et al. Serum soluble CD23 levels and CD23 expression on peripheral blood 
mononuclear cells in juvenile chronic arthritis. Clin Exp Rheumatol 16, 611-6 (1998). 
53. Vaiopoulos, G. et al. Hemoglobin levels correlate with serum soluble CD23 and TNF-Rs 
concentrations in patients with rheumatoid arthritis. Haematologia (Budap) 29, 89-99 
(1998). 
54. Kleinau, S., Martinsson, P., Gustavsson, S. & Heyman, B. Importance of CD23 for 
collagen-induced arthritis: delayed onset and reduced severity in CD23-deficient mice. J 
Immunol 162, 4266-70 (1999). 
55. Ribbens, C. et al. Increased synovial fluid levels of soluble CD23 are associated with an 
erosive status in rheumatoid arthritis (RA). Clin Exp Immunol 120, 194-9 (2000). 
 231 
56. De Miguel, S. et al. Mechanisms of CD23 hyperexpression on B cells from patients with 
rheumatoid arthritis. J Rheumatol 28, 1222-8 (2001). 
57. Swendeman, S. L. & Thorley-Lawson, D. Soluble CD23/BLAST-2 (S-CD23/Blast-2) and its 
role in B cell proliferation. Curr Top Microbiol Immunol 141, 157-64 (1988). 
58. Kijimoto-Ochiai, S. & Uede, T. CD23 molecule acts as a galactose-binding lectin in the 
cell aggregation of EBV-transformed human B-cell lines. Glycobiology 5, 443-8 (1995). 
59. Liu, Y. J. et al. Recombinant 25-kDa CD23 and interleukin 1 alpha promote the survival 
of germinal center B cells: evidence for bifurcation in the development of centrocytes 
rescued from apoptosis. Eur J Immunol 21, 1107-14 (1991). 
60. Dalloul, A. H., Fourcade, C., Debre, P. & Mossalayi, M. D. Thymic epithelial cell-derived 
supernatants sustain the maturation of human prothymocytes: involvement of interleukin 
1 and CD23. Eur J Immunol 21, 2633-6 (1991). 
61. Kijimoto-Ochiai, S. CD23 (the low-affinity IgE receptor) as a C-type lectin: a multidomain 
and multifunctional molecule. Cell Mol Life Sci 59, 648-64 (2002). 
62. Hibbert, R. G. et al. The structure of human CD23 and its interactions with IgE and CD21. 
J Exp Med 202, 751-60 (2005). 
63. Wurzburg, B. A., Tarchevskaya, S. S. & Jardetzky, T. S. Structural changes in the lectin 
domain of CD23, the low-affinity IgE receptor, upon calcium binding. Structure 14, 1049-
58 (2006). 
64. Beavil, A. J., Edmeades, R. L., Gould, H. J. & Sutton, B. J. Alpha-helical coiled-coil 
stalks in the low-affinity receptor for IgE (Fc epsilon RII/CD23) and related C-type 
lectins. Proc Natl Acad Sci U S A 89, 753-7 (1992). 
65. Yokota, A. et al. Two forms of the low-affinity Fc receptor for IgE differentially mediate 
endocytosis and phagocytosis: identification of the critical cytoplasmic domains. Proc 
Natl Acad Sci U S A 89, 5030-4 (1992). 
66. Yokota, A. et al. Two species of human Fc epsilon receptor II (Fc epsilon RII/CD23): 
tissue-specific and IL-4-specific regulation of gene expression. Cell 55, 611-8 (1988). 
67. Moulder, K. The role of RGD in CD23-mediated cell adhesion. Immunol Today 17, 198-9 
(1996). 
68. Steiner, B., Trzeciak, A., Pfenninger, G. & Kouns, W. C. Peptides derived from a 
sequence within beta 3 integrin bind to platelet alpha IIb beta 3 (GPIIb-IIIa) and inhibit 
ligand binding. J Biol Chem 268, 6870-3 (1993). 
69. Conrad, D. H. Fc epsilon RII/CD23: the low affinity receptor for IgE. Annu Rev Immunol 8, 
623-45 (1990). 
70. Aubry, J. P., Pochon, S., Graber, P., Jansen, K. U. & Bonnefoy, J. Y. CD21 is a ligand for 
CD23 and regulates IgE production. Nature 358, 505-7 (1992). 
71. Aubry, J. P. et al. CD23 interacts with a new functional extracytoplasmic domain 
involving N-linked oligosaccharides on CD21. J Immunol 152, 5806-13 (1994). 
72. Bjorck, P., Elenstrom-Magnusson, C., Rosen, A., Severinson, E. & Paulie, S. CD23 and 
CD21 function as adhesion molecules in homotypic aggregation of human B lymphocytes. 
Eur J Immunol 23, 1771-5 (1993). 
73. Bonnefoy, J. Y. et al. Regulation of IgE synthesis by CD23/CD21 interaction. Int Arch 
Allergy Immunol 107, 40-2 (1995). 
74. Lecoanet-Henchoz, S. et al. CD23 regulates monocyte activation through a novel 
interaction with the adhesion molecules CD11b-CD18 and CD11c-CD18. Immunity. 3, 119-
125 (1995). 
75. Borland, G. et al. alphavbeta5 integrin sustains growth of human pre-B cells through an 
RGD-independent interaction with a basic domain of the CD23 protein. J Biol Chem 282, 
27315-26 (2007). 
76. Sayers, I., Housden, J. E., Spivey, A. C. & Helm, B. A. The importance of Lys-352 of 
human immunoglobulin E in FcepsilonRII/CD23 recognition. J Biol Chem 279, 35320-5 
(2004). 
77. Bonnefoy, J. Y. et al. A new pair of surface molecules involved in human IgE regulation. 
Immunol Today 14, 1-2 (1993). 
78. Yu, P., Kosco-Vilbois, M., Richards, M., Kohler, G. & Lamers, M. C. Negative feedback 
regulation of IgE synthesis by murine CD23. Nature 369, 753-6 (1994). 
79. Fremeaux-Bacchi, V. et al. Soluble CD21 (sCD21) forms biologically active complexes 
with CD23: sCD21 is present in normal plasma as a complex with trimeric CD23 and 
inhibits soluble CD23-induced IgE synthesis by B cells. Int Immunol 10, 1459-66 (1998). 
80. Beavil, R. L., Graber, P., Aubonney, N., Bonnefoy, J. Y. & Gould, H. J. CD23/Fc epsilon 
RII and its soluble fragments can form oligomers on the cell surface and in solution. 
Immunology 84, 202-6 (1995). 
81. McCloskey, N. et al. Soluble CD23 monomers inhibit and oligomers stimulate IGE 
synthesis in human B cells. J Biol Chem 282, 24083-91 (2007). 
 232 
82. Gould, H. J. & Sutton, B. J. IgE in allergy and asthma today. Nat Rev Immunol 8, 205-17 
(2008). 
83. Aubry, J. P. et al. The 25-kDa soluble CD23 activates type III constitutive nitric oxide-
synthase activity via CD11b and CD11c expressed by human monocytes. J Immunol 159, 
614-22 (1997). 
84. Rezzonico, R., Chicheportiche, R., Imbert, V. & Dayer, J. M. Engagement of CD11b and 
CD11c beta2 integrin by antibodies or soluble CD23 induces IL-1beta production on 
primary human monocytes through mitogen-activated protein kinase-dependent 
pathways. Blood 95, 3868-77 (2000). 
85. Conrad, D. H., Ford, J. W., Sturgill, J. L. & Gibb, D. R. CD23: an overlooked regulator of 
allergic disease. Curr Allergy Asthma Rep 7, 331-7 (2007). 
86. Conrad, D. H., Kilmon, M. A., Studer, E. J. & Cho, S. The low-affinity receptor for IgE (Fc 
epsilon RII or CD23) as a therapeutic target. Biochem Soc Trans 25, 393-7 (1997). 
87. Arnaout, M. A., Goodman, S. L. & Xiong, J. P. Structure and mechanics of integrin-based 
cell adhesion. Curr Opin Cell Biol 19, 495-507 (2007). 
88. Arnaout, M. A., Mahalingam, B. & Xiong, J. P. Integrin structure, allostery, and 
bidirectional signaling. Annu Rev Cell Dev Biol 21, 381-410 (2005). 
89. Yamada, S., Brown, K. E. & Yamada, K. M. Differential mRNA regulation of integrin 
subunits alpha V, beta 1, beta 3, and beta 5 during mouse embryonic organogenesis. Cell 
Adhes.Commun. 3, 311-325 (1995). 
90. Guo, W. & Giancotti, F. G. Integrin signalling during tumour progression. Nat Rev Mol 
Cell Biol 5, 816-26 (2004). 
91. Clark, R. A., Ashcroft, G. S., Spencer, M. J., Larjava, H. & Ferguson, M. W. Re-
epithelialization of normal human excisional wounds is associated with a switch from 
alpha v beta 5 to alpha v beta 6 integrins. Br.J.Dermatol. 135, 46-51 (1996). 
92. Issekutz, T. B. In vivo blood monocyte migration to acute inflammatory reactions, IL-1 
alpha, TNF-alpha, IFN-gamma, and C5a utilizes LFA-1, Mac-1, and VLA-4. The relative 
importance of each integrin. J Immunol 154, 6533-40 (1995). 
93. Humphries, M. J. Integrin structure. Biochem Soc Trans 28, 311-39 (2000). 
94. Xiong, J. P. et al. Crystal structure of the extracellular segment of integrin alpha 
Vbeta3. Science 294, 339-345 (2001). 
95. Shimaoka, M., Takagi, J. & Springer, T. A. Conformational regulation of integrin 
structure and function. Annu Rev Biophys Biomol Struct 31, 485-516 (2002). 
96. Shi, M. et al. The Crystal Structure of the Plexin-Semaphorin-Integrin Domain/Hybrid 
Domain/I-EGF1 Segment from the Human Integrin {beta}2 Subunit at 1.8-A Resolution. 
J.Biol Chem 280, 30586-30593 (2005). 
97. Adair, B. D. et al. Three-dimensional EM structure of the ectodomain of integrin 
{alpha}V{beta}3 in a complex with fibronectin. J.Cell Biol. 168, 1109-1118 (2005). 
98. Xiong, J. P. et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 
in complex with an Arg-Gly-Asp ligand. Science 296, 151-155 (2002). 
99. Takagi, J., Isobe, T., Takada, Y. & Saito, Y. Structural interlock between ligand-binding 
site and stalk-like region of beta1 integrin revealed by a monoclonal antibody 
recognizing conformation-dependent epitope. J Biochem 121, 914-21 (1997). 
100. Kamata, T., Handa, M., Sato, Y., Ikeda, Y. & Aiso, S. Membrane-proximal {alpha}/{beta} 
stalk interactions differentially regulate integrin activation. J Biol Chem 280, 24775-83 
(2005). 
101. Ruoslahti, E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 
12, 697-715 (1996). 
102. Papadopoulos, G. K., Ouzounis, C. & Eliopoulos, E. RGD sequences in several receptor 
proteins: novel cell adhesion function of receptors? Int J Biol Macromol 22, 51-7 (1998). 
103. Villard, V. et al. Synthetic RGD-containing alpha-helical coiled coil peptides promote 
integrin-dependent cell adhesion. J Pept Sci 12, 206-12 (2006). 
104. Pfaff, M. et al. Selective recognition of cyclic RGD peptides of NMR defined conformation 
by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J.Biol.Chem. 269, 
20233-20238 (1994). 
105. Pierschbacher, M. D. & Ruoslahti, E. Influence of stereochemistry of the sequence Arg-
Gly-Asp-Xaa on binding specificity in cell adhesion. J Biol Chem 262, 17294-8 (1987). 
106. Schaffner, P. & Dard, M. M. Structure and function of RGD peptides involved in bone 
biology. Cell Mol Life Sci 60, 119-32 (2003). 
107. Takagi, J. Structural basis for ligand recognition by RGD (Arg-Gly-Asp)-dependent 
integrins. Biochem Soc Trans 32, 403-6 (2004). 
108. Pedchenko, V., Zent, R. & Hudson, B. G. Alpha(v)beta3 and alpha(v)beta5 integrins bind 
both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of 
the alpha3 chain of type IV collagen: implication for the mechanism of endothelia cell 
adhesion. J Biol Chem 279, 2772-80 (2004). 
 233 
109. Vogel, B. E. et al. A novel integrin specificity exemplified by binding of the alpha v beta 
5 integrin to the basic domain of the HIV Tat protein and vitronectin. J.Cell Biol. 121, 
461-468 (1993). 
110. Tselepis, V. H., Green, L. J. & Humphries, M. J. An RGD to LDV motif conversion within 
the disintegrin kistrin generates an integrin antagonist that retains potency but exhibits 
altered receptor specificity. Evidence for a functional equivalence of acidic integrin-
binding motifs. J Biol Chem 272, 21341-8 (1997). 
111. Pfaff, M., McLane, M. A., Beviglia, L., Niewiarowski, S. & Timpl, R. Comparison of 
disintegrins with limited variation in the RGD loop in their binding to purified integrins 
alpha IIb beta 3, alpha V beta 3 and alpha 5 beta 1 and in cell adhesion inhibition. Cell 
Adhes.Commun. 2, 491-501 (1994). 
112. Gupta, S., Li, H. & Sampson, N. S. Characterization of fertilin beta-disintegrin binding 
specificity in sperm-egg adhesion. Bioorg Med Chem 8, 723-9 (2000). 
113. Evans, J. P. Fertilin beta and other ADAMs as integrin ligands: insights into cell adhesion 
and fertilization. Bioessays 23, 628-39 (2001). 
114. Maeshima, Y., Colorado, P. C. & Kalluri, R. Two RGD-independent alpha vbeta 3 integrin 
binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 275, 
23745-50 (2000). 
115. Dong, L. J., Hsieh, J. C. & Chung, A. E. Two distinct cell attachment sites in entactin are 
revealed by amino acid substitutions and deletion of the RGD sequence in the cysteine-
rich epidermal growth factor repeat 2. J Biol Chem 270, 15838-43 (1995). 
116. ffrench-Constant, C. & Colognato, H. Integrins: versatile integrators of extracellular 
signals. Trends Cell Biol 14, 678-86 (2004). 
117. Yee, K. L., Weaver, V. M. & Hammer, D. A. Integrin-mediated signalling through the 
MAP-kinase pathway. IET Syst Biol 2, 8-15 (2008). 
118. Calderwood, D. A., Shattil, S. J. & Ginsberg, M. H. Integrins and actin filaments: 
reciprocal regulation of cell adhesion and signaling. J Biol Chem 275, 22607-10 (2000). 
119. Calderwood, D. A. & Ginsberg, M. H. Talin forges the links between integrins and actin. 
Nat Cell Biol 5, 694-7 (2003). 
120. Lad, Y., Harburger, D. S. & Calderwood, D. A. Integrin cytoskeletal interactions. Methods 
Enzymol 426, 69-84 (2007). 
121. Humphries, M. J. et al. Integrin structure: heady advances in ligand binding, but 
activation still makes the knees wobble. Trends Biochem.Sci. 28, 313-320 (2003). 
122. Calderwood, D. A. Talin controls integrin activation. Biochem Soc Trans 32, 434-7 (2004). 
123. Calderwood, D. A. Integrin activation. J Cell Sci 117, 657-66 (2004). 
124. van der Flier, A. & Sonnenberg, A. Function and interactions of integrins. Cell Tissue Res 
305, 285-98 (2001). 
125. Takagi, J. & Springer, T. A. Integrin activation and structural rearrangement. Immunol 
Rev 186, 141-63 (2002). 
126. Gline, S. E., Cambier, S., Govaerts, C. & Nishimura, S. L. A 50-A separation of the 
integrin alpha v beta 3 extracellular domain C termini reveals an intermediate activation 
state. J.Biol.Chem. 279, 54567-54572 (2004). 
127. Gottschalk, K. E., Gunther, R. & Kessler, H. A three-state mechanism of integrin 
activation and signal transduction for integrin alpha(v)beta(3). Chembiochem. 3, 470-473 
(2002). 
128. Giancotti, F. G. & Ruoslahti, E. Integrin signaling. Science 285, 1028-32 (1999). 
129. Zeisel, M. B. et al. Cross talk between MyD88 and focal adhesion kinase pathways. J 
Immunol 174, 7393-7 (2005). 
130. Barberis, L. et al. Distinct roles of the adaptor protein Shc and focal adhesion kinase in 
integrin signaling to ERK. J Biol Chem 275, 36532-40 (2000). 
131. Renard, P. & Raes, M. The proinflammatory transcription factor NFkappaB: a potential 
target for novel therapeutical strategies. Cell Biol Toxicol 15, 341-4 (1999). 
132. Lien, E. & Ingalls, R. R. Toll-like receptors. Crit Care Med 30, S1-11 (2002). 
133. Semaan, N., Alsaleh, G., Gottenberg, J. E., Wachsmann, D. & Sibilia, J. Etk/BMX, a Btk 
Family Tyrosine Kinase, and Mal Contribute to the Cross-Talk between MyD88 and FAK 
Pathways. J Immunol 180, 3485-91 (2008). 
134. Alam, N. et al. The integrin-growth factor receptor duet. J Cell Physiol 213, 649-53 
(2007). 
135. Lee, J. W. & Juliano, R. Mitogenic signal transduction by integrin- and growth factor 
receptor-mediated pathways. Mol Cells 17, 188-202 (2004). 
136. Eliceiri, B. P., Klemke, R., Stromblad, S. & Cheresh, D. A. Integrin alphavbeta3 
requirement for sustained mitogen-activated protein kinase activity during angiogenesis. 
J Cell Biol 140, 1255-63 (1998). 
 234 
137. Barillari, G. et al. Inflammatory cytokines synergize with the HIV-1 Tat protein to 
promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor 
and the alpha v beta 3 integrin. J.Immunol. 163, 1929-1935 (1999). 
138. Masson-Gadais, B., Houle, F., Laferriere, J. & Huot, J. Integrin alphavbeta3, requirement 
for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation 
of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones 8, 
37-52 (2003). 
139. Woodard, A. S. et al. The synergistic activity of alphavbeta3 integrin and PDGF receptor 
increases cell migration. J Cell Sci 111 ( Pt 4), 469-78 (1998). 
140. Maile, L. A. & Clemmons, D. R. The alphaVbeta3 integrin regulates insulin-like growth 
factor I (IGF-I) receptor phosphorylation by altering the rate of recruitment of the Src-
homology 2-containing phosphotyrosine phosphatase-2 to the activated IGF-I receptor. 
Endocrinology 143, 4259-64 (2002). 
141. Brooks, P. C. et al. Insulin-like growth factor receptor cooperates with integrin alpha v 
beta 5 to promote tumor cell dissemination in vivo. J.Clin.Invest 99, 1390-1398 (1997). 
142. Faccio, R., Takeshita, S., Zallone, A., Ross, F. P. & Teitelbaum, S. L. c-Fms and the 
alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest 111, 749-
58 (2003). 
143. Flaherty, S. F., Golenbock, D. T., Milham, F. H. & Ingalls, R. R. CD11/CD18 leukocyte 
integrins: new signaling receptors for bacterial endotoxin. J Surg Res 73, 85-9 (1997). 
144. Harris, E. S., McIntyre, T. M., Prescott, S. M. & Zimmerman, G. A. The leukocyte 
integrins. J Biol Chem 275, 23409-12 (2000). 
145. Stewart, M., Thiel, M. & Hogg, N. Leukocyte integrins. Curr Opin Cell Biol 7, 690-6 
(1995). 
146. Dugas, B., Mossalayi, M. D., Damais, C. & Kolb, J. P. Nitric oxide production by human 
monocytes: evidence for a role of CD23. Immunol Today 16, 574-80 (1995). 
147. Smith, J. W., Vestal, D. J., Irwin, S. V., Burke, T. A. & Cheresh, D. A. Purification and 
functional characterization of integrin alpha v beta 5. An adhesion receptor for 
vitronectin. J.Biol.Chem. 265, 11008-11013 (1990). 
148. Charo, I. F., Nannizzi, L., Smith, J. W. & Cheresh, D. A. The vitronectin receptor alpha v 
beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular 
attachment and spreading on fibronectin. J.Cell Biol. 111, 2795-2800 (1990). 
149. Hultenby, K., Reinholt, F. P., Heinegard, D., Andersson, G. & Marks, S. C., Jr. 
Osteopontin: a ligand for the alpha v beta 3 integrin of the osteoclast clear zone in 
osteopetrotic (ia/ia) rats. Ann N Y Acad Sci 760, 315-8 (1995). 
150. Yokoyama, K., Zhang, X. P., Medved, L. & Takada, Y. Specific binding of integrin alpha v 
beta 3 to the fibrinogen gamma and alpha E chain C-terminal domains. Biochemistry 38, 
5872-5877 (1999). 
151. Denis, C., Williams, J. A., Lu, X., Meyer, D. & Baruch, D. Solid-phase von Willebrand 
factor contains a conformationally active RGD motif that mediates endothelial cell 
adhesion through the alpha v beta 3 receptor. Blood 82, 3622-3630 (1993). 
152. Sriramarao, P., Mendler, M. & Bourdon, M. A. Endothelial cell attachment and spreading 
on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. J.Cell Sci. 
105 ( Pt 4), 1001-1012 (1993). 
153. Gao, A. G., Lindberg, F. P., Dimitry, J. M., Brown, E. J. & Frazier, W. A. 
Thrombospondin modulates alpha v beta 3 function through integrin-associated protein. 
J.Cell Biol. 135, 533-544 (1996). 
154. Zhang, H., Li, Z., Viklund, E. K. & Stromblad, S. P21-activated kinase 4 interacts with 
integrin alpha v beta 5 and regulates alpha v beta 5-mediated cell migration. J.Cell Biol. 
158, 1287-1297 (2002). 
155. Horton, M. A. The alpha v beta 3 integrin "vitronectin receptor". Int.J.Biochem.Cell Biol. 
29, 721-725 (1997). 
156. Conforti, G., Calza, M. & Beltran-Nunez, A. Alpha v beta 5 integrin is localized at focal 
contacts by HT-1080 fibrosarcoma cells and human skin fibroblasts attached to 
vitronectin. Cell Adhes.Commun. 1, 279-293 (1994). 
157. Panetti, T. S., Wilcox, S. A., Horzempa, C. & McKeown-Longo, P. J. Alpha v beta 5 
integrin receptor-mediated endocytosis of vitronectin is protein kinase C-dependent. 
J.Biol.Chem. 270, 18593-18597 (1995). 
158. van Leeuwen, R. L. et al. Attachment, spreading and migration of melanoma cells on 
vitronectin. The role of alpha V beta 3 and alpha V beta 5 integrins. Exp.Dermatol. 5, 
308-315 (1996). 
159. Felding-Habermann, B., Ruggeri, Z. M. & Cheresh, D. A. Distinct biological consequences 
of integrin alpha v beta 3-mediated melanoma cell adhesion to fibrinogen and its plasmic 
fragments. J.Biol.Chem. 267, 5070-5077 (1992). 
 235 
160. Zimolo, Z. et al. Soluble alpha v beta 3-integrin ligands raise [Ca2+]i in rat osteoclasts 
and mouse-derived osteoclast-like cells. Am.J.Physiol 266, C376-C381 (1994). 
161. Miyauchi, A. et al. Binding of osteopontin to the osteoclast integrin alpha v beta 3. 
Osteoporos Int 3 Suppl 1, 132-5 (1993). 
162. Seftor, R. E. et al. Role of the alpha v beta 3 integrin in human melanoma cell invasion. 
Proc.Natl.Acad.Sci.U.S.A 89, 1557-1561 (1992). 
163. Danen, E. H. et al. Emergence of alpha 5 beta 1 fibronectin- and alpha v beta 3 
vitronectin-receptor expression in melanocytic tumour progression. Histopathology 24, 
249-256 (1994). 
164. Vellon, L., Menendez, J. A. & Lupu, R. alpha(V)beta(3) integrin regulates heregulin 
(HRG)-induced cell proliferation and survival in breast cancer. Oncogene (2005). 
165. Tsuchiya, S. et al. Establishment and characterization of a human acute monocytic 
leukemia cell line (THP-1). Int J Cancer 26, 171-6 (1980). 
166. Sundstrom, C. & Nilsson, K. Establishment and characterization of a human histiocytic 
lymphoma cell line (U-937). Int J Cancer 17, 565-77 (1976). 
167. Schneider, U., Schwenk, H. U. & Bornkamm, G. Characterization of EBV-genome negative 
"null" and "T" cell lines derived from children with acute lymphoblastic leukemia and 
leukemic transformed non-Hodgkin lymphoma. Int J Cancer 19, 621-6 (1977). 
168. Hurley, E. A., Klaman, L. D., Agger, S., Lawrence, J. B. & Thorley-Lawson, D. A. The 
prototypical Epstein-Barr virus-transformed lymphoblastoid cell line IB4 is an unusual 
variant containing integrated but no episomal viral DNA. J Virol 65, 3958-63 (1991). 
169. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227, 680-5 (1970). 
170. Myszka, D. G. Improving biosensor analysis. J Mol Recognit 12, 279-84 (1999). 
171. Riener, C. K., Kada, G. & Gruber, H. J. Quick measurement of protein sulfhydryls with 
Ellman's reagent and with 4,4'-dithiodipyridine. Anal Bioanal Chem 373, 266-76 (2002). 
172. Lecoanet-Henchoz, S. et al. CD23 regulates monocyte activation through a novel 
interaction with the adhesion molecules CD11b-CD18 and CD11c-CD18. Immunity 3, 119-
25 (1995). 
173. Kijimoto-Ochiai, S. & Noguchi, A. Two peptides from CD23, including the inverse RGD 
sequence and its related peptide, interact with the MHC class II molecule. Biochem 
Biophys Res Commun 267, 686-91 (2000). 
174. White, L. J. et al. Inhibition of apoptosis in a human pre-B-cell line by CD23 is mediated 
via a novel receptor. Blood 90, 234-43 (1997). 
175. Ruoslahti, E. & Pierschbacher, M. D. New perspectives in cell adhesion: RGD and 
integrins. Science 238, 491-7 (1987). 
176. Gehlsen, K. R., Sriramarao, P., Furcht, L. T. & Skubitz, A. P. A synthetic peptide derived 
from the carboxy terminus of the laminin A chain represents a binding site for the alpha 
3 beta 1 integrin. J Cell Biol 117, 449-59 (1992). 
177. Ivaska, J. et al. A peptide inhibiting the collagen binding function of integrin alpha2I 
domain. J Biol Chem 274, 3513-21 (1999). 
178. Wayner, E. A. & Carter, W. G. Identification of multiple cell adhesion receptors for 
collagen and fibronectin in human fibrosarcoma cells possessing unique alpha and 
common beta subunits. J Cell Biol 105, 1873-84 (1987). 
179. Mayer, R. J. et al. CD23 shedding: requirements for substrate recognition and inhibition 
by dipeptide hydroxamic acids. Inflamm Res 51, 85-90 (2002). 
180. Roman, V. et al. Characterization of a constitutive type III nitric oxide synthase in human 
U937 monocytic cells: stimulation by soluble CD23. Immunology 91, 643-8 (1997). 
181. Gresham, H. D., Graham, I. L., Anderson, D. C. & Brown, E. J. Leukocyte adhesion-
deficient neutrophils fail to amplify phagocytic function in response to stimulation. 
Evidence for CD11b/CD18-dependent and -independent mechanisms of phagocytosis. J 
Clin Invest 88, 588-97 (1991). 
182. Shahan, T. A. et al. Identification of CD47/integrin-associated protein and alpha(v)beta3 
as two receptors for the alpha3(IV) chain of type IV collagen on tumor cells. Cancer Res 
59, 4584-90 (1999). 
183. Fujimoto, T. T., Katsutani, S., Shimomura, T. & Fujimura, K. Thrombospondin-bound 
integrin-associated protein (CD47) physically and functionally modifies integrin 
alphaIIbbeta3 by its extracellular domain. J Biol Chem 278, 26655-65 (2003). 
184. Gonzalez, M., Merino, R., Gonzalez, A. L. & Merino, J. The ability of B cells to 
participate in allogeneic cognate T-B cell interactions in vitro depends on the presence 
of CD4+ T cells during their development. J Immunol 155, 1091-100 (1995). 
185. Paul-Eugene, N. et al. Ligation of CD23 triggers cAMP generation and release of 
inflammatory mediators in human monocytes. J Immunol 149, 3066-71 (1992). 
186. Gadgil, H. S. et al. Proteome of monocytes primed with lipopolysaccharide: analysis of 
the abundant proteins. Proteomics 3, 1767-80 (2003). 
 236 
187. Blystone, S. D., Lindberg, F. P., Williams, M. P., McHugh, K. P. & Brown, E. J. Inducible 
tyrosine phosphorylation of the beta3 integrin requires the alphaV integrin cytoplasmic 
tail. J Biol Chem 271, 31458-62 (1996). 
188. Fernandez, N., Renedo, M., Garcia-Rodriguez, C. & Sanchez Crespo, M. Activation of 
monocytic cells through Fc gamma receptors induces the expression of macrophage-
inflammatory protein (MIP)-1 alpha, MIP-1 beta, and RANTES. J Immunol 169, 3321-8 
(2002). 
189. Torsteinsdottir, I., Arvidson, N. G., Hallgren, R. & Hakansson, L. Monocyte activation in 
rheumatoid arthritis (RA): increased integrin, Fc gamma and complement receptor 
expression and the effect of glucocorticoids. Clin Exp Immunol 115, 554-60 (1999). 
190. Reumaux, D., Kuijpers, T. W., Hordijk, P. L., Duthilleul, P. & Roos, D. Involvement of 
Fcgamma receptors and beta2 integrins in neutrophil activation by anti-proteinase-3 or 
anti-myeloperoxidase antibodies. Clin Exp Immunol 134, 344-50 (2003). 
191. Nagahata, H., Sawada, C., Higuchi, H., Teraoka, H. & Yamaguchi, M. Fc receptor-
mediated phagocytosis, superoxide production and calcium signaling of beta 2 integrin-
deficient bovine neutrophils. Microbiol Immunol 41, 747-50 (1997). 
192. Nagahata, H., Higuchi, H., Goji, N., Noda, H. & Kuwabara, M. Functional characteristics 
of enhanced Fc receptor expression of beta 2 integrin-deficient bovine mononuclear 
phagocytes. Microbiol Immunol 40, 389-95 (1996). 
193. Lecoanet-Henchoz, S. et al. Mouse CD23 regulates monocyte activation through an 
interaction with the adhesion molecule CD11b/CD18. Eur J Immunol 27, 2290-4 (1997). 
194. Wilder, R. L. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis 
and related rheumatic diseases. Ann.Rheum.Dis. 61 Suppl 2, ii96-ii99 (2002). 
195. Switala-Jelen, K. et al. The biological functions of beta3 integrins. Folia Biol (Praha) 50, 
143-52 (2004). 
196. Hutchings, H., Ortega, N. & Plouet, J. Extracellular matrix-bound vascular endothelial 
growth factor promotes endothelial cell adhesion, migration, and survival through 
integrin ligation. Faseb J 17, 1520-2 (2003). 
197. Tsou, R. & Isik, F. F. Integrin activation is required for VEGF and FGF receptor protein 
presence on human microvascular endothelial cells. Mol Cell Biochem 224, 81-9 (2001). 
198. Matsumoto, T. & Claesson-Welsh, L. VEGF receptor signal transduction. Sci STKE 2001, 
RE21 (2001). 
199. Gloe, T., Sohn, H. Y., Meininger, G. A. & Pohl, U. Shear stress-induced release of basic 
fibroblast growth factor from endothelial cells is mediated by matrix interaction via 
integrin alpha(v)beta3. J Biol Chem 277, 23453-8 (2002). 
200. Harwood, F. L., Goomer, R. S., Gelberman, R. H., Silva, M. J. & Amiel, D. Regulation of 
alpha(v)beta3 and alpha5beta1 integrin receptors by basic fibroblast growth factor and 
platelet-derived growth factor-BB in intrasynovial flexor tendon cells. Wound Repair 
Regen 7, 381-8 (1999). 
201. Klein, S. et al. Basic fibroblast growth factor modulates integrin expression in 
microvascular endothelial cells. Mol Biol Cell 4, 973-82 (1993). 
202. Liu, G., Eskin, S. G. & Mikos, A. G. Integrin alpha(v)beta(3) is involved in stimulated 
migration of vascular adventitial fibroblasts by basic fibroblast growth factor but not 
platelet-derived growth factor. J.Cell Biochem. 83, 129-135 (2001). 
203. Mawatari, K., Liu, B. & Kent, K. C. Activation of integrin receptors is required for growth 
factor-induced smooth muscle cell dysfunction. J Vasc Surg 31, 375-81 (2000). 
204. Asano, Y. et al. Increased expression of integrin alpha(v)beta3 contributes to the 
establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. J Immunol 175, 
7708-18 (2005). 
205. Chin, S. L. et al. A role for alphaV integrin subunit in TGF-beta-stimulated 
osteoclastogenesis. Biochem Biophys Res Commun 307, 1051-8 (2003). 
206. Scaffidi, A. K. et al. alpha(v)beta(3) Integrin interacts with the transforming growth 
factor beta (TGFbeta) type II receptor to potentiate the proliferative effects of 
TGFbeta1 in living human lung fibroblasts. J.Biol.Chem. 279, 37726-37733 (2004). 
207. Kuemmerle, J. F. Occupation of alphavbeta3-integrin by endogenous ligands modulates 
IGF-I receptor activation and proliferation of human intestinal smooth muscle. Am J 
Physiol Gastrointest Liver Physiol 290, G1194-202 (2006). 
208. Strieth, S. et al. Antiangiogenic combination tumor therapy blocking alpha(v)-integrins 
and VEGF-receptor-2 increases therapeutic effects in vivo. Int J Cancer 119, 423-31 
(2006). 
209. Ross, F. P. & Teitelbaum, S. L. alphavbeta3 and macrophage colony-stimulating factor: 
partners in osteoclast biology. Immunol Rev 208, 88-105 (2005). 
210. Elsegood, C. L. et al. M-CSF induces the stable interaction of cFms with alphaVbeta3 
integrin in osteoclasts. Int J Biochem Cell Biol 38, 1518-29 (2006). 
 237 
211. Hofmeister, V., Schrama, D. & Becker, J. C. Anti-cancer therapies targeting the tumor 
stroma. Cancer Immunol Immunother 57, 1-17 (2008). 
212. Harris, T. D. et al. Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 
3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother.Radiopharm. 
18, 627-641 (2003). 
213. Kumar, C. C. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced 
angiogenesis. Curr.Drug Targets. 4, 123-131 (2003). 
214. Rader, C., Popkov, M., Neves, J. A. & Barbas, C. F., 3rd. Integrin alpha(v)beta3 targeted 
therapy for Kaposi's sarcoma with an in vitro evolved antibody. Faseb J 16, 2000-2 
(2002). 
215. Gutheil, J. C. et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a 
humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6, 3056-61 
(2000). 
216. Janssen, M. L. et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding 
peptides in a nude mouse model. Cancer Res. 62, 6146-6151 (2002). 
217. Duffield, J. S. The inflammatory macrophage: a story of Jekyll and Hyde. Clin Sci (Lond) 
104, 27-38 (2003). 
218. Pollard, J. W. Tumour-educated macrophages promote tumour progression and 
metastasis. Nat Rev Cancer 4, 71-8 (2004). 
219. Mantovani, A., Allavena, P. & Sica, A. Tumour-associated macrophages as a prototypic 
type II polarised phagocyte population: role in tumour progression. Eur J Cancer 40, 
1660-7 (2004). 
220. Chandhoke, S. K., Williams, M., Schaefer, E., Zorn, L. & Blystone, S. D. Beta 3 integrin 
phosphorylation is essential for Arp3 organization into leukocyte alpha V beta 3-
vitronectin adhesion contacts. J.Cell Sci. 117, 1431-1441 (2004). 
221. Boettiger, D., Huber, F., Lynch, L. & Blystone, S. Activation of alpha(v)beta3-vitronectin 
binding is a multistage process in which increases in bond strength are dependent on 
Y747 and Y759 in the cytoplasmic domain of beta3. Mol Biol Cell 12, 1227-37 (2001). 
222. Butler, B., Williams, M. P. & Blystone, S. D. Ligand-dependent activation of integrin 
alpha vbeta 3. J Biol Chem 278, 5264-70 (2003). 
223. Li, Z., Xi, X. & Du, X. A mitogen-activated protein kinase-dependent signaling pathway in 
the activation of platelet integrin alpha IIbbeta3. J Biol Chem 276, 42226-32 (2001). 
224. Maile, L. A., Badley-Clarke, J. & Clemmons, D. R. Structural analysis of the role of the 
beta 3 subunit of the alpha V beta 3 integrin in IGF-I signaling. J.Cell Sci. 114, 1417-1425 
(2001). 
225. Zhang, B., Hirahashi, J., Cullere, X. & Mayadas, T. N. Elucidation of molecular events 
leading to neutrophil apoptosis following phagocytosis: cross-talk between caspase 8, 
reactive oxygen species, and MAPK/ERK activation. J Biol Chem 278, 28443-54 (2003). 
226. Weyts, F. A., Li, Y. S., van Leeuwen, J., Weinans, H. & Chien, S. ERK activation and 
alpha v beta 3 integrin signaling through Shc recruitment in response to mechanical 
stimulation in human osteoblasts. J.Cell Biochem. 87, 85-92 (2002). 
227. Moore, C., Shen, X. D., Fondevila, C. & Coito, A. J. Fibronectin-alpha4beta1 integrin 
interactions modulate p42/44 MAPK phosphorylation in steatotic liver cold ischemia-
reperfusion injury. Transplant Proc 37, 432-4 (2005). 
228. Bergh, J. J. et al. Integrin {alpha}V{beta}3 Contains a Cell Surface Receptor Site for 
Thyroid Hormone that is Linked to Activation of MAPK and Induction of Angiogenesis. 
Endocrinology (2005). 
229. Crews, C. M., Alessandrini, A. & Erikson, R. L. The primary structure of MEK, a protein 
kinase that phosphorylates the ERK gene product. Science 258, 478-80 (1992). 
230. McGettrick, H. M. et al. Chemokine- and adhesion-dependent survival of neutrophils 
after transmigration through cytokine-stimulated endothelium. J Leukoc Biol 79, 779-88 
(2006). 
231. Paoletti, S. et al. A rich chemokine environment strongly enhances leukocyte migration 
and activities. Blood 105, 3405-12 (2005). 
232. Ji, J. F., He, B. P., Dheen, S. T. & Tay, S. S. Interactions of chemokines and chemokine 
receptors mediate the migration of mesenchymal stem cells to the impaired site in the 
brain after hypoglossal nerve injury. Stem Cells 22, 415-27 (2004). 
233. Gillitzer, R. Inflammation in human skin: a model to study chemokine-mediated 
leukocyte migration in vivo. J Pathol 194, 393-4 (2001). 
234. Ogata, M. et al. Chemotactic response toward chemokines and its regulation by 
transforming growth factor-beta1 of murine bone marrow hematopoietic progenitor cell-
derived different subset of dendritic cells. Blood 93, 3225-32 (1999). 
235. Helming, L. & Gordon, S. Macrophage fusion induced by IL-4 alternative activation is a 
multistage process involving multiple target molecules. Eur J Immunol 37, 33-42 (2007). 
 238 
236. Mantovani, A., Schioppa, T., Porta, C., Allavena, P. & Sica, A. Role of tumor-associated 
macrophages in tumor progression and invasion. Cancer Metastasis Rev 25, 315-22 
(2006). 
237. Schoppmann, S. F. et al. Tumor-associated macrophages express lymphatic endothelial 
growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 161, 947-
56 (2002). 
238. Valkovic, T. et al. Correlation between vascular endothelial growth factor, angiogenesis, 
and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch 
440, 583-8 (2002). 
239. Loiarro, M. et al. Peptide-mediated interference of TIR domain dimerization in MyD88 
inhibits interleukin-1-dependent activation of NF-{kappa}B. J Biol Chem 280, 15809-14 
(2005). 
240. Sekimoto, H., Eipper-Mains, J., Pond-Tor, S. & Boney, C. M. {alpha}V{beta}3 integrins 
and Pyk2 mediate IGF-I activation of Src and MAPK in 3T3-L1 cells. Mol.Endocrinol. 
(2005). 
241. Bhattacharyya, S. P. et al. Both adhesion to immobilized vitronectin and FcepsilonRI 
cross-linking cause enhanced focal adhesion kinase phosphorylation in murine mast cells. 
Immunology 98, 357-62 (1999). 
242. Armulik, A., Velling, T. & Johansson, S. The integrin beta1 subunit transmembrane 
domain regulates phosphatidylinositol 3-kinase-dependent tyrosine phosphorylation of 
Crk-associated substrate. Mol Biol Cell 15, 2558-67 (2004). 
243. Lyman, S., Gilmore, A., Burridge, K., Gidwitz, S. & White, G. C., 2nd. Integrin-mediated 
activation of focal adhesion kinase is independent of focal adhesion formation or integrin 
activation. Studies with activated and inhibitory beta3 cytoplasmic domain mutants. J 
Biol Chem 272, 22538-47 (1997). 
244. Danilkovitch, A., Skeel, A. & Leonard, E. J. Macrophage stimulating protein-induced 
epithelial cell adhesion is mediated by a PI3-K-dependent, but FAK-independent 
mechanism. Exp Cell Res 248, 575-82 (1999). 
245. Flo, T. H. et al. Involvement of CD14 and beta2-integrins in activating cells with soluble 
and particulate lipopolysaccharides and mannuronic acid polymers. Infect Immun 68, 
6770-6 (2000). 
246. Troelstra, A. et al. Lipopolysaccharide-coated erythrocytes activate human neutrophils 
via CD14 while subsequent binding is through CD11b/CD18. J Immunol 162, 4220-5 
(1999). 
247. Abdelilah, S. G. et al. Molecular characterization of the low-affinity IgE receptor Fc 
epsilonRII/CD23 expressed by human eosinophils. Int Immunol 10, 395-404 (1998). 
248. Martinez, F. O., Gordon, S., Locati, M. & Mantovani, A. Transcriptional profiling of the 
human monocyte-to-macrophage differentiation and polarization: new molecules and 
patterns of gene expression. J Immunol 177, 7303-11 (2006). 
249. Kimball, E. S., Kovacs, E., Clark, M. C. & Schneider, C. R. Activation of cytokine 
production and adhesion molecule expression on THP-1 myelomonocytic cells by 
macrophage colony-stimulating factor in combination with interferon-gamma. J Leukoc 
Biol 58, 585-94 (1995). 
250. Shi, C., Zhang, X., Chen, Z., Robinson, M. K. & Simon, D. I. Leukocyte integrin Mac-1 
recruits toll/interleukin-1 receptor superfamily signaling intermediates to modulate NF-
kappaB activity. Circ Res 89, 859-65 (2001). 
251. Cornaglia-Ferraris, P., De Maria, A., Cirillo, C., Cara, A. & Alessandri, G. Adhesion of 
human neuroblasts to HIV-1 tat. Pediatr Res 38, 792-6 (1995). 
252. Gavrilovskaya, I. N., Brown, E. J., Ginsberg, M. H. & Mackow, E. R. Cellular entry of 
hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 
integrins. J Virol 73, 3951-9 (1999). 
253. Roivainen, M. et al. Entry of coxsackievirus A9 into host cells: specific interactions with 
alpha v beta 3 integrin, the vitronectin receptor. Virology 203, 357-365 (1994). 
254. Guerrero, C. A. et al. Integrin alpha(v)beta(3) mediates rotavirus cell entry. 
Proc.Natl.Acad.Sci.U.S.A 97, 14644-14649 (2000). 
255. Chu, J. J. & Ng, M. L. Interaction of West Nile virus with alpha v beta 3 integrin mediates 
virus entry into cells. J.Biol.Chem. 279, 54533-54541 (2004). 
256. Au, B. T., Williams, T. J. & Collins, P. D. Zymosan-induced IL-8 release from human 
neutrophils involves activation via the CD11b/CD18 receptor and endogenous platelet-
activating factor as an autocrine modulator. J Immunol 152, 5411-9 (1994). 
257. Wong, K. F., Luk, J. M., Cheng, R. H., Klickstein, L. B. & Fan, S. T. Characterization of 
two novel LPS-binding sites in leukocyte integrin betaA domain. Faseb J 21, 3231-9 
(2007). 
 239 
258. Goldman, M. J. & Wilson, J. M. Expression of alpha v beta 5 integrin is necessary for 
efficient adenovirus-mediated gene transfer in the human airway. J.Virol. 69, 5951-5958 
(1995). 
259. Wickham, T. J., Filardo, E. J., Cheresh, D. A. & Nemerow, G. R. Integrin alpha v beta 5 
selectively promotes adenovirus mediated cell membrane permeabilization. J.Cell Biol. 
127, 257-264 (1994). 
260. Wickham, T. J., Mathias, P., Cheresh, D. A. & Nemerow, G. R. Integrins alpha v beta 3 
and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73, 
309-319 (1993). 
261. Jimenez-Martinez, M. C. et al. [Expression of B7 molecules and TLR-9 on corneal 
epithelial cells infected with adenovirus: clinico-pathological implications in viral 
keratoconjunctivitis]. Arch Soc Esp Oftalmol 81, 391-400 (2006). 
262. Triantafilou, M., Triantafilou, K., Wilson, K. M., Takada, Y. & Fernandez, N. High affinity 
interactions of Coxsackievirus A9 with integrin alphavbeta3 (CD51/61) require the 
CYDMKTTC sequence of beta3, but do not require the RGD sequence of the CAV-9 VP1 
protein. Hum Immunol 61, 453-9 (2000). 
263. Lafrenie, R. M., Lee, S. F., Hewlett, I. K., Yamada, K. M. & Dhawan, S. Involvement of 
integrin alphavbeta3 in the pathogenesis of human immunodeficiency virus type 1 
infection in monocytes. Virology 297, 31-8 (2002). 
264. Tachado, S. D., Zhang, J., Zhu, J., Patel, N. & Koziel, H. HIV impairs TNF-alpha release 
in response to Toll-like receptor 4 stimulation in human macrophages in vitro. Am J 
Respir Cell Mol Biol 33, 610-21 (2005). 
265. Meier, A. et al. MyD88-dependent immune activation mediated by human 
immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol 81, 8180-91 
(2007). 
266. Heil, F. et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 
and 8. Science 303, 1526-9 (2004). 
267. Forsyth, C. B., Plow, E. F. & Zhang, L. Interaction of the fungal pathogen Candida 
albicans with integrin CD11b/CD18: recognition by the I domain is modulated by the 
lectin-like domain and the CD18 subunit. J Immunol 161, 6198-205 (1998). 
268. Lavigne, L. M. et al. Integrin engagement mediates the human polymorphonuclear 
leukocyte response to a fungal pathogen-associated molecular pattern. J Immunol 178, 
7276-82 (2007). 
269. Sturtevant, J. & Calderone, R. Candida albicans adhesins: Biochemical aspects and 
virulence. Rev Iberoam Micol 14, 90-7 (1997). 
270. Blasi, E. et al. Biological importance of the two Toll-like receptors, TLR2 and TLR4, in 
macrophage response to infection with Candida albicans. FEMS Immunol Med Microbiol 
44, 69-79 (2005). 
271. Corbucci, C. et al. Immune response to Candida albicans is preserved despite defect in 
O-mannosylation of secretory proteins. Med Mycol 45, 709-19 (2007). 
272. Netea, M. G. et al. Toll-like receptor 2 suppresses immunity against Candida albicans 
through induction of IL-10 and regulatory T cells. J Immunol 172, 3712-8 (2004). 
273. Perera, P. Y. et al. CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 
to elicit full lipopolysaccharide and taxol-inducible gene expression. J Immunol 166, 574-
81 (2001). 
274. Sabroe, I., Jones, E. C., Usher, L. R., Whyte, M. K. & Dower, S. K. Toll-like receptor 
(TLR)2 and TLR4 in human peripheral blood granulocytes: a critical role for monocytes in 
leukocyte lipopolysaccharide responses. J Immunol 168, 4701-10 (2002). 
275. Petersen, M. M., Steadman, R. & Williams, J. D. Protein kinase C activation modulates 
tumour necrosis factor-alpha priming of human neutrophils for zymosan-induced 
leukotriene B4 release. Immunology 75, 275-80 (1992). 
276. Steadman, R., Petersen, M. M. & Williams, J. D. CD11b/CD18-dependent stimulation of 
leukotriene B4 synthesis by human neutrophils (PMN) is synergistically enhanced by 
tumour necrosis factor alpha and low dose diacylglycerol. Int J Biochem Cell Biol 28, 771-
6 (1996). 
277. Hynes, R. O. A reevaluation of integrins as regulators of angiogenesis. Nat Med 8, 918-21 
(2002). 
278. Mazzone, A. & Ricevuti, G. Leukocyte CD11/CD18 integrins: biological and clinical 
relevance. Haematologica 80, 161-75 (1995). 
279. Goncalves, R. M. et al. Increased serum levels of CXCL8 chemokine in acute toxoplasmic 
retinochoroiditis. Acta Ophthalmol Scand 85, 871-6 (2007). 
280. Polyak, S. J., Khabar, K. S., Rezeiq, M. & Gretch, D. R. Elevated levels of interleukin-8 in 
serum are associated with hepatitis C virus infection and resistance to interferon 
therapy. J Virol 75, 6209-11 (2001). 
 240 
281. Grygorczuk, S. et al. Concentrations of macrophage inflammatory proteins MIP-1alpha 
and MIP-1beta and interleukin 8 (il-8) in lyme borreliosis. Infection 32, 350-5 (2004). 
282. Bartosik-Psujek, H. & Stelmasiak, Z. The levels of chemokines CXCL8, CCL2 and CCL5 in 
multiple sclerosis patients are linked to the activity of the disease. Eur J Neurol 12, 49-
54 (2005). 
283. Torikai, E., Kageyama, Y., Suzuki, M., Ichikawa, T. & Nagano, A. The effect of infliximab 
on chemokines in patients with rheumatoid arthritis. Clin Rheumatol 26, 1088-93 (2007). 
284. al-Janadi, M., al-Balla, S., al-Dalaan, A. & Raziuddin, S. Cytokine profile in systemic 
lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 
13, 58-67 (1993). 
285. Al-Mutairi, S. et al. Lupus patients with pulmonary involvement have a pro-inflammatory 
cytokines profile. Rheumatol Int 27, 621-30 (2007). 
286. Szodoray, P., Alex, P., Brun, J. G., Centola, M. & Jonsson, R. Circulating cytokines in 
primary Sjogren's syndrome determined by a multiplex cytokine array system. Scand J 
Immunol 59, 592-9 (2004). 
287. Kucharzik, T., Stoll, R., Lugering, N. & Domschke, W. Circulating antiinflammatory 
cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 100, 
452-6 (1995). 
288. Bousvaros, A. et al. Elevated serum vascular endothelial growth factor in children and 
young adults with Crohn's disease. Dig Dis Sci 44, 424-30 (1999). 
289. Wu, H. et al. Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific 
humanized mAb. Proc Natl Acad Sci U S A 95, 6037-42 (1998). 
290. Gramoun, A. et al. Effects of Vitaxin, a novel therapeutic in trial for metastatic bone 
tumors, on osteoclast functions in vitro. J Cell Biochem 102, 341-52 (2007). 
291. Posey, J. A. et al. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti 
alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother.Radiopharm. 
16, 125-132 (2001). 
292. Coleman, K. R., Braden, G. A., Willingham, M. C. & Sane, D. C. Vitaxin, a humanized 
monoclonal antibody to the vitronectin receptor (alphavbeta3), reduces neointimal 
hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. 
Circ Res 84, 1268-76 (1999). 
293. Rosenwald, M. S. in Washington Post E05 (Washington, 2004). 
294. Bonnefoy, J. Y. et al. A new role for CD23 in inflammation. Immunol Today 17, 418-20 
(1996). 
 
 
